Studies of Virus Receptor Interactions and Virulence Determinants of Feline Calicivirus by Ossiboff, Robert James
  
 
STUDIES OF VIRUS RECEPTOR INTERACTIONS AND VIRULENCE 
DETERMINANTS OF FELINE CALICIVIRUS 
 
 
 
 
 
 
 
 
A Dissertation 
Presented to the Faculty of the Graduate School 
of Cornell University 
In Partial Fulfillment of the Requirements for the Degree of 
Doctor of Philosophy 
 
 
 
 
 
by 
Robert James Ossiboff 
January 2009
  
 
 
 
 
 
 
 
 
 
 
 
© 2009 Robert James Ossiboff
  
STUDIES OF VIRUS RECEPTOR INTERACTIONS AND VIRULENCE 
DETERMINANTS OF FELINE CALICIVIRUS 
Robert James Ossiboff, Ph. D.  
Cornell University 2009 
 
 The virus-receptor interaction is critical for establishing infection in host cells. 
The interaction (i) allows the virion to attach specifically to the host cell membrane, 
(ii) is often required to permit the process of infection further downstream, and (iii) 
strongly influences viral tropism and pathogenesis. 
 Feline calicivirus (FCV) is a common feline pathogen. Infection is generally 
asymptomatic or causes mild upper respiratory signs and oral ulceration; morbidity is 
high while mortality is low. During the last decade however, there have been 
outbreaks of extremely virulent viruses that cause systemic disease and result in 
mortality rates as high as 50%. One objective of these studies was to characterize in 
vitro properties of FCV isolates of high and low virulence and to identify in vitro 
correlates to virulence.  
 FCV, a small nonenveloped virus containing a positive sense RNA genome, is 
known to bind two cellular receptors, feline junctional adhesion molecule A (fJAM-A) 
and α2,6 sialic acid. A second objective was to elucidate the details of the FCV-fJAM-
A interaction by determining the regions of fJAM-A required for FCV binding and 
selecting FCV mutants resistant to neutralization by soluble fJAM-A. 
 Analysis of FCV in vitro properties demonstrated that highly virulent isolates 
were able to spread more efficiently in tissue culture than other isolates investigated. 
Highly virulent isolates were also more susceptible to neutralization by soluble 
fJAM-A than other isolates. Lastly, sequence analysis of the FCV structural protein 
 did not identify conserved sequence unique to highly virulent viruses.  
 Mutagenesis studies identified that while the binding of FCV to fJAM-A 
requires the extracellular membrane-distal loop, all domains of the protein were 
required for successful infection. Selection of FCV mutants resistant to receptor 
neutralization and measurements of protein hydrophobicity provided genetic and 
biological evidence indicating that FCV undergoes a significant conformational 
change upon interaction with fJAM-A. 
 This work shows that FCV interaction with fJAM-A results in changes to the 
capsid likely to be important for subsequent steps in infection, and suggests a 
determinant of virulence in FCV is accelerated entry post-binding. 
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Introduction 
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1.1 Study Relevance 
 Feline calicivirus (FCV) is a common feline pathogen that causes a variety of 
clinical syndromes. While vaccination with attenuated-live FCV vaccines is widely 
practiced, vaccinated cats can still be asymptomatic carriers of the virus and are not 
protected from all circulating strains of FCV (Dawson et al., 1993, Gaskell et al., 
1982, Knowles et al., 1990, Pedersen & Hawkins, 1995).  Typically, FCV infection is 
either asymptomatic or causes mild upper respiratory signs, oral ulceration, and fever 
(Hoover & Kahn, 1975, Reubel et al., 1992).  Morbidity is high, with prevalence rates 
of avirulent or mildly virulent FCV in multiple-cat environments as high as 36% 
(Bannasch & Foley, 2005, Binns et al., 2000). Fatal disease is unusual. In 1998 
however, there was a reported outbreak of atypical FCV that caused severe systemic 
disease, with a fatal hemorrhagic-like fever being noted in some animals (Pedersen et 
al., 2000). Since that initial report, there have been multiple other documented 
outbreaks of extremely virulent FCV [termed virulent systemic (VS-) FCV due to the 
systemic nature of the symptoms caused by infection] that have resulted in mortality 
rates as high as 50%  (Coyne et al., 2006, Hurley et al., 2004, Pesavento et al., 2004, 
Schorr-Evans et al., 2003). The extremely virulent nature of these viruses as well as 
the speed with which they can spread within veterinary hospitals and shelters 
(Pedersen et al., 2000, Schorr-Evans et al., 2003) makes their early identification 
imperative for limiting morbidity and mortality.  Unfortunately, at present only 
pathologic examination of diseased tissues can confirm a FCV infection as being VS- 
in nature. Therefore, the identification of an in vitro characteristic of these virulent 
viruses would have great utility as a diagnostic. Understanding the molecular 
determinants of the shift in virulence of these viruses could also permit the creation of 
better vaccines or the development of antivirals or therapeutics to be used in the event 
of an outbreak. 
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 The Caliciviridae, the virus family to which FCV belongs, contains several 
viruses of considerable medical and veterinary significance. Caliciviruses infect a 
wide variety of species including humans, rabbits, swine, bovines, sea lions, reptiles 
and cats (Green et al., 2000).  The study of many viruses in this family is limited by 
the lack of culture systems. This is particularly true of the human noroviruses, which 
are responsible for > 90% of all cases of infectious gastroenteritis (Atreya, 2004, 
Mead et al., 1999). The absence of a cell culture system has greatly hindered norovirus 
investigation, for which there is urgent need for an effective vaccine (Estes et al., 
2000). FCV can serve as a model for the related noroviruses; information gained 
regarding the interaction of FCV with cellular receptors is likely to be helpful in 
designing vaccines or therapeutics to prevent norovirus-receptor interactions. 
 
1.2 Clinical signs of FCV infection 
 FCV infection in cats causes a variety of clinical presentations, ranging from 
asymptomatic to hemorrhagic-like systemic disease, and occurs in both acute and 
chronic forms (Reubel et al., 1992, Studdert, 1978). The most common clinical 
presentations of FCV infection are acute upper respiratory tract disease (URTD) and 
oral ulceration. Disease occurs after an incubation period of 2 to 10 days. Typical 
signs include fever (39.5 to 40.5° C), rhinitis, sneezing, excess salivation, serous or 
mucopurulent nasal and ocular discharge, and conjunctival hyperemia; disease may 
progress to include depression, anorexia, and /or lethargy. Ulcerative glossitis is 
frequently observed on the external nares, oral mucosa and tongue [as reviewed in 
(Hurley & Sykes, 2003, Studdert, 1978)]. Fatal disease is rare, although mortalities are 
occasionally observed in young kittens (< 12 weeks of age) and are generally 
associated with pneumonia (Kahn & Gillespie, 1971, Love & Baker, 1972).  
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 Chronic FCV infection has also been implicated in the pathogenesis of feline 
gingivostomatitis. In some studies of the disease, it has been identified in up to 100% 
of cases (Knowles et al., 1991, Reubel et al., 1992), and in one case report, resolution 
of chronic gingivostomatitis resulted in the cessation of FCV shedding (Addie et al., 
2003). However, while FCV isolated from a cat with chronic gingivostomatitis could 
cause acute disease experimentally, chronic disease could not be replicated with the 
isolated virus (Knowles et al., 1991, Poulet et al., 2000). Therefore, it is possible that 
FCV is not the cause of chronic gingivostomatitis, but instead an opportunistic 
infection. 
 FCV has also been documented to cause polyarthritis in cats, also referred to as 
“limping syndrome.” This syndrome was reproduced experimentally in cats when 
infected with specific strains of FCV and caused synovitis when joints were directly 
inoculated with virus as well as when infected orally, albeit with less frequency, 
(Dawson et al., 1994, TerWee et al., 1997). Lameness has also been described in cats 
infected with strains associated with classical respiratory and oral signs (Poulet et al., 
2000). 
 During the last decade there have been several outbreaks of extremely virulent 
FCV in both the US (Hurley et al., 2004, Pedersen et al., 2000, Schorr-Evans et al., 
2003) and the UK (Coyne et al., 2006); these strains, termed VS-FCV, cause systemic 
disease and are associated with high mortality rates (50%). Clinical findings of these 
outbreaks include unresponsive fever, oral cavity and skin ulceration (lingual, 
mucocutaneous junctions, nose, pinnae, footpads, and distal extremities), edema of the 
head, pinnae, and paws, jaundice, and bleeding tendencies (Coyne et al., 2006, Hurley 
et al., 2004, Pesavento et al., 2004, Schorr-Evans et al., 2003). Outbreaks have ranged 
from a small number of affected animals to up to 50 (Hurley et al., 2004, Pesavento et 
al., 2008). In all reported outbreaks, vaccinated cats have been susceptible, suggesting 
4 
that currently available vaccines do not protect cats from VS disease. Captive exotic 
felids also appear to be susceptible to VS disease (Harrison et al., 2007). 
 Other documented disease syndromes associated with FCV infection are 
abortion (van Vuuren et al., 1999), neurologic signs (Sato et al., 2004),  and lower 
urinary tract disease (Rice et al., 2002). FCV-like viruses have also been isolated from 
dogs with gastrointestinal disease (Evermann et al., 1985, Gabriel et al., 1996, 
Martella et al., 2002). Whether or not FCV was the causative agent for the observed 
clinical signs or if the virus was simply passing through the GI tract of the dogs is 
unclear. 
 
1.3 Pathogenesis 
 FCV infection is believed to be transmitted oronasally, with cats being 
susceptible to infection via the nasal, oral or conjunctival routes; aerosol, droplet and 
fomite transmission are considered the most likely modes of infection (Radford et al., 
2007, Studdert, 1978). The virus readily replicates in conjunctiva, oral mucosa and 
tongue epithelium (Studdert, 1978). However, virus can often be readily recovered 
from feces and intestines. As many of the Caliciviridae are gastrointestinal pathogens,  
it is possible fecal-oral routes of transmission and infection may be playing an 
important but currently overlooked role in FCV pathogenesis. 
   
1.4 Taxonomy 
 FCV is a member of the family Caliciviridae. The family is divided into four 
genera: Lagovirus, Norovirus, Sapovirus, and Vesivirus (Green et al., 2000).  
Noroviruses and sapoviruses contain important human pathogens that cause acute 
gastroenteritis. The type lagovirus species is rabbit hemorrhagic disease virus 
(RHDV), and the genus includes other viruses that cause clinical disease of veterinary 
5 
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importance in rabbits. FCV belongs to the genus vesivirus; other viruses of note within 
this genus that are of veterinary significance are San Miguel sea lion virus (SMSV) 
and vesicular exanthema of swine virus (VESV). The addition of  two additional 
genera, Becovirus and Recovirus, has been recommended following genomic sequence 
analysis of pathogenic bovine enteric virus Newbury agent-1 and Tulane virus, a 
calicivirus isolated from stool samples from rhesus macaques  (Farkas et al., 2008, 
Oliver et al., 2006).  
 
1.5 Calicivirus genome structure and organization 
 Caliciviruses contain a single-stranded, positive sense RNA genome. The 
genome of FCV is ~ 7.7 kb in length, contains three open reading frames (ORFs), and 
is polyadenylated at its 3’ terminus (see Figure 1.1) (Carter et al., 1992, Clarke & 
Lambden, 1997). The 5’ ORF (ORF1) encodes a polyprotein (~ 1800 amino acids) 
that contains six non-structural proteins (Carter, 1989, Sosnovtseva et al., 1999). 
ORF2 and ORF3 encode the structural proteins; the beginning of ORF3 overlaps the 
end of ORF2 by 4 nucleotides. ORF2 encodes the major capsid protein (VP1; ~670 
amino acids), and ORF3, located at the 3’ end of the genome, encodes a minor 
structural protein (VP2; ~100 amino acids) (Carter, 1989, Sosnovtsev et al., 2005). 
During infection, there is abundant production of subgenomic RNAs (~2.4 kb) that are 
3’-coterminal with the full length genome and contain ORFs 2 and 3 (Carter et al., 
1992, Neill & Mengeling, 1988, Neill et al., 1991). RNA secondary structure (single 
stem loop) is predicted to exist in the 3’ noncoding region of FCV (Seal et al., 1994). 
 
1.6 Translation and processing 
 Translation of the calicivirus RNA genome and subgenome occurs in the 
absence of a 5’-cap or internal ribosome entry site. Instead, FCV genomic and  
Figure 1.1. Translation and processing of the FCV genome and subgenome. A 
schematic representation of the translation of both the full-length and subgenomic 
mRNA of FCV and the resulting processing of proteins is shown. Individual proteins 
and designations currently used in the literature are indicated; the sites of cleavage by 
the viral proteinase (if applicable) are denoted by an arrow.
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subgenomic RNA are covalently linked to a virally-encoded 15.5 kD protein, VPg 
(Herbert et al., 1997, Sosnovtsev & Green, 2000). Interactions between calicivirus 
VPg and the eukaryotic initiation factors (eIFs) 4E and 3 have been demonstrated, and 
it is thought the VPG is acting as a cap substitute during the initiation of translation on 
virus mRNA (Chaudhry et al., 2006, Goodfellow et al., 2005). Removal of the VPG 
substantially decreases the efficiency of in vitro translation of FCV RNA (Burroughs 
& Brown, 1978, Dunham et al., 1998, Herbert et al., 1997), and mutation to a tyrosine 
residue within VPg thought to be important for covalent linkage to the FCV genome 
was lethal (Mitra et al., 2004). 
 Translation of ORF1 results in a polyprotein containing the FCV non-structural 
proteins. The polyprotein is autocatalytically processed by the virus-encoded 
proteinase-polymerase, which is located at the C-terminus of the polyprotein (Figure 
1.1) (Sosnovtsev et al., 2002, Sosnovtseva et al., 1999). The liberated proteins p32 
[NS2], p39 [NTPase; NS3] , p30 [NS4] , p13 [VPg; NS5], and  p76 [proteinase-
polymerase; NS6/7] participate in protein-protein interactions with each other as well 
as the structural proteins, presumably to play key roles in virus replication and 
encapsidation (Kaiser et al., 2006, Sosnovtsev et al., 2002). The function of an 
additional small protein, p5.6 [NS1], released from the N-terminus of the polyprotein, 
is unknown. 
 The structural proteins are translated from the second and third ORFs as found 
in both the full-length and subgenomic RNAs of FCV. ORF2 encodes the 73 kDa 
capsid precursor protein. The N-terminal end of the capsid precursor, the 11 kDa 
leader capsid, is cleaved from the mature 62 kDa capsid protein by the calicivirus 
proteinase-polymerase (Carter et al., 1992, Neill et al., 1991, Sosnovtsev et al., 1998).  
The minor structural capsid protein, VP2, is translated from ORF3. The reinitiation of 
ORF3 translation following termination of VP1 synthesis is achieved in a 
9 
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termination/reinitiation process that requires upstream sequence located at the 3’ end 
of ORF2  (Luttermann & Meyers, 2007). Although VP2 is not visible in the 
crystallographic structures of two caliciviruses, it is essential for productive replication 
in the synthesis and maturation of infectious FCV virions, and is possibly involved in 
RNA encapsidation (Sosnovtsev et al., 2005, Sosnovtsev & Green, 2000).  
 
1.7 Calicivirus structure 
 The calicivirus virion is icosahedral with distinctive depressions that appear 
cup-like by negative-stain electron microscopy (Figure 1.2A); this characteristic 
appearance is the name-sake of the family (calici- is derived from the Latin word for 
cup-shaped, calyx). Cryo-electron microscopy (cryo-EM) reconstructions have been 
determined for noroviruses [virus-like particles (VLPs) of recombinant Norwalk virus 
(NV) and  Parksville virus, and native murine norovirus], sapoviruses (recombinant 
Grimsby VLPs), lagoviruses [recombinant VLPs of RHDV], and vesiviruses [SMSV, 
primate calicivirus Pan-1, and most recently, FCV] (Bhella et al., 2008, Chen et al., 
2004, Katpally et al., 2008, Prasad et al., 1994, Prasad et al., 2000, Thouvenin et al., 
1997). Crystallographic structures have been determined for two members of the 
Caliciviridae, native SMSV (serotype 4) and VLPs of recombinant NV (Chen et al., 
2006, Prasad et al., 1999). 
 Structural data show that caliciviruses exhibit T = 3 icosahedral symmetry. 
They are composed of 180 copies of the major capsid protein arranged into 90 arch-
like dimers that form the icosahedral lattice. The characteristic cup-like depressions 
appear at the five- and three-fold positions, created by the protruding capsomeres 
(Figure 1.2B). The crystal structure of closely related SMSV4 (~50% identity to FCV 
mature capsid protein) and NV both consist of three quasiequivalent subunits (A, B, 
and C). A and B subunits form A/B dimers, and the two C subunits  
Figure 1.2. Calicivirus structure. (A) Negative-stain transmission electron microscopy 
images of FCV particles. (B) Capsid structure of the closely related calicivirus, 
SMSV4. A, B, and C quasiequivalent positions and the 5- and 3-fold axes are 
indicated. (C) Structure of the SMSV4 capsid monomer demonstrating the structural 
domains of the protein: NTA (green), Shell (red), Protrusion (P1 subdomain, yellow; 
P2 subdomain, blue).
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interact to form C/C dimers. Individual subunits are composed of three structural 
domains: N-terminal arm (NTA), shell, and protruding domain (Figure 1.2C)  (Chen et 
al., 2006, Prasad et al., 1999).  
 The shell domain forms an icosahedral scaffold that encapsidates the virus 
genome. The shell domain folds into an eight-stranded β-barrel, a common structural 
feature seen in the capsids of many other viruses (Harrison, 2001, Rossmann & 
Johnson, 1989). The eight strands form two four-stranded antiparallel sheets. In 
addition to shell-shell domain interactions, the β-barrel also interacts with the NTA 
domain. One strand of one β-sheet of the S domain interacts with the N-terminal loop 
of the NTA of the opposing subunit, forming extensive domain-swapping interactions. 
In SMSV, the β-barrel configuration and the shell/NTA domain interactions maintain 
the icosahedral symmetry of the capsid (Chen et al., 2006). 
 The protruding domain of caliciviruses can be divided into two distinct 
subdomains, the proximal P1 and the distal P2 subdomains (Figure 1.2C). The P2 
subdomain is a large insertion in the P1 subdomain. As such, P2 divides P1 into two 
polypeptide segments located N- and C- terminal to P2. The fold of the calicivirus P 
domain, a twisted β-sheet formed by the four strands in the C-terminal portion of P1 
and a lone α-helix, is not seen in any other proteins (Chen et al., 2006, Prasad et al., 
1999).  The P2 domain contains a compact barrel of six β-strands that are connected 
by loops of various lengths. Neutralizing epitopes of FCV mapped on the structure of 
SMSV consist  of loops connecting the β-strands of the compact barrel (Chen et al., 
2006, Radford et al., 1999, Tohya et al., 1997). Despite low sequence similarity 
between SMSV and NV, the six strands are arranged in a similar manner in each virus; 
the conservation of the fold in the P2 domain across two genera despite weak 
sequence homology suggests that this fold is conserved in all caliciviruses (Chen et al., 
2006).  
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 Interactions between residues in the protrusion domain are responsible for the 
formation of dimers. In SMSV4, only the distal P2 subdomain is involved in dimer 
formation, whereas in recombinant NV VLPs, both P1 and P2 contribute residues 
important for dimer formation (Chen et al., 2006, Prasad et al., 1999). The P domain 
alone of NV, when expressed in bacteria and purified, forms extensive dimers that 
demonstrate the same conformation seen in the crystal structure of recombinant NV 
VLPs (Choi et al., 2008). 
 In cryo-EM reconstructions of another norovirus, mouse norovirus, extensive 
interactions of both P1 and P2 result in the formation of a secondary shell created by 
the P1 subdomain. This conformation is made possible by the extension of the P 
domain away from the S domain by the flexible hinge region present in all 
caliciviruses (Figure 1.2) (Katpally et al., 2008). The structure of SMSV4 also shows 
an additional point of flexibility not observed in Norwalk virus, between the P1 and P2 
subdomains (Chen et al., 2006). Conformational changes within the capsid are likely 
important for viral entry and delivery of genomic material (discussed in Section 1.10), 
and such areas of flexibility may play important roles in mediating such structural 
alterations. 
 
1.8 Calicivirus cell surface receptors 
 Cellular receptors have been identified for human noroviruses, RHDV, and 
FCV.  Both the human noroviruses and RHDV attach to complex carbohydrate histo-
blood group antigens (HBGAs) on the surface of susceptible cells (Huang et al., 2005, 
Marionneau et al., 2002, Ruvoen-Clouet et al., 2000). For noroviruses, HBGAs appear 
to be required for efficient infection in vivo (Hutson et al., 2002). Furthermore, 
susceptibility to norovirus infection is dependent on the individual’s HBGA 
expression (Lindesmith et al., 2003). Recent structural studies examining the binding 
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of HBGAs to recombinant P domain dimers show that the HBGAs bind in a surface-
exposed shallow depression in the outermost face of the P-domain (Choi et al., 2008). 
However, human cells expressing the appropriate HBGAs are unable to efficiently 
endocytose or be infected by norovirus VLPs (White et al., 1996). Additionally,  
strains of human noroviruses have been identified that do not bind HBGAs (Huang et 
al., 2005, Lindesmith et al., 2005). In light of these facts, it is hypothesized that 
presently unidentified co-receptor(s) are necessary for infectious entry of noroviruses.  
 The kinetics and biochemical binding of FCV to a permissive cell line, 
Crandell-Reese feline kidney (CRFK) cells, was first investigated by Kreutz et al 
(1994).  This study showed that the treatment of CRFK cells with proteases increased 
FCV binding while cells treated with neuraminidase and O-glycanase showed a 
decreased binding ability (Kreutz et al., 1994). Since that publication, two cellular 
receptors have been identified for FCV. Makino et al. (2006) used a cDNA library of a 
permissive feline cell line to identify that feline junctional adhesion molecule A 
(fJAM-A) as a cellular binding molecule of FCV. Expression of fJAM-A in non-
permissive tissue culture cells led to binding and infection by a tissue culture adapted 
strain of FCV (F4); furthermore, an antibody generated against fJAM-A reduced the 
ability of FCV to bind to and infect permissive feline cells (Makino et al., 2006).  
Shortly thereafter, a carbohydrate receptor, α2,6-linked sialic acid, was identified 
(Stuart & Brown, 2007).  Treatment of CRFK cells with selective neuraminidases 
showed that cleavage of α2,6- but not α2,3-linked sialic acid reduced the binding and 
infection by a tissue-culture adapted vaccine strain of FCV (F9). Treatment of cells 
with proteases and metabolic inhibitors suggested that the recognized carbohydrate 
moiety was present on a N-linked glycoprotein. 
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1.9 Junctional adhesion molecule A 
 Junctional adhesion molecule A (JAM-A) is a type I transmembrane 
glycoprotein (MW 36-41 kDa). It consists of a N-terminal signal peptide, an 
extracellular domain [composed of two immunoglobulin (Ig-) like domains - a 
membrane-distal D1 and a membrane-proximal D2], a transmembrane domain, and a 
short cytoplasmic domain that contains a type II PDZ domain-binding motif (Figure 
1.3A) (Ebnet et al., 2000, Mandell & Parkos, 2005). The two Ig-like domains in the 
extracellular domain of the protein classify JAM-A as a member of the 
immunoglobulin superfamily (IgSF).  
 JAM-A belongs to a family of proteins important in maintaining intercellular 
tight junctions (Martin-Padura et al., 1998). In humans and mice, JAM-A localizes to 
the intercellular tight junctions of endothelial and epithelial cells (Liu et al., 2000, 
Mandell et al., 2004). Crystallographic structure of recombinant human and murine 
JAM-A shows that in solution, JAM-A forms homodimers that are stabilized by ionic 
and hydrophobic interactions between residues in the D1 domain dimerization motif 
(Fig. 1.3B) (Kostrewa et al., 2001, Prota et al., 2003). In addition, JAM-A has been 
shown to naturally form homodimers on the surface of cells (Bazzoni et al., 2000) . 
The formation of homodimers is critical in establishing a regulated tight junctional 
barrier between cells, and it is thought that homophilic interactions between JAM-A 
dimers on opposing cell surfaces are important for forming intercellular tight junctions 
(Liu et al., 2000, Mandell et al., 2004, Martin-Padura et al., 1998, Williams et al., 
1999).  
 JAM-A is also expressed on the surface of platelets, leukocytes and 
erythrocytes (Gupta et al., 2000, Williams et al., 1999). It is believed to play a role in 
modulating leukocyte transmigration as well as platelet activation and aggregation 
(Babinska et al., 2002, Ozaki et al., 1999, Sobocka et al., 2004). Deficiencies in  
Figure 1.3. JAM-A structure. (A) Schematic representation of feline JAM-A. (B & C) 
Crystal structure of hJAM-A ectodomain dimer as viewed from the side (B) and above 
(C). For one monomer, the membrane-distal D1 domain is shown in blue, the 
membrane-proximal D2 domain in red, and the linker region between the two domains 
in yellow. Panel C demonstrates the sites of contact between adjacent monomers in 
dimer formation.
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JAM-A expression or function result in leukocytes becoming trapped between 
endothelial cells as they respond to inflammation (Khandoga et al., 2005, Martin-
Padura et al., 1998, Ostermann et al., 2005). Additionally, JAM-A has been shown to 
play a role in both angiogenesis (Naik et al., 2003a, Naik et al., 2003b) and cell 
migration of epithelial and endothelial cells (Naik & Naik, 2006, Severson et al., 
2008). Severson et al (2008) showed in tissue culture cells that JAM-A dimerization 
regulated epithelial cell migration indirectly through signaling events that altered the 
expression levels of another adhesion protein, integrin β1. This suggests that JAM-
JAM interactions are likely to play an important role in the regulation of expression 
levels of other cellular adhesion proteins. 
 
1.10 IgSF cell surface proteins as viral receptors 
 Animal viruses utilize host cellular factors as receptors to allow for specific 
attachment to the host cell surface. IgSF proteins, of which JAM-A is a member, are 
important in the fundamental cellular processes of binding, adhesion, or recognition. 
As such, several different virus families utilize IgSF proteins as viral receptors. 
JAM-A has been shown to be a functional receptor for both FCV and mammalian 
orthoreoviruses (Reoviridae) (Barton et al., 2001, Makino et al., 2006). The σ1 
attachment protein of reoviruses engages residues present within the dimerization 
motif of the human JAM-A D1 domain (Campbell et al., 2005, Forrest et al., 2003, 
Guglielmi et al., 2007).  Coxsackie B viruses (Picornaviridae) and most adenovirus 
(Adenoviridae) subgroups utilize the coxsackievirus and adenovirus receptor (CAR) 
(Bergelson et al., 1997). Like JAM-A, CAR has two extracellular Ig-like domains, 
localizes to tight junctions in polarized epithelial cells or to sites of cell-cell contact, 
and forms homodimers mediated by a dimerization motif within its D1 domain 
dimerization motif (Cohen et al., 2001, Martin-Padura et al., 1998). Comparable to the 
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interaction of the reovirus σ1 protein with JAM-A, the adenovirus fiber knob protein 
also interacts with residues found mostly within the dimer interface of the CAR D1 
domain (Bewley et al., 1999, Law & Davidson, 2005). Coxsackie B viruses interact 
with the distal end of the CAR D1 domain via surface residues in the canyon region of 
the capsid that surrounds the five-fold icosahedral axes (He et al., 2001). Poliovirus, 
another member of the Picornaviridae, uses a nectin-like protein PVR (the poliovirus 
receptor) (He et al., 2000). PVR contains three Ig-like loops in the extracellular 
domain; poliovirus engages the membrane distal D1 domain of PVR (He et al., 2000). 
Intercellular adhesion molecule-1 (ICAM-1) serves as the cellular receptor for three 
more members of the Picornaviridae, human rhinovirus (HRV14 and HRV16) and 
Coxsackie A virus (CAV21).  These viruses also engage ICAM-A via the membrane 
distal D1 domains of the receptor (Kolatkar et al., 1999, Olson et al., 1993, Xiao et al., 
2001). The spike glycoprotein of mouse hepatitis virus (Coronaviridae), binds to the 
murine carcinoembryonic antigen cell adhesion molecule (CEACAM) at the 
membrane distal D1 domain (Dveksler et al., 1993, Dveksler et al., 1991). Rabies 
virus (Rhabdoviridae) is able to enter cells expressing the neural cell adhesion 
molecule (CD56) (Thoulouze et al., 1998). Lastly, a PVR-like molecule, PVR-related 
protein 1, was capable of mediating the entry of several alphaherpesviruses, including 
herpes simplex virus 1 and 2, porcine pseudorabies virus, and bovine herpesvirus 1 
(Geraghty et al., 1998). It is not known what regions of fJAM-A are required for FCV 
binding, but as illustrated above, the membrane distal D1 domain of the receptor is 
likely to be involved in the interaction. 
 
1.11 Entry of nonenveloped viruses 
 To deliver their genomic material into the cytosol or nucleus in the host cell, 
viruses must breach the complex barrier of membranes surrounding the cell.  
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Enveloped viruses are surrounded by a lipid membrane; as such, delivery of the 
genome containing viral nucleocapsid is achieved following fusion of the viral and 
cellular membranes. However, nonenveloped viruses lacking a lipid bilayer must 
breach cellular membranes directly to gain access to the cytosol or nucleus. For most 
nonenveloped viruses, this is believed to occur following conformational changes 
within the capsid structure initiated by environmental or cellular factors such as 
receptors, low pH or proteases [as reviewed in (Tsai, 2007)]. 
 For polioviruses, rhinoviruses, and most related enteroviruses, the cue 
promoting conformational change within the capsid is interaction with the cellular 
receptor at physiological temperatures (Crowell & Philipson, 1971, De Sena & 
Mandel, 1977, Lonberg-Holm & Korant, 1972). The induced conformational changes 
result in the formation of a 135S altered (A-) particle. Compared to the 160S native 
picornavirus virion, the A-particle displays (a) modified sedimentation behavior, (b) 
increased hydrophobicity, and (c) altered antigenicity (De Sena & Mandel, 1977, 
Fenwick & Cooper, 1962). Structurally, the N-terminus extension of one of capsid 
protein (VP1) and an additional myristoylated capsid protein (VP4), present on the 
interior of the native virion, are externalized or released, respectively, in the 
A-particle. The exposed VP1 N-terminal extension, which is predicted to form an 
amphipathic helix, enables the A particle to attach to liposomes (Fricks & Hogle, 
1990); furthermore, A-particles form channels in planar bilayers (Tosteson & Chow, 
1997). Together, these data suggest that in the presence of receptor, the channels 
become a pore, allowing the RNA genome to be extruded into the cytosol (Hogle, 
2002). This hypothesis is supported by findings in live cells that poliovirus genome 
release is highly efficient and rapid, occurring within vesicles or membrane 
invaginations within 100-200 nm of the plasma membrane (Brandenburg et al., 2007). 
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 For the first 30 minutes of experimental infections of poliovirus, A-particles 
are the predominant form of cell-associated virus, although a significant amount of 
A-particles elute from the cells. At later times post infection however, the appearance 
of a second altered form of the virus is noted. These particles sediment at 80S and are 
devoid of the RNA genome (De Sena & Mandel, 1977).  The increase in prevalence of 
80S particles correlates with the disappearance of 135S particles (Fricks & Hogle, 
1990). The trigger for conversion to the 80S subunit is unknown, but it does not 
require receptor (Hogle, 2002). 
 For other nonenveloped viruses, such as papillomaviruses, reoviruses, and 
rotaviruses, conformational changes are triggered by cellular proteases. 
Papillomaviruses are taken into cells by endocytosis and are trafficked to the trans-
Golgi. While in the trans-Golgi, the virus is exposed to the calcium-dependent serine 
endoprotease, furin. The papillomavirus minor virion protein L2 contains a consensus 
furin recognition site. Furin cleavage of the N terminus of the L2 protein is a 
necessary step for viral infection, and recent evidence suggests that cleavage of L2 
exposes the membrane-disrupting C terminus which primes the virus for endosomal 
escape by membrane penetration (Kamper et al., 2006, Richards et al., 2006). 
Reovirus penetration of endolysosomal membranes also requires proteolytic priming 
within the endolysosomal system. Cysteinyl cathepsins B and L are responsible for the 
degradation of the reovirus outer capsid protein σ3 (Baer & Dermody, 1997, Ebert et 
al., 2002, Ebert et al., 2001). σ3 is normally in complex with an additional reovirus 
outer capsid protein, μ1; cleavage of σ3 allows for the conversion of μ1 into a 
protease-sensitive, hydrophobic conformer (Chandran et al., 2002, Liemann et al., 
2002). This structural transition primes the particle for membrane penetration 
(Chandran et al., 2002). For rotaviruses, trypsin-mediated cleavage of the outer capsid 
protein VP4 within the intestinal lumen generates a protein fragment (VP5*) that is 
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able to disrupt membranes (Denisova et al., 1999, Estes et al., 1981). This cleavage 
event is what permits rotavirus to permeabilize cellular membranes (Arias et al., 
1996). 
 Low endosomal pH is also an important cue for the conformational alterations 
of several nonenveloped viruses. Canine parvovirus (CPV) possesses a phospholipase 
(PLA2) present at the N terminus of the VP1 structural protein (Suikkanen et al., 
2003). Exposure to the acidic environment of the endolysosomal compartment 
triggered exposure of the N-terminus of VP1 and the activity of PLA2; the exact role 
of the PLA2 in parvovirus entry is unknown, but it is suggested that  it has a critical 
function in the process (Mani et al., 2006, Suikkanen et al., 2003). Adenoviruses also 
undergo conformational alterations following exposure to low pH. Studies 
investigating the effect of pH on the ability of adenovirus to penetrate membranes 
showed that endosomal acidification enhanced membrane lysis by the virus (Seth et 
al., 1984); furthermore it was discovered that capsid disassembly occurs within 
endosomes and appeared to require acidification (Greber et al., 1993). The reduced pH 
of the endosome promotes membrane lysis by destabilizing the adenovirus capsid. 
This destabilization results in the dissociation of proteins and liberates a pH-
independent membrane lytic factor (Wiethoff et al., 2005). 
 
1.12 Entry of feline calicivirus 
 Little is known about the details regarding the entry process of FCV or any of 
the other members of the Caliciviridae. The sensitivity of FCV infection to the effects 
of chloroquine suggested that FCV entry into cells requires a low pH-dependent step 
(Kreutz & Seal, 1995). Expanding on the initial studies, Stuart & Brown (2006) found 
that FCV infects cells via clathrin-mediated endocytosis. Furthermore, they showed 
that early during entry, FCV permeabilizes membranes as evident by cell 
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susceptibility to the translational inhibitor, α-sarcin. Inhibition of cellular acidification 
prevented virus-induced intoxication by the translational inhibitor, suggesting that 
acidification is a required step for virus uncoating and cytoplasmic delivery of the 
genome (Stuart & Brown, 2006). 
 Recently, a cryo-EM reconstruction of FCV (vaccine isolate F9) complexed 
with fJAM-A was determined by Bhella et al (2008). As no crystallographic structure 
has been determined for either FCV or fJAM-A, the cryo-EM data was mapped to the 
crystal structures of SMSV4 and hJAM-A, respectively. The structure showed fJAM-
A binding to FCV-F9 at 4°C induced significant alterations in the capsid structure, as 
evident by both a rotation of the P domain dimer about its local two-fold symmetry 
axis and a rotation of the S domain in the opposite direction of the P-domain rotation 
(Bhella et al., 2008). These data suggest that, as discussed for other nonenveloped 
viruses, conformational changes within the FCV particle are likely important in the 
process of entry and uncoating. 
 
1.13 Virus capsids as metastable structures 
 Interactions of poliovirus with its cellular receptor result in the formation of 
the A-particle, exposing the N terminal extension of VP1 and releasing the 
myristoylated-VP4. While the receptor induced conformation to the A particle is 
irreversible, transient and reversible exposure of the N terminal extension of VP1 and 
VP4 occurs at physiologic temperatures (Li et al., 1994). This process has been termed 
“breathing” and it has also been demonstrated in another picornavirus (rhinovirus) as 
well in the nonenveloped insect virus, Flock house virus (Nodaviridae) (Bothner et al., 
1998, Lewis et al., 1998). In rhinoviruses, “breathing” could be blocked through the 
use of WIN compounds, drugs that bind to a hydrophobic pocket in VP1 resulting in 
the stabilization of the capsid and inhibition of uncoating (Lewis et al., 1998). WIN-
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resistant mutants generally blocked the binding of the molecules to the pocket by 
altering residues adjacent to the pocket.  Although resistant to WIN compound 
neutralization, these viruses were so unstable they spontaneously lost VP4 at 
physiologic temperatures (Heinz et al., 1989, McKinlay, 1993). 
 Some plant viruses also exhibit capsid dynamics, but in the way of large-scale, 
reversible quaternary structure changes. This was first observed for Brome mosaic 
virus (BMV), an RNA virus with T=3 icosahedral symmetry, much like that found in 
the Picornaviridae and Caliciviridae. When BMV particles are treated with EDTA 
and exposed to neutral pH, the particles swell resulting in a 40 Å increase in diameter 
(Incardona & Kaesberg, 1964). Particle swelling is also observed in two other groups 
of plant viruses, the sobemovirus and tombusvirus groups [as reviewed by (Johnson, 
2003)]. Structural studies later showed that virus particle expansion is due to charge 
repulsion at the quasi-3-fold symmetry axes following deprotonation of carboxyl 
clusters postulated to bind divalent metal ions (Durham & Hendry, 1977, Robinson & 
Harrison, 1982). The biological role of plant virus swelling is unknown, and it is 
unclear whether the phenomenon represents a single function for all plant viruses in 
which it is found (Johnson, 2003). 
 The structural flexibility of particles has also been studied through the use of 
biochemical inactivators such as azridines. The picornavirus foot-and-mouth disease 
virus (FMDV) demonstrates a higher buoyant density (1.43 g/ml) than other members 
of the Picornaviridae (poliovirus, coxsackie and ECHO viruses, and swine vesicular 
disease virus) which have a buoyant density in CsCl of 1.32 g/ml. FMDV is also 
unstable below pH 7, resulting in capsid disruption and RNA release, while the 
picornaviruses mentioned above are stable at pH 3 [as reviewed in (Witz & Brown, 
2001)]. The more open structure of FMDV permits rapid inactivation by N-acetyl-
ethyleneimine (AEI), an inactivant that reacts preferentially with viral nucleic acid 
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without affecting viral proteins, at both 25° and 37°C. In contrast, while poliovirus 
particles are inactivated rapidly by AEI at 37°C (when the particles are swollen due to 
breathing), they are inactivated much slower at 25°C (Burrage et al., 2000). Like 
FMDV, vesicular exanthema of swine virus (VESV), a member of the vesivirus genus 
of the Caliciviridae with a buoyant density of 1.38 g/ml, was rapidly inactivated 
following incubation with AEI at 37°C. Suspension of virus in 1M NaCl however 
reduced the diameter of the particles from 35 nm to 25 nm, and inactivation of VESV 
by AEI was reduced considerably (Witz & Brown, 2001).  
  Of all virus particles studied to date, such particle dynamics and fluctuations 
appear to be “built-in” (Johnson, 2003). For animal viruses, these dynamics suggest 
that the viruses are primed to undergo larger, concerted, and irreversible changes upon 
interaction with specific host factors (Hogle, 2002). The observation of virus breathing 
or A-particle conversion (in the absence of receptor in hypotonic buffers) at 37°C but 
not room temperature (Li et al., 1994, Wetz & Kucinski, 1991), suggests that the 
activation energy in this conversion pathway is high.  This high activation energy may 
serve to kinetically trap the virus in a metastable state. Virus interactions with its 
receptor may then serve to lower the activation barrier for the conversion, triggering 
the conformational change. Such a barrier may be useful to the virus as it prevents 
virus aggregation that would likely occur due to the permanent exposure of the 
hydrophobic peptides (Johnson, 2003). Additionally, it would exclude entry into cells 
lacking the appropriate receptor(s).  
 
1.14 Determinants of virulence 
 When virus infection results in clinical disease within the host, the resulting 
disease symptoms may exhibit dramatic variation in their severity. In some cases, 
these variations are a product of host-mediated pathogenesis, where more aggressive 
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responses to infection result in damage to host tissues. Such is the case for the 
pathogenesis of Dengue virus (Flaviviridae), which generally causes a benign 
syndrome termed dengue fever; however, infection can also cause dengue 
hemorrhagic fever, a severe syndrome characterized by hemostatic disorders, 
increased vascular permeability, and often internal bleeding and shock (Halstead, 
1988). While virulent virus genotypes may play a minor role in causing dengue 
hemorrhagic fever (Holmes & Twiddy, 2003), current evidence suggests that the most 
likely cause of the severe syndrome is antibody dependent enhancement [as reviewed 
in (Stephenson, 2005)]. In this phenomenon, host dengue-specific antibodies bound to 
Fc receptors on the surface of monocytes and macrophages serve as co-receptor for the 
virus, enhancing the efficiency of virus binding and increasing the number of infected 
cells. Thereby, preexisting host antibodies to the virus serve to increase viral load, 
shorten incubation times, and ultimately increase disease severity. 
 Theiler’s murine encephalomyelitis virus (TMEV) is a neurovirulent 
picornavirus of mice. Upon establishing a persistent infection,  the virus induces 
axonal demyelination that leads to a spastic paralysis. The loss of myelin, however, is 
primarily immune-mediated [as reviewed in (Lipton et al., 2005)]. TMEV replication 
within the CNS triggers the expansion of virus-specific CD4+ T cells and the 
recruitment of monocytes.  Recruited monocytes differentiate into macrophages. The 
activated macrophages and cytokines secreted by the activated T cells result in 
bystander damage to the myelin sheaths. The infection, and thereby myelin damage, is 
perpetuated by TMEV infection of macrophages recruited to the site. 
 However for other viruses, such as poliovirus (Picornaviridae), virulence is 
largely determined by the viral genotype. The vast majority of poliovirus infections 
are asymptomatic and characterized by a primary, transient viremia; in about 5% of 
the cases the virus spreads and replicates in other tissues causing a secondary viremia, 
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resulting in a sore throat, headache, and/or fever (Sabin, 1956). However, in less than 
1% of poliovirus infections, paralytic disease occurs due to virus replication within 
motor neurons. Much of the work determining molecular determinants of poliovirus 
neurovirulence has been determined through the analysis of attenuated vaccine strains 
of neurovirulent isolates [as reviewed in (Blondel et al., 1998)]. While many mutations 
were found in the attenuated strains, there were several notable trends.  All three 
vaccine strains contained changes to the 5’ non coding region of the poliovirus 
genome that strongly associated with attenuation. The mutations were present within 
the internal ribosome entry site important in the initiation of translation. One 
hypothesis for attenuation is that alterations to the secondary structure of the IRES 
limit the binding of cellular initiation factors; an alternative explanation is that the 
mutations permit the binding of inhibitory factors present in neuronal cells (Blondel et 
al., 1998). Other mutations were present within the structural proteins VP1, VP3, and 
VP4 (Bouchard et al., 1995, Westrop et al., 1989). How the mutations in the structural 
proteins alter virulence is unknown, but it has been hypothesized they are implicated 
in viral uncoating or in viral assembly. While the investigation of attenuated mutants 
may provide insight for possible molecular determinants of virulence, it is difficult to 
determine if similar changes present in poliovirus populations play an important role 
in conferring neurovirulence. Nevertheless, it is clear that polioviruses are capable of 
producing a range of clinical disease that is not solely mediated by the host response. 
 In viruses that contain segmented genomes, such as reoviruses and 
bunyaviruses, genetic determinants of virulence can be tracked with the production of 
reassortant viruses. Reassortant viruses are produced following co-infection of 
permissive tissue culture cells with two different characterized viruses. By examining 
the disease phenotype produced by animals infected with the reassortant viruses and 
comparing it to the disease phenotype of the parent viruses, individual genome 
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segments can be linked with pathogenesis. Using reassortant reoviruses, many of the 
pathogenic phenotypes observed in infected mice infected have been mapped to 
specific viral gene segments (Hrdy et al., 1982, Sherry & Fields, 1989, Wilson et al., 
1994). Reassortant bunyaviruses identified that both neurovirulence and 
neuroinvasiveness map to particular genome segments (Endres et al., 1991, Janssen et 
al., 1986). 
 In birds, the virulence of influenza is determined by the ability of the virus to 
spread systemically. Systemic pathogenesis has been linked primarily to properties of 
the hemagglutinin glycoprotein (HA) [as reviewed in (Steinhauer, 1999)]. The virus 
HA serves to both bind sialic acid-containing cell surface receptors and, following 
endocytosis, mediate fusion of the viral and cellular envelopes. It is translated as a 
precursor (HA0) which is post-translationally cleaved into two subunits (HA1 and 
HA2). Cleavage of HA0 is necessary for infectivity, as it activates the fusion potential 
of the HA. For most influenza viruses, the HA is cleaved by extracellular trypsin-like 
proteases. This limits the spread of the virus to host tissues where the appropriate 
proteases are encountered (Compans et al., 1970, Laver, 1971, Skehel, 1972). In 
contrast, the HAs of highly pathogenic viruses are cleaved intracellularly. This 
cleavage is performed by the ubiquitously expressed protease furin within the 
endoplasmic reticulum (Vey et al., 1992, Walker et al., 1994). The cleavage of HA by 
intracellular proteases is made possible by either the insertion of basic amino acids 
within the peptide connecting HA1 and HA2 or the lack of a carbohydrate moiety 
(Horimoto & Kawaoka, 1995, Horimoto & Kawaoka, 1997, Kawaoka et al., 1984, 
Kawaoka & Webster, 1989). In both cases it is believed that the changes allows for 
greater accessibility of the cleavage site for activating proteases than less pathogenic 
strains. Such intracellular cleavage permits the virus to spread systemically, which in 
avian hosts is associated with high virulence. 
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 It is unknown whether the spectrum of disease syndromes observed in FCV 
infection is due to viral genotype, host response, or a combination of both. In a study 
by Foley et al (2006), affected tissues of cats experimentally inoculated with an FCV 
isolate causing systemic disease displayed elevated cytokines, suggesting that 
pathogenesis is at least partly immune-mediated. But, as the disease syndrome has 
been replicated using viruses isolated from virulent systemic outbreaks of FCV, there 
is likely a strong viral genetic component (Foley et al., 2006, Pedersen et al., 2000). 
 
1.15 Thesis Overview 
 This thesis will investigate (a) the interactions between FCV and its cellular 
receptor fJAM-A at the molecular level, and (b) the molecular determinants of 
virulence in strains of FCV that cause different clinical disease syndromes.  
 In Chapter 2, a panel of FCV field isolates from animals various clinical 
histories will be studied and sequenced in an attempt to identify in vitro properties that 
correlate with virulence in vivo.  
 Chapter 3 will examine the regions and residues of fJAM-A required for FCV 
binding and infection through the creation of deletion and chimeric receptors and 
structure guided mutagenesis studies. 
 In Chapter 4, FCV isolates resistant to neutralization by soluble fJAM-A will 
be selected and mutations mapped onto the crystal structure of FCV-5 determined at a 
resolution of 3.6 Å. Furthermore, studies looking at the hydrophobicity of viruses 
preincubated with soluble receptor will be used to determine if FCV undergoes a 
conformational change after interacting with fJAM-A. 
 Finally, Chapter 5 will present a summary of the thesis research as well as a 
discussion of future research directions. 
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CHAPTER 2 
Feline caliciviruses (FCV) isolated from cats with virulent systemic (VS) disease 
possess in vitro phenotypes distinct from other FCV isolates* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Ossiboff, R. J., Sheh, A., Shotton, J., Pesavento, P. A. & Parker, J. S. (2007). 
Feline caliciviruses (FCVs) isolated from cats with virulent systemic disease possess 
in vitro phenotypes distinct from those of other FCV isolates. J Gen Virol 88, 506-27. 
 
[Author Alex Sheh was a technician in the lab who developed the plaque assay used in 
this study. Author Justine Shotton was a Leadership Program student who helped with 
the sequencing of the proteinase-polymerase coding region. Author Dr. Patricia 
Pesavento was a collaborator on this study and provided many of the highly virulent 
FCV isolates.] 
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2.1 Abstract 
 During the past decade, several outbreaks of severe systemic disease associated 
with Feline calicivirus (FCV) have occurred in the United States and the United 
Kingdom. This new disease has caused high mortality in the affected animals and has 
been termed virulent systemic (VS)-FCV disease. Currently, there are no genetic or in 
vitro diagnostic methods to distinguish viruses isolated from cases of VS-FCV disease 
from other isolates. Here we investigated five in vitro properties as well as the capsid 
and proteinase-polymerase sequences of a set of FCV isolates that included seven 
isolates from five distinct VS-FCV outbreaks ("VS isolates"). Although all of the FCV 
isolates we investigated had similar kinetics of growth under single-cycle conditions, 
VS isolates infected tissue culture cells more efficiently under multiple-cycle growth 
conditions. Moreover, we found that cells infected with VS isolates showed cytopathic 
effects earlier than cells infected with non-VS isolates, although no difference in 
relative ATP levels were noted at times when morphologic changes were first seen. 
Both VS- and other (non-VS) isolates of FCV demonstrated similar temperature 
stabilities. Phylogenetic analyses and alignments of the capsid and proteinase-
polymerase regions of the genome did not reveal any conserved changes that 
correlated with virulence and the VS isolates did not segregate into a unique clade. 
Our results suggest that VS isolates have arisen independently several times since first 
being described and can more efficiently spread in tissue culture than other isolates 
when infected at low multiplicity. 
 
2.2 Introduction 
 Feline calicivirus (FCV) is a common pathogen of cats. Infected cats can be 
clinically normal or show signs of oral ulceration and/or mild upper respiratory 
disease. Less commonly, limping, abortion, and severe pneumonia can occur; 
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however, fatal disease is unusual (Hurley et al., 2004, Pesavento et al., 2004, Coyne et 
al., 2006). The prevalence of avirulent or mildly virulent FCV in multiple cat 
environments is as high as 36% (Binns et al., 2000, Bannasch & Foley, 2005). During 
the last decade however, epizootics of a severe form of FCV disease with mortality 
rates as high as 50% have occurred (Hurley et al., 2004, Coyne et al., 2006). These 
epizootics, designated virulent systemic (VS-) FCV, have been reported in the United 
States, and recently in the United Kingdom (Pedersen et al., 2000, Schorr-Evans et al., 
2003, Hurley et al., 2004, Coyne et al., 2006). The clinicopathologic features of VS-
FCV disease differ substantially from ‘classical’ FCV disease; reported signs of VS-
FCV disease include high persistent fever, anorexia, depression, facial and limb 
edema, sores or alopecia on the face, pinnae and feet, pulmonary edema, coagulation 
abnormalities, pancreatitis and hepatic necrosis (Pedersen et al., 2000, Hurley et al., 
2004, Pesavento et al., 2004). In all of the reported outbreaks vaccinated cats have 
been affected, suggesting that current vaccines may not protect against VS disease 
(Coyne et al., 2006).  
 FCV belongs to the Vesivirus genus of the family Caliciviridae and contains a 
positive-sense RNA genome (~ 7.6 kb) packaged within a nonenveloped capsid. The 
icosahedral capsid is assembled from 90 homodimers of the major capsid protein VP1. 
Two genogroups of FCV have been defined by phylogenetic analysis. Of the isolates 
characterized, only isolates from Japan are members of genogroup II (Sato et al., 
2002), while all other VS-FCV isolates studied to date appear to be members of 
genogroup I (Geissler et al., 1997, Glenn et al., 1999). All feline caliciviruses are 
considered to belong to a single antigenically diverse serotype, but individual isolates 
vary in their levels of cross neutralization (Kalunda et al., 1975). Initial reports 
indicate that VS-FCV isolates cannot be genetically distinguished from non-VS-FCV 
isolates (Hurley et al., 2004, Abd-Eldaim et al., 2005, Foley et al., 2006). 
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 Here we characterized the in vitro growth properties, stabilities, cytopathic 
effects and sequences of seven VS-FCV isolates from five distinct VS-FCV outbreaks 
and compared them to the F9 vaccine strain and three non VS-FCV clinical isolates. 
Based on the results herein we conclude that the cohort of VS-FCV isolates we 
analyzed share the common properties of rapid growth kinetics and an increased 
propensity to spread in tissue culture in vitro. These properties appear to differ from 
both the F9 vaccine strain and the three non VS-FCV isolates and may in part explain 
the increased virulence of these viruses in vivo. 
 
2.3 Methods 
 Cells and viruses. Crandell feline kidney (CRFK) cells were grown in Eagle’s 
minimal essential medium (EMEM) (CellGro) supplemented with 5% fetal bovine 
serum (HyClone), 100 U ml-1 of penicillin, 100 μg ml-1 streptomycin, 0.25 μg ml-1 
amphotericin B, 1 mM sodium pyruvate, and non-essential amino acids (CellGro). The 
clinical FCV isolates investigated in this study and the analyses performed are listed in 
Table 2.1. The FCV isolate VS-FCV-Ari was isolated from an infected cat during a 
VS-FCV outbreak in Sacramento, California in 1998. FCV isolates Kaos, George 
Walder, and Jengo were isolated from sick cats during a VS-FCV outbreak in Los 
Angeles, California in 2002. Isolates FCV-5, Deuce, and Georgie were isolated from 
VS-FCV infected cats from Massachusetts in 2001, North Carolina in 2004 and 
Florida in 2003, respectively. Isolates FCV-127, FCV-131, and FCV-796 were all 
obtained from Dr. Ed Dubovi at the New York State Animal Health Diagnostic Center 
at Cornell University. FCV-131 originated from a shelter in Harrisburg, PA that 
experienced an outbreak of non-VS FCV in 2003. FCV-127 came from a shelter in 
North Adams, Massachusetts where numerous cats suffered from a pneumonic form of 
FCV in 2004. FCV-796 was isolated from a cat in Tampa, Florida that presented with  
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Table 2.1. FCV isolates investigated 
 
* Single cycle growth curve 
† Multiple cycle growth curve 
‡ Thermal inactivation 
§ Temperature maintenance 
¶ ATP cell viability assay 
# Proteinase-polymerase and capsid sequencing 
 
Isolate Origin Description 
Analysis 
Kinetics Stability 
ATP¶ SEQ# 
S* M† I‡ M§ 
Ari Sacramento, CA 
VS-FCV, 
1998 x     x 
FCV-5 Bellingham, MA 
VS-FCV, 
2001 x x x x x x 
Kaos Los Angeles, CA 
VS-FCV, 
2002 x x x  x x 
Jengo Los Angeles, CA 
VS-FCV, 
2002 x     x 
George 
Walder 
Los Angeles, 
CA 
VS-FCV, 
2002 x     x 
Georgie Florida VS-FCV, 2003      x 
Deuce North Carolina 
VS-FCV, 
2004 x x x x x x 
FCV-131 Harrisburg, PA 
Non-VS-FCV, 
2003     x x 
FCV-127 North Adams, MA 
Non-VS-FCV, 
2004 x x x x x x 
FCV-796 Tampa, FL Non-VS-FCV, 2004 x x x x x x 
F9 
(VR-782) ATCC Vaccine strain x x x x x x 
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excessive drooling and lingual ulceration in 2004. For the duration of the paper, strains 
FCV-127, -131, and -796 will be referred to as “non-VS.” This designation is made 
based on the clinical history that accompanied the isolates. The F9 vaccine strain (VR-
782) of FCV was obtained from the ATCC. Third passage viral stocks were prepared 
from twice plaque purified viruses amplified in CRFK cells. 
 Plaque assay. Viruses were titrated on CRFK cells. In brief, confluent CRFK 
monolayers were inoculated with serial virus dilutions in Dulbecco’s modified Eagle’s 
medium (DMEM) (CellGro) with 0.1% BSA (Calbiochem). Viral adsorption was 
carried out at room temperature for 60 min with gentle agitation every 10 minutes. 
Monolayers were then overlaid with 3 ml of EMEM containing 5% fetal bovine 
serum, 100 U ml-1 of penicillin, 100 μg ml-1 streptomycin, 0.25 μg ml-1 amphotericin 
B, 1 mM sodium pyruvate, non-essential amino acids, and 1% Bacto-agar (Difco 
Laboratories). After incubation at 37 ºC for 48 hours in humidified 5% CO2, the 
overlay was removed, the cells fixed with 10% buffered formalin (Fisher), and stained 
with 1% (w/v) crystal violet solution. After washing, the plaques were counted and 
titer was expressed as plaque forming units per ml (p.f.u ml-1). 
 Recovery of viral RNA, RT-PCR, sequencing and analysis. Total RNA was 
extracted from infected cell culture lysates using a commercial kit (RNEasy Mini, 
Qiagen). First strand cDNA from the capsid region of the genome was synthesized 
from viral RNA using a degenerate anti-sense primer 
(5'-YTGACCMAGTGCAGYCTTRTCCAATTC-3') (adapted from Poulet et al., 
2005), predicted to anneal to bp 7380-7405 of the FCV-Urbana sequence (GenBank 
accession: L40021), and Accuscript High-Fidelity reverse transcriptase (Stratagene), 
per manufacturer’s directions. The open reading frame (ORF) was amplified by PCR 
using Pfu Ultra DNA polymerase (Stratagene) from the first strand cDNA template 
using the anti-sense primer above and a sense primer 
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(5'-TACACTGTGATGTGTTCGAAGTTTGAGC-3') (Martella et al., 2002) that 
anneals to bp 5286-5313 of the FCV-Urbana genome. Thermal cycling conditions 
were 95 ºC for 2 minutes, followed by 40 cycles of 95 ºC for 30 seconds, 50 ºC for 1 
minute, and 68 ºC, 3 minutes, with a final extension step of 68 ºC for 10 minutes. The 
resulting ~2.1 kb PCR products, encompassing the entirety of the capsid ORF, were 
purified and sequenced directly.  
 cDNA from the region encompassing the proteinase-polymerase region of 
ORF1 was amplified from viral RNA using the SuperScript One-Step RT-PCR system 
(Invitrogen) and sense (5’-ATTGGVAARGGYGGYGTNAARMAY-3’) and anti-
sense (5’-AGCACGTTAGCGCAGGTT-3’) primers predicted to anneal to bp 3143-
3166 and 5322-5339 of the FCV-Urbana genome, respectively. Thermal cycling 
conditions consisted of 50º C for 30 minutes, 94º C for 2 minutes, 5 cycles of 94º C 
for 15 seconds, 52º C for 1 minute, 72º C for 2.5 minutes, followed by 35 cycles of 94º 
C for 15 seconds, 52º C for 30 seconds, 72º C for 2.5 minutes, with a final extension 
step of 72º C for 10 minutes. The resulting ~2.2 kb PCR products were cloned into the 
pGEM T-Easy Vector (Promega) and sequenced by the Cornell University Life 
Sciences Core Laboratories Center. 
 Sequences were compared to other FCV capsid or proteinase-polymerase 
sequences contained in the NCBI Nucleotide database 
(http://www.ncbi.nlm.nih.gov/entrez/) (Table 2.2). Determination of ORFs and amino 
acid sequence was performed using Vector NTI Advance (Invitrogen Life 
Technologies). Sequence alignments were carried out using ClustalX (Thompson et 
al., 1997). Similarity tables were constructed using Vector NTI Advance. Construction 
of phylogenetic trees inferred from nucleotide sequence was performed using 3 
methods: the distance (neighbor-joining) method using the ClustalX software, the 
Bayesian method with the software MRBAYES (Huelsenbeck and Ronquist, 2001,  
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Table 2.2. FCV Isolates used in sequence analysis 
 
Isolate Genbank Accession(s) Reference* 
FCV-127 DQ910786¶,# This paper 
FCV-131 DQ910787¶,# This paper 
FCV-796 DQ910788¶,# This paper 
Deuce† DQ910789¶,# This paper 
FCV-5† DQ910790¶,# This paper 
Georgie† DQ910791¶,# This paper 
George Walder† DQ910792¶,# This paper 
Jengo† DQ910793¶,# This paper 
Ari† DQ910794¶,# This paper 
Kaos† DQ910795¶,# This paper 
UTCVM-NH1 AY560113¶,# Abd-Eldaim et al. (2005) 
UTCVM-NH2 AY560114¶,# Abd-Eldaim et al. (2005) 
UTCVM-NH3 AY560115¶,# Abd-Eldaim et al. (2005) 
UTCVM-H1† AY560116¶,# Abd-Eldaim et al. (2005) 
UTCVM-H2† AY560117¶,# Abd-Eldaim et al. (2005) 
USDA AY560118¶,# Abd-Eldaim et al. (2005) 
182cvs5A AF031875¶ Baulch-Brown et al. (1999) 
V83A AF031876¶ Baulch-Brown et al. (1999) 
V274 AF031877¶ Baulch-Brown et al. (1999) 
V276 AF032106¶ Baulch-Brown et al. (1999) 
V77 AF038126¶ Baulch-Brown et al. (1999) 
F9‡ M86379¶,# Carter et al. (1992) 
2280 X99445¶ Geissler et al. (1997) 
KS109 X99446¶ Geissler et al. (1997) 
KS20 X99447¶ Geissler et al. (1997) 
KS40 X99448¶ Geissler et al. (1997) 
KS8 X99449¶ Geissler et al. (1997) 
LS015 AF109464 Glenn et al. (1999) 
F65 AF109465¶,# Glenn et al. (1999) 
JOK63 AF109466¶ Glenn et al. (1999) 
LS012 AF109467¶ Glenn et al. (1999) 
A4 AF109468¶ Glenn et al. (1999) 
213/95 AF283778¶ Martella et al. (2002) 
CVXPOLYCYS M32296# Neill et al. (1990) 
CFI/68 M32819¶; U13992# Neill et al. (1991); 
Unpublished 
NADC L09718¶ Seal et al. (1993) 
KCD L09719¶ Seal et al. (1993) 
255 U07130¶ Seal & Neill (1995) 
LLK U07131¶ Seal & Neill (1995) 
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Table 2.2 (Continued) 
 
Urbana L40021¶,# Sosnovtsev & Green (1995) 
FCV2024‡ AF479590¶,# Thumfart & Meyers (2002) 
F4‡ D90357¶;D31836# Tohya et al. (1991); Oshikamo 
et al.(1994) 
FCV-U1 AF357010¶ Unpublished 
AF486286 AF486286¶ Unpublished 
V66/97 AJ009721¶ Unpublished 
FCV-U2 AY053460¶ Unpublished 
Cranleigh AY299541¶ Unpublished 
FCV/DD/2006/GE DQ424892¶,# Unpublished 
FRG§ NC_001543# Meyers et al. (2000) 
whn/China/03/2005§ DQ069282¶ Unpublished 
* The reference cited is the first publication to provide sequence for the isolate.  
Isolates designated as unpublished do not have a publication associated with 
the accession. 
† VS-FCV isolate 
‡ Vaccine strain 
§ Rabbit hemorrhagic disease virus (RHDV) isolate used as outgroup 
¶ Capsid sequence 
# Proteinase-polymerase sequence 
 
Ronquist and Huelsenbeck, 2003), and the maximum-likelihood method using the 
software PAUP* Version 4.0 Beta (Sinauer Associates). Neighbour-joining and 
maximum-likelihood generated trees were bootstrapped with the corresponding, 
aforementioned software. Construction and bootstrapping of phylogenetic trees 
inferred from amino acid sequence was performed using ClustalW utilizing the 
BLOSUM series (80, 62, 40 and 30) weight matrices for proteins. Constructed trees 
were visualized using NJPLOT (Perriere & Gouy, 1996). 
 Temperature inactivation and stability experiments. Thermal inactivation 
of virus isolates was performed using a thermal cycler (MyCycler, BioRad). Virus 
samples were incubated at 37.0, 41.8, 46.2, 52.2, 56.9, and 62.0 °C in thin-wall PCR 
tubes (Fisher) for 30 min then plaque titrated. Viral stability was investigated by 
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maintaining virus in aliquots at room temperature, 4 ºC, and -80 ºC for up to 10 weeks. 
Aliquots in triplicate were plaque titrated at regular intervals. 
 Generation of single- and multiple-cycle growth curves. CRFK cell 
monolayers were infected with different FCV isolates at multiplicities of 5 and 0.01, 
for single- and multiple-cycle growth curves respectively. Virus was adsorbed to cells 
for 1 h at room temperature in DMEM plus 0.1% BSA; EMEM plus 5% fetal bovine 
serum supplemented as above was then added and the cells were incubated for various 
times at 37 °C in 5% CO2. At various times post-infection samples were frozen and 
stored at -80 °C for later titration. Prior to plaque assay, all samples were frozen and 
thawed three times. Viral growth at each time point was calculated by subtracting the 
log10 p.f.u ml-1 at T = 0 from the log10 p.f.u ml-1 measured at the time point. Results 
are expressed as the change in plaque titer over time with the mean and standard 
deviation of three replicates shown. 
 Cell viability assay. The viability of infected CRFK cells was evaluated using 
a commercial assay of ATP levels (CellTiter-Glo Reagent, Promega) according to the 
manufacturer’s recommendations. 96-well plates were read using a Veritas Microplate 
Luminometer (Turner Biosystems). Relative luminescence units of experimental wells 
were compared to control wells to determine percent change in ATP. 
 Statistical analyses. Comparisons of titer levels between sets of three 
replicates were analyzed by ANOVA using the Analyse-it (Analyse-it Software) 
statistical analysis add-in for Microsoft Excel. Graphs were prepared using 
Kaleidagraph (Synergy Software). 
 
2.4 Results 
 Single cycle kinetics of growth of different FCV isolates in CRFK cells. We 
compared the growth kinetics of nine FCV isolates that differed in virulence (Table  
56 
Figure 2.1. Single and multiple cycle growth kinetics of selected FCV isolates. 
CRFK monolayers were infected with viruses at an m.o.i. of (A) 5 or (B) 0.01 and 
change in viral titer was determined by plaque assay. The mean log10 titer (log10 titer 
at each time point minus log10 titer at T=0) of three replicates is shown. Isolates from 
cats diagnosed with VS disease are shown with solid lines and hollow markers. The 
vaccine strain and non-VS isolates are displayed with dashed lines and solid markers. 
Significant time points as determined by analysis of variance are indicated (*). 
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2.1). We found that all of the FCV isolates tested grew rapidly during a single round 
of viral replication that was characterized by a lag phase of ~ 3.5 h followed by  
logarithmic growth that lasted 3 to 4.5 h (Figure 2.1A). Peak yields of virus were 
produced for all except vaccine strain, F9, at 8-12 h post-infection. We noted that viral 
yield of all the isolates except F9 decreased 0.5 to 1 log10 from peak titer at 8-12 h 
post-infection by 24 h post-infection. The single cycle growth kinetics of VS-FCV 
isolates were not statistically different from those of non-VS isolates; however, cells 
infected with the VS-FCV isolates Ari and Deuce yielded the most virus (2.5 log10). 
We conclude that FCV isolates have a short replicative cycle in CRFK cells (10 to 12 
h) and that FCV isolates of differing virulence have similar single cycle growth 
kinetics, but may differ in the final yield of virus produced. 
 Multiple cycle kinetics of growth of FCV in CRFK cells. We noted that 
virulent FCV isolates tended to produce larger plaques and hypothesized that these 
isolates would spread faster than less virulent isolates in tissue culture. We therefore 
examined the growth kinetics of three VS-FCV isolates, two non-VS isolates, and the 
vaccine strain, F9, during multiple replicative cycles to evaluate their ability to spread 
in tissue culture. Consistent with their larger plaque size, we found that the growth 
kinetics of VS-FCV isolates were faster than those of non-VS isolates (Figure 2.1B). 
By 4 h post-infection (h p.i.) the titers of VS-FCV isolates were increasing 
logarithmically, and had yielded 2 log10 of infectious virus. In contrast, the vaccine 
strain F9 and isolate 796 had not yet entered logarithmic growth. FCV-127, a non-VS 
isolate that produced large plaques, was growing logarithmically at 4 h p.i., but had 
produced 10-fold less infectious virus than the three VS-FCV isolates. The differences 
in log titers at 4 and 8 h p.i. between the VS-FCV and non-VS isolates were 
statistically significant as determined by analysis of variance (p <0.0001). The final 
yields of virus varied; however, the two highest yields (~5.5 and 4.8 log10) were 
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attained by VS-FCV isolates Deuce and Kaos, respectively. From these results we 
conclude that VS-FCV isolates appear to produce infectious virions earlier when cells 
are infected at low multiplicity and may attain higher yields than less virulent isolates 
in CRFK cells. 
 Cytopathic effect of different FCV isolates. During the multiple cycle 
growth kinetic experiments, we noted that cells infected with VS-FCV isolates 
displayed morphologic changes of rounding and detachment from the vessel surface 
earlier than other FCV isolates (Figure 2.2A). From 14 h p.i. onwards, we frequently 
observed clusters of VS-FCV infected cells that were rounded up and partially or fully 
detached from the plate surface. In contrast, few non-VS isolate-infected cells 
displayed such morphologic changes at 14 h p.i. and larger clusters of cells with such 
morphologic alterations were absent. Non-VS isolate FCV-127, which was isolated 
from a kitten with severe pneumonia, caused more severe morphologic changes than 
isolate FCV-796 suggesting that the severity of the cytopathic effects we saw in part 
correlated with virulence. These observations suggested that VS-FCV isolates caused 
increased cytopathogenicity. The mechanisms that underlie FCV cytopathogenicity are 
not fully understood, although FCV infection is known to induce apoptosis (Roberts et 
al., 2003, Sosnovtsev et al., 2003, Natoni et al., 2006). To test the possibility that VS-
FCV isolates caused increased cytopathic effect in infected cells, we measured the 
intracellular ATP levels of cells infected with VS-FCV, non-VS isolates and the F9 
vaccine strain at different times after infection in cells infected at multiplicities of 0.01 
and 5 (Figures 2.2B and 2.2C). Intracellular ATP levels have been used to quantify the 
cytotoxic effect of the cytokine tumor necrosis factor α (Crouch et al., 1993) and as an 
indicator of the cytopathic effect of murine leukemia virus on CHO-K1 cells (Bruce et 
al., 2005). Under multiple cycle growth conditions (m.o.i. = 0.01), at 14 h p.i. cells 
infected with VS-FCV isolates had ATP levels that were equal to or higher than  
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Figure 2.2. Intracellular ATP levels in FCV-infected cells. 
(A) Confluent monolayers of CRFK cells were infected with the indicated FCV 
isolates at an m.o.i. of 0.01. At 14 h p.i. phase contrast images of cell morphology 
were collected using a 40× objective with a CCD camera. (B) Intracellular ATP levels 
in CRFK monolayers at different times following infection with viruses under multiple 
cycle conditions (m.o.i of 0.01) (C) or single cycle conditions (m.o.i. of 5). ATP levels 
were expressed as a percentage of the mean level of mock-infected cells. Each data 
point represents the mean ± standard deviation of three replicates. For clarity, the T=0 
h data point in graph (B) has been omitted and an axis break is indicated between 0 
and 12 h p.i. The omitted data point was not statistically different from the results 
determined at T=12 h. Isolates from cats diagnosed with VS disease are shown with 
solid lines and hollow markers. The vaccine strain and non-VS isolates are displayed 
with dashed lines and solid markers. 
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control levels, despite obvious changes in cell morphology (Figure 2.2A). ATP levels 
in cells infected with all FCV isolates diverged from control levels by 16 to 20 h p.i. 
(Figure 2.2B). Non-VS isolates 796 and 131 demonstrated the most rapid decrease in 
ATP with levels at 50% of control levels at 20 h p.i. For all of the isolates we 
investigated, the cellular ATP levels dropped to 25-50% of control levels by 24 h p.i. 
Under single cycle growth conditions (m.o.i. = 5), ATP levels in infected cells fell 
below control levels at 10 to 14 h p.i. (Figure 2.2C). Cells infected with the vaccine 
strain F9 displayed the earliest divergence from uninfected control ATP levels at 10 h 
p.i. By 14 h p.i., cells infected with non-VS isolates had ATP levels that were only 25-
50% of the levels of the uninfected control, whereas, cells infected with VS-FCV 
isolates maintained ATP levels 70-90% of the control. We conclude that under 
multiple cycle conditions cells infected with VS-FCV isolates show cytopathic effects 
as early as 14 h p.i., although the ATP content of those cells is similar to uninfected 
cells. In addition, under single cycle conditions, cells infected with VS-FCV isolates 
maintain ATP levels longer than cells infected with the non-VS isolates and the 
vaccine strain F9. 
 Temperature inactivation of different FCV isolates. During VS-FCV 
outbreaks, rapid virus spread has been mediated partly by fomites (Pedersen et al., 
2000, Schorr-Evans et al., 2003, Hurley et al., 2004). These observations suggested to 
us that VS-FCV isolates might be more environmentally stable than non-VS isolates. 
To address this possibility, we examined the resistance of selected isolates to thermal 
inactivation (Table 2.1 and Figure 2.3). Aliquots of virus were incubated at 37.0, 41.8, 
46.2, 52.2, 56.9, and 62.0 °C for 30 minutes in a thermal cycler and then assayed for 
infectivity by plaque assay. We found that all isolates substantially lost infectivity 
following a 30 minute incubation at 46.2 °C (Figure 2.3). The F9 vaccine strain was 
most sensitive to thermal inactivation, losing all infectivity following 30 min  
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Figure 2.3. Thermal inactivation of FCV. Virus aliquots were incubated for 30 
minutes at the indicated temperatures, and then the remaining infectivity was 
determined by plaque assay. Each data point represents the mean log10 p.f.u ml-1 ± 
standard deviation of three replicates. Isolates from cats diagnosed with VS disease are 
shown with solid lines and hollow markers. The vaccine strain and non-VS isolates are 
displayed with dashed lines and solid markers. 
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incubation at 52.2 °C. The other isolates were fully inactivated at 56.9 °C, except for 
isolate FCV-5 (fully inactivated at 62 °C). We conclude that all of the isolates we  
examined were more resistant to thermal inactivation than F9, but exhibited differing 
temperature stabilities with respect to each other. 
 Stability of different FCV isolates at room temperature, 4 °C and -80 °C. 
We further evaluated the stabilities of different FCV isolates, by assaying their 
infectivity following extended incubations at room temperature, 4 °C and -80 °C 
(Figure 2.4). Isolates stored at room temperature lost 2 to 5 log10 of infectivity after 
three days, with the two VS-FCV isolates Deuce and FCV-5 and the non-VS isolate 
127 decreasing in infectivity by 2 to 3 log10 and the vaccine strain F9 and non-VS 
isolate 796 decreasing by 4 to 5 log10. By day 6, isolates FCV-5, 796 and F9 had 
completely lost infectivity. FCV-Deuce completely lost infectivity by day 10, while 
isolate 127 retained a low level of infectivity at the conclusion of the 12 day 
experiment (Figure 2.4). We noted that as viral titers dropped, the variability of the 
plaque assays increased with standard deviations ranging from 0.75 to 2 log10. We 
found no obvious correlation between the temperature stability of different FCV 
isolates and their virulence. 
 When a limited set of isolates, the vaccine strain F9 and two VS-FCV isolates 
(FCV-5 and Deuce) were maintained at 4 ºC, we observed that the vaccine strain F9 
began to drop in titer by the 10th day of the experiment (Figure 2.4). The VS-FCV 
isolates maintained full infectivity until day 21. By the third week, all isolates 
exhibited similar rates of infectivity loss and by 6 to 10 weeks had completely lost 
infectivity. Although the two VS-FCV strains demonstrated enhanced stability over 
the vaccine strain at 4 °C during the first two weeks of storage, further testing will be 
necessary to confirm that VS-FCV isolates are more stable at 4 °C than other FCV 
isolates. Similar to our findings above, as viral titers dropped, the variability of the  
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Figure 2.4. Stability of FCV over time when maintained at room temperature, 4 ºC 
and -80 ºC. Aliquots of virus were maintained at room temperature, 4 °C, and -80 °C 
for the indicated number of days then the remaining infectivity was determined by 
plaque assay. Each data point represents the mean log10 p.f.u ml  of three replicates. 
As viral titers dropped, the variability of the plaque assays increased. Standard 
deviations ranged from 0.75 to 2 log10 beginning on the fourth day of the room 
temperature experiment, and from 1.5 to 3 log10 beginning on day 35 of the 4 °C 
experiment. Therefore, the standard deviation bars have been omitted for clarity. 
Titers were also observed to oscillate around the zero titer mark for isolates FCV-5, 
Deuce, F9, and 796 by values up to 1.5 log10 (RT assay) and 3 log10 (4 °C assay). 
These data points have also been omitted for clarity. The first data point indicating 
loss of infectivity is indicated (*). Isolates from cats diagnosed with VS disease are 
shown with solid lines and hollow markers. The vaccine strain and non-VS isolates are 
displayed with dashed lines and solid markers. 
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plaque assays increased. None of the isolates tested lost infectivity when stored at 80 
°C for 8 weeks (Figure 2.4).  
 Sequence comparison of VS-FCV isolates and other FCV isolates. 
Abd-Eldaim et al. (2005) and Foley et al. (2006) have suggested that certain residues 
within the hypervariable region of the capsid protein sequence are unique to VS-FCV 
isolates. We therefore sequenced the capsid VP1-encoding second ORF of the FCV 
genome for all the isolates and performed nucleotide and primary amino acid sequence 
alignments and phylogenetic analyses to investigate the relatedness of these sequences 
and 37 other FCV complete capsid sequences (Table 2.2). Capsid amino acid sequence 
alignments (ClustalW) revealed that no residues were unique to the VS-FCV isolates 
we investigated. We used Rabbit hemorrhagic disease virus (RHDV), a Calicivirus in 
the genus Lagovirus, as an outgroup to root the phylogenies. Using nucleotide 
(neighbor-joining method) and amino acid (BLOSUM) based phylogenies, we found 
that the VS-FCV isolates did not form a unique clade (Figures 2.5A and B). As 
expected, isolates collected from the same outbreak of VS-FCV in Los Angeles, CA in 
2002 (George Walder, Jengo, and Kaos) clustered together in nucleotide and amino 
acid analyses, with determined bootstrap values of 100%. The VS-FCV isolates Ari, 
Georgie, Deuce and FCV-5 as well as two other previously described VS-FCV isolates 
(Abd-Eldaim et al., 2005) were not closely related. Trees generated utilizing the 
Bayesian method and maximum likelihood method of phylogenetic inference also 
showed a clustering of the three VS-FCV isolates from the Los Angeles outbreak 
while the remainder of the VS-FCV isolates were scattered throughout the tree. 
 We also sequenced the portion of the first ORF that encodes the proteinase-
polymerase (pro-pol). Sequences from isolates investigated in this paper were 
compared with 14 previously published pro-pol sequences (Table 2.2). Similar to  
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Figure 2.5. Phylogenetic analysis of FCV capsid nucleotide and protein 
sequences. Phylogenetic analysis was performed on the (A) nucleotide sequences and 
(B) protein sequences of ORF2 for all the FCV isolates used in this study and 37 other 
FCV sequences obtained from Genbank. Trees were generated using the nearest-
neighbor distance method. Rabbit hemorrhagic disease virus (RHDV) was used as an 
outgroup for each analysis; outgroup branch lengths have been shortened for 
simplicity. VS-FCV isolates sequenced in this paper (*), VS-FCV isolates previously 
sequenced (†), and FCV field isolates sequenced in this paper (‡) are indicated. 
Vaccine strains are underlined, and the strain name provided in parentheses. Bootstrap 
values greater than 90% are indicated. 
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Figure 2.6. Phylogenetic analysis of FCV proteinase-polymerase nucleotide and 
protein sequences. Phylogenetic analysis was performed on the (A) nucleotide 
sequence and (B) protein sequence of the proteinase-polymerase for all FCV isolates 
used in this study and 14 other FCV sequences obtained from GenBank. Trees were 
generated using the nearest-neighbor distance method. Rabbit hemorrhagic disease 
virus (RHDV) was used as an outgroup for each analysis; outgroup branch lengths 
have been shortened for simplicity. VS-FCV isolates sequenced in this paper (*), VS-
FCV isolates previously sequenced (†), and FCV field isolates sequenced in this paper 
(‡) are indicated. Vaccine strains are underlined, and the strain name provided in 
parentheses. Bootstrap values greater than 90% are indicated. 
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results from the capsid region, pro-pol sequence alignments (ClustalW) revealed no 
residues unique to the VS-FCV isolates investigated. The overall nucleotide identity 
was 80.6 ± 3.1% and the amino acid identity was 92.9 ± 2.1%. This was not different 
than the nucleotide (82.6 ± 5.4%) or primary amino acid (94.4 ± 2.2%) sequence 
similarity between the VS- isolates investigated. Phylogenetic trees were rooted as 
above, using the sequence of the RHDV pro-pol. Both nucleotide (neighbor-joining 
method) and amino acid (BLOSUM) based phylogenies were similar to those of the 
capsid sequences and VS-FCV isolates did not segregate from other FCV isolates 
(Figures 2.6A and B). The three isolates from the 2002 Los Angeles outbreak grouped 
together (bootstrap values of 100%). The sequences of the other VS-FCV isolates 
Deuce, Georgie, FCV-5, Ari, and the two Tennessee isolates were not closely related. 
Similar results were obtained when phylogenies were inferred using Bayesian and 
maximum-likelihood methods. We conclude that VS-FCV isolates do not represent a 
unique clade of FCV, but instead appear to have arisen independently multiple times 
in different geographic locations. 
 
2.5 Discussion 
 The reported outbreaks of VS-FCV have been characterized by severe clinical 
disease, rapid spread and high mortality rates (Pedersen et al., 2000, Schorr-Evans et 
al., 2003, Hurley et al., 2004, Pesavento et al., 2004, Coyne et al., 2006). As 
vaccinated cats appear to be as susceptible to this form of FCV as unvaccinated cats, 
disease control is currently problematic. A major difficulty is that viruses associated 
with VS disease cannot be distinguished from other FCV isolates in vitro. One study 
reported that sequences from a small set of VS-FCV isolates were no more similar to 
each other than to other non-VS field isolates of FCV (Abd-Eldaim et al., 2005). 
Despite this, the disease has been reproduced in experimental animals indicating that 
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the genetic differences are likely hidden by the high variability of the FCV genome 
(Pedersen et al., 2000). The initial goal of our study was to identify in vitro 
phenotypes of VS-FCV isolates that would distinguish them from other less virulent 
FCV isolates and which could be used as a correlate to identify the underlying 
genotype(s) associated with FCV virulence. 
 Previous reports have described the single cycle growth kinetics of “classical” 
isolates of FCV (Studdert et al., 1970, Kreutz & Seal, 1995). This is the first report of 
single cycle growth kinetics of VS-FCV isolates, as well the first report of multiple 
cycle growth kinetics for any FCV isolate. All of the FCV isolates we investigated 
displayed similar single cycle growth kinetics, and our findings are generally similar 
to those previously published (Studdert et al., 1970, Kreutz & Seal, 1995). Although 
VS- and non-VS isolates displayed similar kinetics, the VS-FCV isolates tended to 
replicate to higher titer suggesting higher per cell yields. In contrast, during multiple 
cycle growth we observed that the three VS-FCV isolates produced infectious virions 
earlier and/or to substantially higher titer than the vaccine/non-VS isolate group. 
Given that the VS- and non-VS isolates had similar kinetics of growth during a single 
cycle of replication, these findings indicate that VS-FCV isolates infect CRFK cells 
more efficiently than non-VS strains. Such efficiency suggests that differences in virus 
attachment, entry, establishment of replication sites or release from cells may 
determine the increased growth of VS-FCV isolates and perhaps play a role in the 
increased pathogenicity of VS-FCV isolates. 
 In addition to more efficient infection, we also observed that cells infected with 
VS-FCV isolates at a low multiplicities displayed cytopathic effects earlier than those 
infected with non-VS field isolates or the vaccine strain. Surprisingly, VS-FCV 
infected cells had similar or higher ATP levels than the uninfected controls at time 
points when cytopathic effects were first readily seen. Under single cycle conditions, 
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VS-FCV-infected cells maintained ATP levels for longer than the non-VS isolates. By 
maintaining cellular ATP levels, VS-FCV isolates may delay the onset of the final 
stages of apoptosis, thus allowing the production and/or release of more virus 
particles. Recently it was reported that intracellular pools of ATP and other 
nucleotides are able to directly block cytochrome C-initiated apoptosome formation 
and caspase activation (Chandra et al., 2006). Alternatively, maintaining intracellular 
ATP levels may serve to promote energy-dependent apoptotic cell death and prevent 
cellular necrosis (Chiarugi, 2005). This may prove advantageous to viral replication in 
vivo by limiting the inflammatory reaction initiated by necrotic cells. 
 Fomite transmission has been implicated as an important factor in the rapid 
spread observed during the documented VS-FCV outbreaks (Pedersen, et al., 2000, 
Hurley, et al., 2004). We therefore hypothesized that VS-FCV isolates might possess 
increased environmental stability over non-VS isolates. However, while individual 
isolates displayed minor differences in their sensitivity to temperature inactivation, 
there was no correlation with virulence. We noted, however, that the vaccine strain F9 
was completely inactivated at a lower temperature than the other isolates we tested, 
suggesting that some capsid stability was lost during the selection for attenuation of 
the F9 strain. The F9 strain has been extensively used to evaluate the sensitivity of 
caliciviruses to environmental inactivation by various methods (Duizer et al., 2004, 
Tree et al., 2005, Malik et al., 2006). Our results suggest that these findings should be 
tempered by the knowledge that field strains may be more resistant to inactivation than 
vaccine strains. 
 Minor differences in stability between isolates after extended incubation at 
room temperature or 4 °C did not correlate with virulence. In contrast to a previous 
report that indicated that virions were more stable when maintained at 4 °C 
(Komolafe, 1979), we found that all of the isolates we tested lost infectivity when 
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stored for longer than 2-3 weeks at 4 °C, but retained full infectivity when stored at -
80 °C. The reasons for these differences are unclear, but may be due to stabilizing 
effects of serum proteins within the lysate (Komolafe, 1979). Additionally, we also 
found that infectivity was maintained after as many as 56 freeze/thaw cycles. 
Therefore, FCV appears to tolerate multiple freeze/thaw cycles without loss of 
infectivity, indicating that storage of viral lysates at -80 °C is optimal.  
 Previous analyses of the capsid and pro-pol sequences of VS-FCV isolates 
found them to be no more similar to each other than to other non-VS isolates (Hurley 
et al., 2004, Abd-Eldaim et al., 2005, Foley et al., 2006). Our sequence analyses 
support these conclusions and suggest that the different VS-FCV isolates have arisen 
independently in distinct geographic locations. These studies also suggested that there 
were amino acid sequences within the hypervariable region (residues 426-452) of the 
capsid that were unique to VS-FCV isolates. However, when we analyzed all the 
available VS-FCV sequences together, we found there were no sequences or amino 
acid changes unique to all VS- isolates in the capsid or pro-pol regions. 
 We recognize that many of our conclusions are based on two assumptions.  
The first is that the VS-FCV samples we are characterizing still possess the virulent 
nature of the original isolate. Passage in tissue culture has been limited to prevent 
selection of variants. Furthermore, three of the isolates we characterized have been 
used to reproduce the VS-FCV disease in cats (Ari, Pedersen et al., 2000; FCV-5, 
Rong et al., 2006; Kaos, unpublished).  While the other isolates have not been tested in 
vivo, the experience thus far is that VS-FCV isolates can be passed at least three times 
in tissue culture without loss of virulence, and perhaps up to 20 times (Rong, et al., 
2006). The second is that all strains considered non-VS isolates do not cause VS 
disease. However, it is possible that many cases of VS-FCV go undetected. The 
investigated isolate FCV-127 originated from a shelter where numerous cats died due 
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to pneumonia. In all experiments, isolate 127 behaved more like a VS-FCV isolate 
than the other non-VS field isolates. Thus, we speculate that the differences in viral 
growth patterns we noted between VS and non-VS viruses may in fact be shared by 
other ‘virulent’ FCV isolates. Currently, the only means to verify a particular isolate 
causes VS disease is by reproducing the disease syndrome in an experimentally 
infected cat.   
 In summary, we have investigated several viral characteristics in an attempt to 
define an in vitro phenotype unique to virulent systemic strains. Our findings indicate 
that there are differences between VS and non-VS isolates that may serve as markers 
for virulence. We are currently further evaluating the genetic bases of these 
differences. 
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CHAPTER 3 
Identification of regions and residues in feline junctional adhesion molecule A 
(fJAM-A) required for feline calicivirus (FCV) binding and infection*  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Ossiboff, R. J. & Parker, J. S. (2007). Identification of regions and residues in 
feline junctional adhesion molecule required for feline calicivirus binding and 
infection. J Virol 81, 13608-21.
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3.1 Abstract 
 The feline junctional adhesion molecule A (fJAM-A) is a functional receptor 
for feline calicivirus (FCV). fJAM-A is a member of the immunoglobulin superfamily 
(IgSF) and consists of two Ig-like extracellular domains (D1 and D2), a membrane-
spanning domain, and a short cytoplasmic tail. To identify regions of fJAM-A that 
interact with FCV, we purified recombinant fJAM-A ecto-, D1, and D2 domains. We 
found that preincubation of FCV with the ectodomain or D1 was sufficient to inhibit 
FCV infection in plaque reduction assays. In ELISA assays, FCV binding to fJAM-A 
ectodomain was concentration-dependent and saturable; however, FCV bound D1 
alone weakly and was unable to bind D2. To characterize FCV binding to surface 
expressed fJAM-A, we transfected truncated and chimeric forms of fJAM-A into a 
non-permissive cell line and assayed binding by flow cytometry. Only D1 was 
necessary for FCV binding to cells and all other domains could be replaced. Using a 
structure-guided mutational approach, we identified three mutants of fJAM-A within 
D1 (D42N, K43N and S97A) that exhibited a significantly decreased capacity to bind 
FCV.  In contrast to our finding that D1 mediated FCV binding, we found that all 
domains of fJAM-A were necessary to confer susceptibility to FCV infection. 
Furthermore, surface expression of fJAM-A was not sufficient to permit FCV 
infection by all of the isolates we investigated. This indicates that (i) other cellular 
factors are required to permit productive FCV infection, and (ii) that individual FCV 
isolates differ in what factors they require. 
 
3.2 Introduction 
 Members of the Caliciviridae are small, nonenveloped viruses that carry a 
positive-stranded RNA genome of ~7-8 kb. Despite including important human and 
animal pathogens, the Caliciviridae family is relatively understudied. Feline 
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 caliciviruses (FCVs), members of the Vesivirus genus, are highly contagious 
pathogens that cause a variety of mild to severe disease syndromes in cats. Recently, 
feline Junctional Adhesion Molecule-A (fJAM-A) was identified as a functional 
receptor for FCV, the first proteinaceous receptor identified for any member of the 
Caliciviridae (Makino et al., 2006). 
 Virus entry often requires multiple interactions between virus particles and cell 
surface receptors. These interactions are critical determinants of productive virus entry 
and are often important factors in viral pathogenesis. Increasingly, it is being found 
that viral entry is not a passive process, but often involves activation of distinct 
cellular signaling pathways that program correct endocytic uptake of the viral particle 
and/or prime the cell for viral replication (Marsh & Helenius, 2006). Both a 
carbohydrate (α-2,6 sialic acid) and the cell surface glycoprotein fJAM-A have been 
shown to be involved in FCV binding to cells (Makino et al., 2006, Stuart & Brown, 
2007). The roles these molecules play in FCV entry have not been determined.  
 JAM-A is a type I transmembrane glycoprotein (MW 36-41 kDa) and a 
member of the immunoglobulin superfamily (IgSF). It consists of a N-terminal signal 
peptide, an extracellular domain (composed of two Ig-like domains - a membrane-
distal D1 and a membrane-proximal D2), a transmembrane domain, and a short 
cytoplasmic domain (Ebnet et al., 2000, Mandell & Parkos, 2005). JAM-A localizes to 
intercellular tight junctions of endothelial and epithelial cells in humans and mice, and 
is expressed on the surface of platelets, leukocytes and erythrocytes (Liu et al., 2000, 
Mandell et al., 2004, Martin-Padura et al., 1998, Ozaki et al., 1999). In solution, JAM-
A forms homodimers that are stabilized by ionic and hydrophobic interactions 
between residues in the D1 domain dimerization motif. Homodimer formation is 
critical in establishing a regulated tight junctional barrier between cells, and it is 
thought that homophilic interactions between JAM-A dimers on opposing cell surfaces 
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 are important for forming intercellular tight junctions (Liu et al., 2000, Mandell et al., 
2004, Martin-Padura et al., 1998, Ozaki et al., 1999, Williams et al., 1999). JAM-A is 
also believed to play an important role in modulating leukocyte diapedesis and platelet 
aggregation (Babinska et al., 2002a, Babinska et al., 2002b, Khandoga et al., 2005, 
Malergue et al., 1998, Martin-Padura et al., 1998).  
 Several different virus families use IgSF cell surface proteins as receptors. The 
σ1 attachment protein of mammalian orthoreoviruses (Reoviridae) engages residues 
present within the dimerization motif of the human JAM-A D1 domain (Barton et al., 
2001, Campbell et al., 2005, Forrest et al., 2003, Guglielmi et al., 2007). Coxsackie B 
viruses (Picornaviridae) and most adenovirus (Adenoviridae) subgroups utilize the 
coxsackievirus and adenovirus receptor (CAR) (Bergelson et al., 1997). Like JAM-A, 
CAR has two extracellular Ig-like domains, localizes to tight junctions in polarized 
epithelial cells or to sites of cell-cell contact, and forms homodimers mediated by a 
dimerization motif within its D1 domain dimerization motif (Cohen et al., 2001, 
Martin-Padura et al., 1998). Comparable to the interaction of the reovirus σ1 protein 
with JAM-A, the adenovirus fiber knob protein also interacts with residues found 
mostly within the dimer interface of the CAR D1 domain (Bewley et al., 1999, Law & 
Davidson, 2005). Coxsackie B viruses interact with the distal end of the CAR D1 
domain via surface residues in the canyon region of the capsid that surrounds the five-
fold icosahedral axes (He et al., 2001). Other Picornaviridae, including human 
rhinoviruses (HRV14, HRV16), Coxsackie A virus (CAV21), and poliovirus (PV1, 
PV2, PV3), also use IgSF receptors (ICAM-I, ICAM-I, and PVR, respectively) 
(Rossmann et al., 2002). 
 Makino et al. showed that expression of fJAM-A cDNA in non-permissive 
hamster and human cell lines conferred susceptibility to FCV infection, and that 
infection could be blocked with fJAM-A antiserum (Makino et al., 2006). However, a 
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 direct interaction between the virus and receptor was not investigated. In the present 
study, we used both sequence comparisons and structures of the human and murine 
JAM-A molecules to guide mutational analyses of the domains and residues of fJAM-
A required for FCV binding and infection. We show that FCV binds to the membrane-
distal D1 domain of fJAM-A close to the linker region between the D1 and D2 
domains. Replacing two specific fJAM-A residues (Asp 42, Lys 43) with the 
corresponding human sequence substantially diminished virus binding and infection. 
Although the D1 domain was necessary for FCV binding, it was insufficient for 
infection. We found that both the D1 and D2 domains of fJAM-A were required for 
saturable binding of FCV; the cytoplasmic and transmembrane domains were required 
in addition to the extracellular domain for infection of non-permissive CHO cells. 
Lastly, we found that expression of fJAM-A in non-permissive cell lines was not 
sufficient for productive infection by all of the FCV isolates we investigated. 
 
3.3 Methods 
 Cells and viruses. Crandell-Reese feline kidney (CRFK; ATCC #CCL-94) 
and HeLa (ATCC #CCL-2) cells were grown in Eagle’s minimal essential medium 
(EMEM; CellGro) supplemented with 5% fetal bovine serum (HyClone), 100 U ml-1 
of penicillin, 100 μg ml-1 streptomycin, 0.25 μg ml-1 amphotericin B, 1 mM sodium 
pyruvate, and non-essential amino acids (CellGro). Adherent Chinese hamster ovary 
(CHO-K1; ATCC #CCL-61) cells were grown in Ham’s F12 (Hyclone) supplemented 
with 10% fetal bovine serum, 100 U ml-1 of penicillin, 100 μg ml-1 streptomycin, 0.25 
μg ml-1 amphotericin B, 1 mM sodium pyruvate, and non-essential amino acids. 
Suspension Chinese hamster ovary (CHO-S) cells (Invitrogen) were grown in CHO-
Serum Free Medium (-SFM; Gibco). Flp-In T-REx 293 (Invitrogen) cells were 
maintained in Dulbecco’s modified essential medium (DMEM; Hyclone) 
84 
 supplemented with 10% fetal bovine serum, 100 U ml-1 of penicillin and 100 μg ml-1 
streptomycin. Chinese hamster lung (CHL; ATCC #CRL-1935) and Vero (ATCC 
#CCL-81) cells were grown in EMEM supplemented with 10% fetal bovine serum, 
100 U ml-1 of penicillin, 100 μg ml-1 streptomycin, 0.25 μg ml-1 amphotericin B, 1 
mM sodium pyruvate, and non-essential amino acids.  
 The F9 vaccine strain (VR-782) of FCV was obtained from the ATCC. The 
viral isolates FCV-5, Deuce, Kaos, 127 and 131 were previously characterized 
(Ossiboff et al., 2007). Third passage viral stocks were prepared from twice plaque-
purified viruses amplified in CRFK cells. 
 RT-PCR, 3'- and 5'- RACE, and sequencing of fJAM-A. A cDNA of fJAM-
A was prepared from total RNA isolated from CRFK cells using RT-PCR and 5' and 3' 
random amplification of complementary DNA ends. This cDNA was sequenced for 
correctness (Cornell University Life Sciences Core Laboratories Center) and cloned 
into the pCI-neo vector (Promega) to create the pCI-fJAM-A plasmid. Details of the 
primers used for amplification and the cloning strategy are available upon request.  
 Generation and purification of recombinant fJAM-A-GST fusion proteins. 
The fJAM-A extracellular domain (amino acid residues 26-232) and single Ig-like 
domains D1 (residues 26-127) and D2 (residues 132-232) were amplified by PCR 
from the pCI-fJAM-A plasmid using primers that incorporated BamHI and SalI 
restriction sites (Table 3.1). Amplified fragments were cloned into a modified pET-
41A vector (Novagen) that has a 3C protease cleavage site introduced following the 
N-terminal GST and 6× His tags. E.coli (BL21) were grown at 25ºC and protein 
expression of the recombinant plasmids was induced by addition of 0.4 mM isopropyl-
β-D-thiogalactopyranoside (IPTG). Bacteria were harvested by centrifugation, 
resuspended in phosphate-buffered saline (PBS) (137 mM NaCl, 3 mM KCl, 8 mM 
Na2HPO4 [pH 7.5]) containing 0.2% Triton X-100, 1 mM dithiothreitol, and 1 mM  
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 Table 3.1. Primers used to create GST-fusion proteins 
  
Ectodomain Sense 5’-TAGGATCCGGCAGGGGCGCAGTG-3’ 
 Antisense 5’-AGGTCGACCTCCGCGGCTTCCAT-3’ 
D1 Sense 5’-TAGGATCCGGCAGGGGCGCAGTG-3’ 
 Antisense 5’-AGGTCGACCACAGTGAGCTGGAC-3’ 
D2 Sense 5’-TAGGATCCTCCAAGCCCACGGTC-3’ 
 Antisense 5’-AGGTCGACCTCCGCGGCTTCCAT-3’ 
 
phenylmethylsulfonylflouride, and lysed by sonication. Recombinant proteins were 
purified by affinity chromatography using GSTrap Fast Flow columns and Glutathione 
Sepharose 4 Fast Flow beads (GE Healthcare). GST was expressed and purified from 
the empty, modified pET41A vector as described above. When GST-free proteins 
were desired, GST and His tags were cleaved from the recombinant protein using 
HRV 3C protease (Novagen), and removed from the fJAM-A-containing fraction by 
passing the samples back over GSTrap columns. The cleaved proteins contained 4 
additional non-native, N-terminal amino acids (Gly-Pro-Arg-Gly) and 17 additional 
non-native, C-terminal amino acids, including a His tag (Val-Asp-Lys-Leu-Ala-Ala-
Ala-Leu-Glu-His-His-His-His-His-His-His-His).  
 Generation of rabbit fJAM-A specific antiserum. Endotoxin was removed 
from the purified fJAM-A ectodomain using an AffinityPak Detoxigel endotoxin 
removing gel (Pierce). Antibody was produced in a rabbit inoculated three times at 
three week intervals with the purified ectodomain (Cornell Center for Research 
Animal Resources). Pre-immune samples were tested by both ELISA and 
immunofluorescence to verify lack of reactivity. Antiserum was aliquoted and stored 
at -20ºC. 
 Electrophoresis and immunoblot analysis of recombinant fJAM-A. 
Soluble, recombinant fJAM-A full length ectodomain and single Ig-like loop (D1 and 
D2) GST-fusion and 3C-cleaved proteins were separated on 4-15% gradient SDS-
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 PAGE gels (Bio-Rad). Gels were stained with Coomassie blue or transferred to 
nitrocellulose membranes. Membranes were blocked in PBS with 5% non-fat milk 
powder, and then incubated with the fJAM-A rabbit antiserum diluted in blocking 
buffer.  After washing with PBS/0.1% Tween-20, membranes were incubated with 
HRP-conjugated goat anti-rabbit IgG (Jackson Labs). After washing, SuperSignal 
enhanced chemiluminescence substrate (Pierce) was used to detect immunoreactive 
bands. Membranes were stripped (Restore Western Blot Stripping Buffer; Pierce), 
reblocked with blocking buffer, and then incubated with a horseradish-peroxidase-
conjugated anti-GST antibody (GE Healthcare) diluted in blocking buffer. Detection 
of immunoreactive bands was performed as described above. 
 Detection of surface fJAM-A in transiently transfected CHO cells. CHO-
K1 cells (3 × 105 per well) in six-well plates containing 18 mm glass cover slips were 
transiently transfected with pCI-fJAM-A or empty vector using FuGENE 6 (Roche) 
according to the manufacturer’s directions. At 24 h post-transfection (p.t.), cover slips 
were washed with PBS, incubated with the fJAM-A rabbit antiserum (diluted in PBS 
plus 1% BSA) for 1 h on ice, washed, fixed in 2% paraformaldehyde (PFA) in PBS for 
15 min, washed, and then incubated with Alexa 594-conjugated goat anti-rabbit IgG 
(Invitrogen) and DAPI (4’-6’-diamidino-2-phenylindol; Invitrogen) for 1 h. The cover 
slips were mounted on slides using Prolong (Invitrogen). A Nikon TE2000 inverted 
microscope equipped with a 60 × 1.4 NA oil objective linked to a Coolsnap HQ CCD 
camera (Roper) and Openlab software (Improvision) were used to collect fluorescence 
and phase contrast images. Images were then prepared for publication using 
Photoshop and Illustrator software (Adobe Systems). 
 Specificity of fJAM-A antiserum. CRFK and HeLa cells were seeded in six-
well plates containing cover slips as above and incubated overnight. Cells on cover 
slips were washed and then incubated with either fJAM-A rabbit antiserum or a mouse 
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 mAb against hJAM-A (BV-16; Santa Cruz Biotechnology). The cells were washed 
and fixed before being incubated with either Alexa-594 conjugated goat anti-rabbit or 
goat anti-mouse IgG and DAPI. Cover slips were mounted on slides with Prolong. 
Images were obtained as described above. 
 fJAM-A antiserum plaque reduction. Ten-fold dilutions of fJAM-A rabbit 
antiserum in PBS plus 1% BSA were incubated with CRFK cells for 1 h on ice. 
Control wells were incubated with PBS plus 1% BSA, or a 1:10 dilution of rabbit pre-
immune serum in PBS plus 1% BSA. Virus was adsorbed (~20 PFU, as titered on 
CRFK cells/well) to cell monolayers for 1 h at room temperature. Monolayers were 
then overlaid with EMEM containing 5% fetal bovine serum and 1% bacto-agar. After 
incubation at 37ºC for 48 h in humidified 5% CO2, the overlay was removed, the cells 
fixed with 10% buffered formalin, and stained with 1% (w/v) crystal violet solution. 
The plaques were counted and percent reduction from controls calculated. 
 fJAM-A ectodomain, D1 and D2 plaque reduction. Two-fold dilutions of 
purified fJAM-A ectodomain, D1, D2, or GST were incubated with FCV-5 (~20 
PFU/well) in DMEM plus 0.1% BSA for 1 h on ice; control samples were incubated 
with medium only. The virus/receptor mixture was adsorbed to CRFK monolayers for 
1 h at room temperature. Monolayers were then overlaid with 3 ml of EMEM 
containing 5% fetal bovine serum and 1% Bacto-agar. After incubation at 37ºC for 48 
h in humidified 5% CO2, the overlay was removed and plaques were stained as above. 
Plaques were counted and percent reduction from controls calculated. 
 ELISA binding of FCV to fJAM-A ectodomain, D1 and D2. Purified fJAM-
A ectodomain, D1 or D2 (5 μM solutions) in carbonate/bicarbonate buffer (Sigma) 
was bound to 96- well ELISA plates at 4ºC overnight. Wells were blocked with PBS 
containing 0.05% Tween 20 (PBS-T) plus 0.5% BSA for 1 h at room temperature and 
washed three times with PBS-T. Two-fold dilutions of FCV-5 (initial dilution 1:10) 
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 were prepared, and 50 μL of each dilution was bound to plates for 1 h at room 
temperature. After washing, bound virus was detected with rabbit anti-FCV-5 
followed by HRP-conjugated goat anti-rabbit IgG. Antibodies diluted in blocking 
buffer were incubated with plates for 1 h at room temperature. After washing, 
substrate, 2,2’-Azino-bis(3-Ethylbenzthiazoline-6-Sulfonic Acid) (ABTS; Sigma) in a 
citric acid/sodium phosphate buffer, was added to each well and incubated for 15 min. 
Absorbance was measured at 595 nm on a Microplate Biokinetics Reader (BioTek 
Instruments). 
 Creation of fJAM-A deletion, chimeric and point mutants. Deletion and 
chimeric mutants were prepared using a general strategy of amplifying individual 
domains, introducing unique restriction sites on either end, and then joining the 
domains together in the expression vector pCI-Neo to create the desired constructs. 
fJAM-A deletion mutants are named according to the Ig-like domain deleted. Deletion 
mutants were: ΔD1/D2 (fJAM-A amino acid residues 1-27, 128-298; fJAM-A residue 
129 changed from a valine to a glycine); D1/ΔD2 (fJAM-A 1-127, 233-298). Chimeric 
construct were named to indicate the source of the Ig-like domains from N- to C-
termini (fJAM-A, fJ; hJAM-A, hJ; or hCAR, hC). The chimeric mutants created were: 
hJ/fJ (hJAM-A 1-128, fJAM-A 128-298); hC/fJ (hCAR 1-144, fJAM-A 128-298); 
fJ/hJ (fJAM-A 1-131, hJAM-A 133-234, fJAM-A 234-298); fJ/hC (fJAM-A 1-127, 
hCAR 138-227, fJAM-A 234-298). The GPI-fJAM-A chimeric construct was created 
by coupling the fJAM-A ectodomain to the glycosylphosphatidylinositol (GPI) anchor 
of human decay accelerating factor (hDAF) (fJAM-A 1-231, hDAF 345-364; an 
additional alanine was added between the segments). The full length open reading 
frames of hCAR and hJAM-A were also cloned into pCI-Neo. The PCR primers used 
to generate the deletion and chimeric mutants are listed in Table 3.2. fJAM-A D1 
point mutants were generated using the Quick Change Site Directed mutagenesis 
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 Table 3.2 Primers used to create JAM-A chimeric and deletion mutants 
 
Construct Template Orientation Primer (5’-3’) (Restriction sites underlined)    
fJAM-A fJAM-A Sense TAGCTAGCATCGCCAATGGGGACCGA 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
ΔD1/D2 fJAM-A Sense ACACGTACGGGGAGGTCAGCGTCCAGCTC
ACTGTGTTGAATGTGGGGGGCATT 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
D1/ΔD2 fJAM-A Sense TAGCTAGCATCGCCATGGGGACCGA 
  Antisense TAACCTAGGCGGCCCAACGCCAGGGA 
 fJAM-A Sense ATCCTAGGTCCTCCATCCAAGCCCACG 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
hJAM-A hJAM-A Sense TAGCTAGCATCGCCATGGGGACAAAG 
  Antisense ATCTCGAGGGCCTCACACCAGGAATGA 
hCAR hCAR Sense ATGCTAGCGCCACCATGGCGCTCCT 
  Antisense CTCTCGAGCTATACTATAGACCCATCC 
fJ/hJ hJAM-A Sense ATCGTACGGGGAGGTCAGCGTCCAGCTCA
CTGTGCTTGTGCCTCCATCCAAG 
  Antisense ATGCGGCCGCCACAATGCCCCCCACATTC
CGCTCCACAGCTTCCAT 
 fJAM-A Sense AAGCGGCCGCACTTGTCACACTCATTCTC 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
fJ/hC hCAR Sense ATCGTACGGGGAGGTCAGCGTCCAGCTCA
CTGTGCTTGTTAAGCCTTCAGGT 
  Antisense ATGCGGCCGCCACAATGCCCCCCACATTT
AGACGCAACAGGCACT 
 fJAM-A Sense AAGCGGCCGCACTTGTCACACTCATTCTC
CT 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
hJ/fJ hJAM-A Sense TAGCTAGCATCGCCATGGGGACAAAG 
  Antisense TAGGTACCACGATGAGCTTGACCTT 
 fJAM-A Sense ATGGTACCTCCATCCAAGCCCA 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
hC/fJ hCAR Sense ATGCTAGCGCCACCATGGCGCTCCT 
  Antisense TAGGTACCGCACCTGAAGGCTTAACAAG 
 fJAM-A Sense ATGGTACCTCCATCCAAGCCCA 
  Antisense TAACGCGTGGGACCAGGGTCACACCAG 
GPI-
fJAM-A 
fJAM-A Sense TAGCTAGCATCGCCATGGGGACCGA 
  Antisense TAATGCGGCCGCTTCCATGCGCACAGCCT
CT 
 hDAF Sense TAATGCGGCCGCTCCAAATAAAGGAAGT
GGAACC 
  Antisense ATTACGCGTTAAGTCAGCAAGCCCATG 
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 Table 3.3 Primers used to create fJAM-A point mutants  
 
Mutation Orientation Primer (5’-3’) (Restriction sites underlined)   
Y31H Sense CAGGGGCGCAGTGCATACTTCTGAGCCCG 
 Antisense CGGGCTCAGAAGTATGCACTGCGCCCCTG 
D36E Sense GTGTATACTTCTGAGCCCGAGGTCAGGGTACCT
GAGGAC 
 Antisense GTCCTCAGGTACCCTGACCTCGGGCTCAGAAGT
ATACAC 
E41Q Sense CCCGATGTCAGGGTACCTCAGGACAAACCCGCC
AAGTTG 
 Antisense CAACTTGGCGGGTTTGTCCTGAGGTACCCTGACA
TCGGG 
D42N Sense CCCGATGTCAGGGTACCTGAGAACAAACCCGCC
AAGTTG 
 Antisense CAACTTGGCGGGTTTGTTCTCAGGTACCCTGACA
TCGGG 
D42K Sense GCCCGATGTCAGGGTACCTGAGAAGAAACCCGC
CAAGTTG 
 Antisense CAACTTGGCGGGTTTCTTCTCAGGTACCCTGACA
TCGGGC 
D42A Sense CCCGATGTCAGGGTACCTGAGGCCAAACCCGCC
AAGTTG 
 Antisense CAACTTGGCGGGTTTGGCCTCAGGTACCCTGAC
ATCGGG 
K43N Sense CCCGATGTCAGGGTACCTGAGGACAACCCCGCC
AAGTTG 
 Antisense CAACTTGGCGGGGTTGTCCTCAGGTACCCTGAC
ATCGGG 
N56S Sense CGGGCTTCTCCAGCCCGCGCGTGGAG 
 Antisense CTCCACGCGCGGGCTGGAGAAGCCCG 
K75N Sense CACCAGCCTCGTTTGTTATAATAACAAGATCACG
GCCT 
 Antisense AGGCCGTGATCTTGTTATTATAACAAACGAGGC
TGGTG 
A83E Sense GATCACGGCCTCATATGAAGACCGAGTCACCTT
CTCG 
 Antisense CGAGAAGGTGACTCGGTCTTCATATGAGGCCGT
GATC 
S89L Sense GCAGACCGAGTCACCTTCAAGCACAGTGGCATC
ACTTTC 
 Antisense GAAAGTGATGCCACTGTGCTTGAAGGTGACTCG
GTCTGC 
H90P Sense CGAGTCACCTTCTCGCCCAGTGGCATCACTTTC 
 Antisense GAAAGTGATGCCACTGGGCGAGAAGGTGACTCG 
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 Table 3.3 (Continued) 
 
H96K Sense CGCACAGTGGCATCACTTTCAAGTCGGTGACGC
GTAAAGACACG 
 Antisense CGTGTCTTTACGCGTCACCGACTTGAAAGTGATG
CCACTGTGCG 
H96E Sense GGCATCACTTTCGAGTCGGTGACGCGTAAAGAC
ACGGGGACG 
 Antisense CGTCCCCGTGTCTTTACGCGTCACCGACTCGAAA
GTGATGCC 
S97A Sense GGCATCACTTTCCATGCGGTGACGCGTAAAGAC
ACGGG 
 Antisense CCCGTGTCTTTACGCGTCACCGCATGGAAAGTG
ATGCC 
K101E Sense CCATTCGGTGACGCGTGAAGACACGGGGACGTA
CAC 
 Antisense GTGTACGTCCCCGTGTCTTCACGCGTCACCGAAT
GG 
D113E Sense CGTACACTTGCATGGTGTCTGACGAGGGCGGCA
ACACATACGGG 
 Antisense CCCGTATGTGTTGCCGCCCTCGTCAGACACCATG
CAAGTGTACG 
 
strategy (Stratagene). The PCR primers used to generate the point mutants are listed in 
Table 3.3. Common molecular cloning techniques, including overlap PCR, 
Quikchange site directed mutagenesis, and PCR mutagenesis, were utilized to create 
the constructs discussed above. All constructs were sequenced for correctness. 
 Virus-binding assay by flow cytometry. CHO-S cells (106 cells/sample) were 
transiently transfected with plasmid DNA constructs using FuGENE 6. Cells were 
incubated at37ºC in an 8% CO2 humidified atmosphere on a shaker set to 125 
revolutions per minute for 24 h. Cells were washed once in PBS and incubated with 
FCV (MOI = 5) in PBS plus 1% BSA on ice for 30 min. After washing twice, the cells 
were incubated with an antibody for the appropriate receptor (fJAM-A rabbit 
antiserum; anti-hJAM-A mouse mAb; anti-hCAR mouse mAb [Ambion]) and an 
antibody against the virus (anti-FCV mouse mAb [Custom Monoclonals 
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 International]; rabbit anti-FCV antiserum) in PBS plus 1% BSA for 30 min on ice. 
Cells were washed and then fixed in FACS fix buffer (PBS plus 1% PFA and 0.05% 
NaN3). After washing, cells were incubated with the appropriate secondary antibody, 
either Alexa 647-conjugated goat anti-rabbit or goat anti-mouse IgG for the receptor, 
and either Alexa 488-conjugated goat anti-mouse or goat anti-rabbit IgG for the virus 
in PBS plus 1% BSA for 30 min on ice. Cells were washed, suspended in FACS fix, 
and analyzed with a FACSCalibur (Becton Dickinson). Transfected cells were gated 
on positive surface receptor expression and ~10,000 gated cells were analyzed for 
each sample. 
 Virus-infection assay by flow cytometry. CHO-S cells (106/sample) were 
transfected with receptor constructs using FuGENE 6. After overnight incubation, the 
cells were washed in cold PBS and virus was adsorbed (MOI = 0.5; in PBS plus 1% 
BSA) on ice for 30 min. Immediately following virus adsorption, the cells were 
washed to remove unbound virus. Samples to assay virus binding were then incubated 
on ice with fJAM-A rabbit antiserum in PBS plus 1% BSA, washed, and fixed. 
Samples to be tested for infection were resuspended in 2 ml CHO-SFM and incubated 
at 37°C for 24 h with shaking. After 24 h, infected samples were washed in cold PBS, 
incubated with the fJAM-A antiserum as above, then washed, and fixed. All samples 
were then incubated with an anti-FCV mouse mAb in PBS plus 0.1% Triton X-100 
and 10% normal goat serum, followed by Alexa 647-conjugated goat anti-rabbit and 
Alexa 488-conjugated goat anti-mouse IgG in PBS plus 0.1% Triton X-100 and 10% 
normal goat serum. After washing, the cells were suspended in FACS buffer and 
analyzed with a FACSCalibur cytometer. Transfected cells were gated on positive 
surface receptor expression and ~10,000 gated cells in each sample were analyzed for 
expression of FCV capsid antigen. 
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  Creation of a stably fJAM-A transduced CHO-K1 cell line. CHO-K1 cells 
were transfected with pCI-fJAM-A using FuGENE 6. 24 h p.t., G418 (1.2 mg/ml; 
Cellgro) was added to the growth medium. Cells were maintained and passaged in the 
selective medium, and clones selected using cloning cylinders (Fisher). Clonal 
populations were maintained in 400 μg/ml G418. 
 Virus-infection plaque assay. CHO-K1, Flp-In T-REx 293, Vero, HeLa, or 
CHL cells were seeded in six-well plates at a concentration of 3 × 105 cells per well in 
2 ml of appropriate growth medium. The next day, cells were transfected using 
FuGENE 6 and 1 μg DNA of either pCI-fJAM-A or empty vector pCI-Neo (mock); 
cells were incubated for 24 h to allow for protein expression. CRFK, non-transfected 
CHO-K1, and stably transfected CHO-K1 cells expressing fJAM-A were seeded in 
six-well plates at a concentration of 4 × 105 cells per well in appropriate growth 
medium 16 h before infection. Before virus inoculation, cells were washed in PBS, 
and then incubated with selected FCV isolates (MOI = 0.5) diluted in PBS plus 1% 
BSA for 1 h at room temperature. After virus adsorption, the cells were washed with 
PBS, and prewarmed growth medium was added. Samples for each virus were frozen 
immediately at -80ºC to calculate input titers; the remaining samples were incubated at 
37ºC for 24 or 48 h, then frozen at -80ºC, and subjected to three freeze/thaw cycles. 
Plaque assays were performed as previously described (Ossiboff et al., 2007). The 
change in plaque titer was calculated by subtracting the log10 titer of input virus from 
the log10 titer at 24 or 48 h.  The mean and standard deviation of three replicates of a 
representative experiment are shown. 
 Statistical analyses. Analyse-it (Analyse-it Software) statistical analysis add-
in for Microsoft Excel was used to perform ANOVA where necessary. Graphs were 
prepared using Kaleidagraph (Synergy Software). Protein images were prepared using 
PyMOL (DeLano Scientific) (Delano, 2002). 
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3.4 Results 
 Expression and purification of the fJAM-A ectodomain and D1, and D2 
subdomains. To determine if FCV directly binds to the ectodomain of fJAM-A and 
identify which of the two Ig-like domains FCV interacts with, we prepared the 
ectodomain (amino acids 26-232) and the individual Ig-like D1 (amino acids 26-127) 
and D2 (amino acids 132-232) domains of fJAM-A for expression in bacteria. The 
fJAM-A domains were expressed as GST-fusion proteins in a modified pET41a 
plasmid that has a hepatitis C virus 3C protease site inserted in frame at the fusion site 
(Figure 3.1A). After purification by affinity chromatography, the expressed GST 
fusion proteins were of the expected size by SDS-polyacrylamide gel electrophoresis 
analysis (GST-fJAM-A, 53 kDa; GST-D1, 41 kDa; and GST-D2, 41 kDa) (Figure 
3.1B). In addition, when the fusion proteins were cleaved with 3C protease and the 
GST portion removed (see 3.3 Methods), the ectodomain, D1 and D2 proteins were of 
the expected sizes (ecto- [25 kDa], D1 [13.5 kDa] and D2 domain [13.5 kDa]) (Figure 
3.1B). 
 Detection of fJAM-A. To detect expression of fJAM-A cDNA, we prepared a 
rabbit antiserum against the purified fJAM-A cleaved ectodomain. This antiserum 
detected both GST-fused and cleaved fJAM-A proteins in immunoblots, while an anti-
GST antibody recognized only the GST fusion proteins (Figure 3.1C). To test the 
specificity of the fJAM-A antiserum, we expressed the full-length fJAM-A cDNA in 
CHO-K1 cells, which do not form coherent tight junctions or express endogenous 
JAM-A (Martin-Padura et al., 1998, Ostermann et al., 2002). We detected surface 
expression of fJAM-A in CHO-K1 cells transfected with pCI-fJAM-A, but not cells 
transfected with empty vector (Figure 3.1D). As reported for expression of murine and 
human JAM-A, we found that fJAM-A was distributed throughout the plasma 
membrane (Mandell et al., 2004, Martin-Padura et al., 1998). To further test the  
Figure 3.1. Characterization of recombinant fJAM-A ectodomain and fJAM-A 
specific rabbit antisera. (A) GST-Ecto, GST-D1, and GST-D2 were expressed in E. 
coli (BL21).  Soluble recombinant proteins were purified by affinity chromatography. 
The fJAM-A regions of the recombinant proteins were released by 3C protease 
cleavage and (B) the predicted sizes of the fusion and cleaved proteins verified by 
SDS-polyacrylamide gel electrophoresis. A rabbit polyclonal antiserum against 
soluble fJAM-A ectodomain was prepared and (C) its capacity to specifically 
recognize the purified fusion and cleavage proteins confirmed by immunoblotting; a 
higher concentration of antibody was used to detect the cleaved D2 (indicated by an 
asterisk). Membranes were also probed with anti-GST. (D) Surface expression of 
fJAM-A in CHO cells by fluorescence microscopy. CHO-K1 cells were transfected 
with pCI-fJAM-A to express full-length fJAM-A or the empty vector, pCI-Neo. The 
cells were fixed at 24 h p.t. and immunostained with fJAM-A rabbit antiserum 
followed by Alexa 594-conjugated goat anti-rabbit IgG. Nuclei were stained with 
DAPI. (E) The fJAM-A rabbit antiserum recognizes JAM-A on feline CRFK, but not 
human HeLa cells. CRFK or HeLa cells were immunostained with either anti-fJAM-A 
or anti-hJAM-A (mAb BV16) followed by Alexa 594-conjugated goat anti-rabbit or 
Alexa 594-conjugated goat anti-mouse IgG; nuclei were stained with DAPI. 
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 specificity of the antiserum, CRFK and HeLa cells were stained with either the fJAM-
A antiserum or a mouse mAb against hJAM-A (Figure 3.1E). The anti-fJAM-A bound 
to CRFK but not HeLa cells, while anti-hJAM-A bound HeLa but not CRFK cells. We 
also tested CHL and Flp-In T-REx 293 cells and, as expected, found that the fJAM-A 
antiserum did not recognize any cell surface antigen.  
 A rabbit antiserum against fJAM-A inhibits FCV plaque formation in 
CRKF cells. Makino et al. showed that fJAM-A mouse antiserum partially inhibited 
FCV binding and blocked infection in permissive CRFK cells (Makino et al., 2006). 
We therefore tested the fJAM-A rabbit antiserum for its capacity to neutralize FCV 
infection of CRFK cells. We found that preincubation of cells with a 1:100 dilution of 
fJAM-A antiserum almost completely inhibited plaque formation (Figure 3.2). In 
contrast, preincubation of monolayers with a 1:10 dilution of pre-immune serum had 
no substantial effect on the number of plaques formed (Figure 3.2). A 1:100 dilution 
of the fJAM-A antiserum also inhibited infection by other FCV isolates (F9, Kaos, 
Deuce, 127, and 131). Based on these findings, we conclude that the fJAM-A rabbit 
antiserum can inhibit FCV infection of CRFK cells. 
 Purified soluble fJAM-A ecto- and D1 domains neutralize FCV infection. 
Neutralization of virus following incubation with soluble receptor has been 
demonstrated for a number of viruses (Goodfellow et al., 2005, Kaplan et al., 1990, 
Martin et al., 1993). Therefore, we used plaque reduction assays to assess the capacity 
of the fJAM-A ectodomain to neutralize FCV-5 infection. We found that 
preincubation of FCV-5 with fJAM-A ectodomain reduced viral infectivity by ~ 50% 
at 234 nM fJAM-A ectodomain, and abolished infectivity at concentrations > 938 nM 
(Figure 3.3A). The fJAM-A ectodomain consists of two Ig-like domains: the 
membrane-distal D1 and membrane-proximal D2. We found that preincubation of 
FCV-5 with purified D1 domain inhibited viral infectivity at similar concentrations to  
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Figure 3.2. Inhibition of FCV infection of CRFK cells by fJAM-A antiserum. Serial 
dilutions of anti-fJAM-A or a 1:10 dilution of rabbit pre-immune serum were pre-
incubated with monolayers of CRFK cells for 1 h on ice.  The cells were then 
inoculated with ~20 PFU of FCV-5 and incubated for an additional 1 h at room 
temperature. The cells were then overlaid with EMEM 5% FBS and 1% Bacto-agar 
and cultured at 37°C for 48 h. The number of plaques in each well was counted and 
the results expressed as the percentage plaque reduction from infected monolayers that 
were untreated. Results shown are the mean plaque reduction ± standard deviation of 6 
replicate wells of a single representative experiment. 
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Figure 3.3. Binding of fJAM-A ectodomain and the D1 and D2 Ig-like domains to 
FCV and their effect on infectivity. (A) FCV-5 was incubated with purified fJAM-A 
ectodomain, D1, D2, or GST for 1 h on ice and then adsorbed to a monolayer of 
CRFK cells for 1 h at room temperature. The cells were then overlaid with EMEM, 
5% FBS and 1% bacto-agar and incubated at 37°C for 48 h. The numbers of plaques 
in each well were counted and the data expressed as the percentage of plaque 
reduction relative to monolayers infected with untreated virus. Data shown is the mean 
of 6 replicates ± standard deviation from one representative experiment. ANOVA was 
performed on three concentrations (3.75, 0.234, and 0.029 μM) to determine statistical 
differences; significant concentrations are indicated by an asterisk. (B) ELISA plates 
were coated with 5 μM solutions of soluble fJAM-A ectodomain, D1 or D2. Serial 
dilutions of FCV-5 were incubated with the immobilized proteins for 1 h and then the 
plates were washed extensively. Bound FCV-5 was detected with rabbit anti-FCV 
serum followed by HRP-conjugated goat anti-rabbit IgG. Colorimetric HRP substrate 
was added and the amount of bound FCV-5 was quantified by absorbance at 595 nm. 
The mean and standard deviations are shown, n=3. As above, ANOVA was performed 
on three concentrations; significant concentrations are indicated by an asterisk. 
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 fJAM-A ectodomain (Figure 3.3A). In contrast, preincubation of FCV-5 with purified 
D2 domain or GST had no effect on infectivity at any of the concentrations we tested 
(Figure 3.3 A). Plaque reduction by the ecto- and D1 domains was statistically greater 
than the D2 domain at 2 of the 3 concentrations (3.75 and 0.234 μM) we analyzed by 
ANOVA (p < 0.0001 and p < 0.003, respectively). Preincubation of FCV-5 with the 
GST-fusion proteins inhibited viral infectivity to the same extent as the cleaved forms 
of the proteins (data not shown). In addition, we found that addition of purified fJAM-
A to cells after virus was adsorbed for 1 h on ice had no effect on virus infectivity 
(data not shown). We conclude from these results that the full-length fJAM-A 
ectodomain and the membrane-distal D1 domain can inhibit FCV-5 infection of CRFK 
cells when preincubated with virus, most likely by preventing virus binding to the 
fJAM-A receptors present on the surface of the cells. 
 Purified FCV-5 particles directly bind to purified fJAM-A ectodomain 
and the D1 domain by ELISA. Our findings thus far strongly suggested that FCV 
directly interacted with fJAM-A ectodomain. To test this hypothesis, we used an 
ELISA to detect direct binding of viral particles to the fJAM-A ecto-, D1, and D2 
domains bound to 96-well plates. We found saturable concentration-dependent 
binding of FCV-5 to plate-bound fJAM-A ectodomain (Figure 3.3B). Higher 
concentrations of FCV bound the plate-bound fJAM-A at similar levels to the highest 
concentration of FCV shown in Figure 3.3B (data not shown). We also found that 
FCV-5 bound to the D1 domain at low levels (Figure 3.3B); however, this binding was 
non-saturable and did not significantly change with increasing concentrations of virus. 
In contrast, FCV did not bind the D2 domain at any of the concentrations we tested 
(Figure 3.3B). ANOVA analysis of three concentrations showed significantly more 
viral binding to the ecto- and D1 domains than the D2 domain at all but the lowest 
concentration of virus (p<0.0001). We also assayed binding of fJAM-A ecto-, D1, or 
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D2 domains to viral particles when virus was bound to the plate. Under these 
conditions, although we detected saturable concentration-dependent binding of soluble 
fJAM-A to virus bound to the solid-phase, we were unable to detect any substantial 
binding of either the D1 or D2 domains to plate-bound virus using the fJAM-A rabbit 
antiserum to detect the bound proteins (data not shown). We hypothesized that our 
difficulty in detecting binding of the D1 domain to virus bound to the plate was 
because the fJAM-A antiserum competed with the virus for binding of D1. As the 
purified fJAM-A ectodomain, D1 and D2 proteins all possessed a C-terminal His tag 
(Figure 3.1A), we also used a rabbit anti-His polyclonal antibody to detect binding of 
fJAM-A ectodomain, D1, or D2 to plate-bound virus. Using the anti-His antibody, our 
findings were similar to the results shown in Fig. 3B; we were able to detect 
concentration-dependent saturable binding of fJAM-A ectodomain and low levels of 
D1 binding, but no detectable binding of D2 to the plate bound virus (data not shown). 
We conclude that FCV-5 can bind directly to the fJAM-A D1 and full-length 
ectodomain, but that saturable concentration-dependent binding requires the D2 
domain. In addition our results suggest that the fJAM-A antiserum inhibits the 
interaction between purified D1 and virus particles perhaps by competing for binding 
to regions of the fJAM-A ectodomain that are involved in FCV binding. 
 FCV binding to fJAM-A deletion and chimeric mutants. To analyze the 
regions of fJAM-A responsible for virus binding, we prepared deletion and chimeric 
mutants of fJAM-A for expression in CHO-S cells (Figure 3.4A). The D1 and D2 
domains were deleted or replaced with those of the related IgSF molecules, human 
JAM-A or human CAR. Binding of virus to CHO-S cells expressing the different 
surface receptor molecules was detected by flow cytometry (Figure 3.4B). We found 
that virus bound to nearly 80% of cells that expressed cell surface full-length fJAM-A. 
However, FCV-5 did not bind above control levels to cells that expressed the single 
Figure 3.4. FCV binding to CHO cells expressing fJAM-A deletion and chimeric 
mutants. (A) A panel of fJAM-A deletion and chimeric mutants was created to 
investigate FCV binding. Chimeric receptors were generated by exchanging single Ig-
like loops from IgSF proteins fJAM-A (red), hJAM-A (yellow) and hCAR (blue). 
Deletion constructs lacking single Ig-like domains, as well as a construct in which the 
transmembrane and cytoplasmic domains were replaced with a GPI-anchor, were 
generated. (B) CHO-S cells were transfected with each construct. At 24 h p.t., FCV 
was adsorbed to the cells on ice for 30 minutes. After washing with cold PBS, the 
bound virus and cell surface fJAM-A were detected with mouse anti-FCV mAb and 
rabbit anti-fJAM-A antibodies followed by Alexa 488-conjugated goat anti-mouse IgG 
and Alexa 647-conjugated goat anti-rabbit IgG. Virus binding and receptor expression 
were analyzed by flow cytometry. (C) Virus binding was measured by determining the 
percentage of receptor positive cells that were positive for virus. The mean (n ≥ 3) (1 × 
104 cells) ± standard deviation is shown.
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D1 or D2 Ig-like loops (Figure 3.4C). In addition, virus did not bind to native hJAM-A 
or hCAR. In contrast, FCV-5 bound to cells expressing chimeric receptors that 
contained the fJAM-A D1 fused with the hJAM-A or hCAR D2 domains, albeit at 
lower levels than wild type receptor (~25% and 60%, respectively; Figure 3.4C). We 
observed only background levels of virus binding to cells that expressed chimeric 
receptors that consisted of the D1 from hJAM-A or hCAR in the fJAM-A background. 
FCV bound to CHO-S cells expressing a GPI-anchored form of fJAM-A at similar 
levels as cells expressing wild type receptor. The background level of virus binding to 
cells transfected with empty vector was 3% (Figure 3.4B). We also investigated the 
binding of FCV isolates Deuce and F9 to the full panel of chimeric receptors by 
immunofluorescence and found levels of binding similar to that of FCV-5. The 
binding of FCV isolates Deuce, F9, 127, 131 and Kaos to both the full-length fJAM-A 
receptor and the GPI-anchored form was detected by flow cytometry. We noted 
similar binding levels for all isolates. We conclude that the fJAM-A D1 domain was 
necessary for FCV binding and that the cytosolic and transmembrane domains were 
not required. However, it appears that the context in which the D1 domain is presented 
on the cell surface is important, as FCV was unable to bind the fJAM-A D1 when it 
was expressed alone, possibly because the viral particle cannot access the domain 
when it lies close to the cell membrane. 
 FCV binding to fJAM-A D1 point mutants. To identify individual regions of 
fJAM-A D1 required for FCV binding, we compared the amino acid sequence of the 
human and feline D1 domain and identified non-identical residues (Figure 3.5A). 
Dissimilar surface exposed residues are indicated on a model of the hJAM-A structure 
(PDB ID # 1NBQ; Figure 3.5B). We prepared eleven point mutants by replacing 
selected feline residues with the corresponding residue of hJAM-A. In addition, we 
prepared a mutant (E60R/K62E) that reversed the charges on 2 of the 4 residues  
Figure 3.5. FCV binding to fJAM-A D1 point mutants. (A) The amino acid sequences 
of the D1 domain of fJAM-A (res 26-125) and hJAM-A (27-126) were aligned and 
nonidentical residues identified (highlighted by red boxes). (B) Identified residues 
were mapped on the hJAM-A crystal structure (PDB ID# 1NBQ; red and blue 
residues), and 11 surface exposed residues were selected to mutate to the hJAM-A 
sequence (blue residues; images were created in PyMOL, Delano Scientific). A 
dimerization mutant (E60R/K62E) that reverses the charges on 2 of the 4 charged 
residues in the dimerization motif was also created. (C) CHO-S cells were transfected 
with each of the constructs. At 24 h p.t., cells were incubated with FCV-5 on ice for 30 
minutes, followed by immunostaining to detect surface expression of receptor and 
FCV binding, and then analyzed by flow cytometry. (D) After gating for receptor 
positive cells, virus binding was measured and expressed as a percentage. The mean of 
at least 3 replicates (1 × 104 cells each) ± standard deviation is shown. To further 
investigate the decreased binding observed with the point mutant D42N, additional 
mutants were made to reverse or eliminate the charge on residue 42, as well as to alter 
other charged residues in the vicinity of residue 42. (E) Virus binding to cells 
expressing the constructs was measured by flow cytometry and (F) virus binding was 
determined as above. The mean (n ≥ 3; 1 × 104 cells each) ± standard deviation is 
shown. Constructs indicated by an asterisk were bound by significantly lower levels of 
virus as determined by ANOVA (p<0.0001).
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 predicted to be involved in fJAM-A dimer formation. Mutations to the charged 
residues involved in salt bridge formations have been shown to prevent hJAM-A 
dimerization (Guglielmi et al., 2007, Kostrewa et al., 2001). Each construct was 
transiently transfected into CHO-S cells and FCV-5 binding was detected by flow 
cytometry (Figure 3.5C). The level of FCV-5 binding to cells expressing the various 
constructs is presented as the percentage of receptor-positive cells that bound virus 
(Figure 3.5D). Of the initial panel of mutant receptors we examined, only cells 
expressing fJAM-A D42N were bound by FCV-5 less effectively than wild type (~ 2.2 
fold fewer cells bound virus) (Figure 3.5D). FCV-5 bound all of the other mutants to 
levels not significantly different than the wild type fJAM-A (Figures.3.5C and D). To 
further investigate the role of fJAM-A residue 42 in binding, we prepared two 
additional fJAM-A mutants where the charge on residue 42 was reversed (D42K) or 
removed (D42A); neither of these changes significantly decreased FCV-5 binding 
when compared to binding to the wild type receptor (Figures 3.5E and F). As residue 
43 of JAM-A also differed between feline (lysine) and human (asparagine) sequences, 
we examined binding of FCV-5 to cells expressing fJAM-A K43N. We found that 
FCV-5 bound 3.5-fold fewer cells expressing this mutant than those expressing the 
wild type receptor (Figures 3.5E and F). We prepared three other mutants that had 
changes to charged residues that were positioned close to residues 42 and 43 in the 
hJAM-A structure. Two of these mutants (E41Q and H96E) bound similar levels of 
FCV-5 as wild type receptor. However, mutant fJAM-A S97A bound ~ 1.7-fold less 
virus than wild type fJAM-A (Figures 3.5E and F). D1 point mutants D42N, K43N 
and S97A were all bound by significantly less virus than the wild-type fJAM-A, as 
determined by ANOVA (p<0.0001). One caveat to these observations is that the cell 
surface expression of the D42N and K43N mutants was lower than that of the wild 
type fJAM-A. Thus, it is possible that some of the lower FCV cell binding could be 
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 attributed to lower levels of expression; however, it is clear that those cells that did 
express lower levels of these mutants still bound far less virus than a comparable 
population of wild type-expressing cells. The binding of FCV isolates F9 and Deuce to 
selected mutants (D42N, S89L, D42K, K43N, E41Q, and E60R/K62E) was also 
measured, with similar binding levels noted (data not shown). Taken together these 
results suggest that residues D42, K43, and S97 of the fJAM-A D1 are likely involved 
in interactions with FCV virions. 
 Capacity of FCV to infect non-permissive CHO cells expressing fJAM-A 
or deletion and chimeric mutants of fJAM-A. We used flow cytometry to examine 
the capacity of low multiplicities of FCV-F9 to infect CHO-S cells transiently 
expressing fJAM-A and the panel of fJAM-A deletion and chimeric mutants. 
Controlling for levels of input capsid bound to cells (solid line), we quantified the 
change in geometric mean fluorescence associated with viral capsid protein levels at 
24 h post-inoculation (dashed line) (Figure 3.6A). In this way, infection was assayed 
by increased intracellular levels of viral capsid protein resulting from viral replication. 
In cells expressing the full-length fJAM-A molecule, we found significantly increased 
expression of viral capsid protein, indicating successful virus entry and infection 
(Figure 3.6B). All of the mutant constructs that were unable to bind FCV (D1/ΔD2, 
ΔD1/D2, hJ/fJ and hC/fJ) (see Figure 3.4C) were also unable to mediate infection 
(Figure 3.6B). Although virus bound to cells expressing the D2 exchange mutant 
constructs (fJ/hJ, fJ/hC) and the GPI-anchored construct (GPI-fJAM), we were unable 
to detect infection in cells expressing these constructs (Figure 3.6B). We also prepared 
a mutant construct of fJAM-A that lacked three conserved C-terminal residues of the 
cytosolic tail (Phe, Leu, Val) known to be required for binding of PDZ domain-
containing proteins (Bazzoni et al., 2000). Both viral binding and infection of CHO-S 
cells expressing this construct were comparable to that mediated by the wild-type  
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Figure 3.6. FCV infection of cells expressing chimeric, deletion or select D1 point 
mutant constructs. (A) F9 was bound to two sets of cells expressing chimeric or 
deletion constructs for 30 minutes on ice. One set of F9-inoculated cells was 
resuspended in growth medium and placed at 37ºC for 24 hours; the other set of cells 
was washed and immediately immunostained for the virus and receptor to determine 
background binding of virus. After 24 hours, the infected cells were washed and 
immunostained for virus and receptor as above. Bound (solid line) and 24 h incubated 
samples (dashed line) were then analyzed by flow cytometry. (B) Infectivity was 
measured by determining the change in mean log virus fluorescence intensity between 
bound and incubated samples. The average of the change in geometric mean (n ≥ 4) ± 
standard error is shown. (C) Cells expressing select D1 point mutant constructs were 
prepared and analyzed in the same fashion. (D) The change in mean virus fluorescence 
intensity was used as a measure for infection, and the average of the change in 
geometric mean (n ≥ 4) ± standard error is shown.
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 receptor construct (data not shown). From these results, we conclude that all domains 
(D1, D2, transmembrane and cytoplasmic) of the fJAM-A receptor are necessary for 
infection, but that interactions with proteins that contain a PDZ domain are not 
required.  
 FCV infection of fJAM-A D1 point mutants. We similarly analyzed the 
fJAM-A D1 point mutants for their capacity to confer susceptibility to FCV infection 
in CHO-S cells. We found that the two fJAM-A mutants with decreased capacity to 
bind virus (D42N, K43N) (see Figures 3.5D and F) also showed a decreased capacity 
to confer susceptibility to infection in CHO-S cells relative to the wild type receptor 
(Figures 3.6C and D). The other point mutations investigated (N56S, S89L, H90P, 
K101E, E41Q) conferred susceptibility to infection at levels similar to the wild-type 
receptor. The mutant S97A, which demonstrated a significant decrease in virus 
binding (see Figure 3.5F), was also able to confer similar levels of susceptibility to 
infection as the wild-type receptor. Lastly, the dimerization mutant (E60R/K62E) also 
conferred susceptibility to CHO-S cell infection by F9. 
 Isolate variation in the capacity to infect fJAM-A expressing cells. In the 
above experiments we used the F9 vaccine strain to assay for infection. However, we 
found that not all of the FCV isolates we examined were able to infect CHO-S cells 
expressing the wild type fJAM-A receptor (data not shown). We selected 6 FCV 
isolates (including the vaccine strain, F9) to investigate the capacity of different 
isolates to infect transiently transfected adherent CHO-K1 cells (Figure 3.7A).  We 
found that four isolates (FCV-5, Deuce, 127 and F9) were able to productively infect 
CHO-K1 cells transiently expressing fJAM-A, with yields ranging from 0.5 to 1.2 logs 
greater than the input titer. The viral yields, however, were considerably lower than 
the yields observed in CRFK cells incubated for 24 h (2.8 – 4.8 logs). Two isolates, 
Kaos and 131, were unable to productively infect the transfected CHO-K1 cells. 
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 Incubation of these isolates with the fJAM expressing CHO-K1 cells resulted in a net 
loss of titer similar to that observed following incubation with CHO-K1 controls.  
The process of transfection using cationic liposomes has been shown to induce a 
robust type I interferon response (Park et al., 2003), and FCV infection is sensitive to 
the presence of type I interferon (Baldwin et al., 2004, Fulton & Burge, 1985, 
Mochizuki et al., 1994). To eliminate the potential effects of a transfection-induced 
anti-viral state, we created a CHO-K1 cell line stably expressing fJAM-A, and then 
repeated the infection assay in the fJAM-A stable cells. The four isolates able to 
productively infect the transiently transfected cells demonstrated enhanced infectivity 
in the stable cell lines, with yields of 1.1 to 2.3 logs higher than the input titer 
following 48 h incubation.  However, infection of FCV isolates 131 and Kaos was still 
greatly restricted in the stably transfected cell line. Neither isolate displayed a net 
increase in viral yield after 24 hours; after 48 hours, the titer of FCV 131 had 
increased 0.35 logs, while Kaos showed no change in titer over the bound virus 
sample.  
 To further investigate the ability of FCV isolates to infect cells expressing 
fJAM-A, we transfected 4 additional cell lines with the receptor and incubated the 
cells for 24 or 48 hours with the selected FCV isolates (Fig. 7B). Results varied by 
both cell line and FCV isolate. Transfected Vero cells were the only cell line identified 
that supported a productive infection of all FCV isolates tested. In contrast, transfected 
HeLa cells were unable to support a productive infection by any of the FCV isolates 
investigated. Transfected CHL cells supported infection by Deuce, Kaos, FCV-127, 
FCV-131 and F9 (following 48 h incubation), but not FCV-5; Flp-In T-REx 293 cells 
supported infection by Deuce, Kaos, and FCV-127, but not isolates FCV-5, FCV-131 
and F9. FCV isolates Deuce and 127 were able to productively infect all of the 
transfected cell lines we tested, other than HeLa cells; isolates FCV-5, Kaos,  
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Figure.3.7. FCV isolate infectivity in non-permissive cell lines expressing fJAM-A. 
(A) FCV isolates (MOI = 0.5) were incubated with monolayers of CHO-K1 cells 
expressing fJAM-A (transiently or stably) for 24 or 48 hours. Virus was also incubated 
for 24 hours with empty CHO-K1 cells, CHO-K1 cells transfected with the empty 
vector (CHO-Mock), and CRFK cells. Infectivity of the samples was determined by 
plaque assay, and the change in titer from virus-bound only samples calculated. The 
mean log10 change in titer of three replicates ± SD of a representative experiment is 
shown. (B) Monolayers of 4 additional non-permissive cell lines (CHL, Flp-In T-REx 
293, Vero, and HeLa) were transiently transfected with fJAM-A and incubated with 
virus (MOI = 0.5) for 24 (CHL, Vero, HeLa) or 48 (Flp-In T-REx 293) hours. 
Infectivity of the samples was determined by plaque assay, and the change in titer 
from virus-bound only samples calculated. The mean log10 titer of three replicates ± 
SD is shown. 
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 FCV-131, and F9 were more restricted and showed differential capacities to infect the 
other transfected cell lines.  All isolates were capable of productive infection in at least 
one fJAM-A expressing non-permissive cell line.  
 
3.5 Discussion 
 Makino et al. showed that fJAM-A is a receptor for FCV (Makino et al., 2006). 
Here we have confirmed and extended those results. We have shown that binding of 
FCV to fJAM-A requires the membrane-distal D1 domain; furthermore, mutations to 
three residues within D1 (D42, K43, and S97) decreased viral binding. The D1 domain 
of fJAM-A is predicted to contain two antiparallel β-sheets (strands ABED and 
GFCC'C''). Structural and biochemical analyses of human and murine JAM-A 
molecules revealed dimer formation though extensive interactions between the GFCC' 
faces of two D1 domains (dimerization interface); at the center of the dimer interface 
are several charged residues critical in mediating JAM-A/JAM-A dimer formation by 
forming four salt bridges (dimerization motif) (Guglielmi et al., 2007, Prota et al., 
2003). Residues D42 and K43 are predicted to reside in a short turn between β-strands 
A and B on the β-sheet opposite the dimerization face of hJAM-A, in close proximity 
to the short linker region between D1 and D2. Interestingly, these residues are also 
contained within a peptide that blocks binding of mAb (F11) to human JAM-A (F11R) 
on the surface of platelets. This mAb induces platelet secretion and aggregation and 
these stimulatory activities are inhibited by a peptide that contains residues 28-50 of 
human JAM-A (Babinska et al., 2002a).  
 We hypothesize that the decreased binding observed in mutations of fJAM-A 
residues D42 and K43 is due to the importance of these residues in the FCV/fJAM-A 
interaction. However, the possibility exists that the mutations D42N and K43N 
introduce N-linked glycosylation sites in the fJAM-A receptor. Although the mutated 
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 fJAM-A constructs do not contain a classical Asn-X-Ser/Thr glycosylation motif at the 
position of the mutation, we cannot rule out atypical glycosylation.  The presence of a 
glycan, and not the actual residue could then be responsible for the decreased binding. 
Another possibility that we cannot completely exclude is that the lower levels of 
surface expressed fJAM-A mutants D42N and K43N relative to the wild-type fJAM-A 
(see Figs. 5C and 5E) were responsible for the decreased virus binding.  However, a 
distinct population of CHO-S cells expressed these mutants at levels comparable to 
cells expressing the wild type receptor, yet these cells bound significantly less virus 
(see Figs. 5C and 5E). Furthermore, mutating residue 97, which resides on a loop 
between β-strands E and F in very close proximity to residues 42 and 43, to an alanine 
resulted in significantly reduced viral binding with expression levels similar to those 
of the wild-type fJAM-A. Thus, taken together our data support the hypothesis that 
FCV binds to the D1 domain of fJAM-A in the vicinity of these residues. 
 Makino et al. reported that the FCV isolates they examined (which included 
the vaccine strain F9) could bind human 293T and monkey Vero cell lines, and that 
anti-hJAM-A antibodies decreased that binding (Makino et al., 2006). Confounding 
this observation, Stuart and Brown (2007) showed negligible binding of radio-labeled 
F9 virions to Vero and 293T cells (Stuart & Brown, 2007).  In agreement with the 
findings of Stuart and Brown, we were unable to detect an interaction between FCV 
and hJAM-A expressed on the surface of CHO cells. Furthermore, we did not detect 
an interaction between FCV and soluble recombinant hJAM-A ectodomain by ELISA 
or surface plasmon resonance studies (data not shown). Therefore, the binding 
detected by Makino et al. seems unlikely to have been mediated by hJAM-A. 
 The mammalian reovirus σ1 protein interacts with human JAM-A via residues 
E61 and K63 present at the dimer interface of D1 and it is the charge on these residues 
that is important for binding (Guglielmi et al., 2007). Mutations to just one of the 
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 residues of the dimerization motif prevented the formation of hJAM-A/hJAM-A 
dimers (Guglielmi et al., 2007). In contrast, FCV binding to cells expressing the 
E60R/K62E dimerization mutant of fJAM-A was similar to that of the wild-type 
fJAM-A (79% and 75%, respectively). The E60R/K62E mutations reverses the charge 
of two residues involved in forming the four predicted salt bridges important in 
dimerization (R58-E60; E60-R58; K62-E120; E120-K62) (Prota et al., 2003). Thus, 
we conclude that the charge of fJAM-A residues E60 and K62 (corresponding to 
hJAM-A E61 and K63) are not important in FCV binding. In addition, we predict the 
E60R/K62E mutant is unable to form fJAM-A/fJAM-A dimers. Therefore, the 
observed binding of FCV to the dimerization mutant suggests that FCV can interact 
with both monomeric and dimeric forms of fJAM-A.  
 The FCV-fJAM-A receptor interaction is also different from the adenovirus-
CAR receptor interaction. The adenovirus attachment fiber protein is similar to the 
reovirus σ1 protein. The fiber protein is a trimer with a globular C-terminal knob that 
engages the coxsackie and adenovirus receptor (CAR), at its amino terminal D1 
domain (Freimuth et al., 1999). Like the σ1 head domain, the fiber knob attaches at the 
dimer interface to residues important in CAR-CAR interactions at the dimer interface 
(Bewley et al., 1999, Seiradake et al., 2006, Stehle & Dermody, 2004).  
 Similar to caliciviruses, coxsackieviruses (Picornaviridae) are small, 
nonenveloped, positive-strand RNA viruses. Group B coxsackieviruses (CVB) utilize 
CAR as a host cell receptor (Bergelson et al., 1997, He et al., 2001, Martino et al., 
2000). CVB also engages the amino terminal Ig-like domain D1 of CAR. However, 
unlike adenoviruses, the CVB interaction with CAR does not involve critical residues 
in the dimerization motif, although the binding site is on the distal end and the lateral 
side (A-G face) of CAR D1 and lies close to the dimer interface (He et al., 2001).  
Residues D42, K43, and S97, which we found were important for FCV binding, are 
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 predicted to also be part of the orthologous lateral A-G face of fJAM-A; however, 
these residues lie much closer to the D1-D2 linker than the dimerization interface. 
 The ectodomain of fJAM-A was sufficient to mediate FCV binding, but when 
expressed on the cell surface with a GPI-anchor, it could not mediate infection. In 
contrast, a GPI-CAR receptor mediated CVB and adenovirus binding and infection 
(Wang & Bergelson, 1999). This finding suggests that the transmembrane and/or the 
cytosolic domains of fJAM-A are required for productive FCV infection of non-
permissive cells. We first hypothesized that signaling via the consensus C-terminal 
type II PDZ domain-binding motif at the carboxyl terminus of the cytoplasmic tail of 
fJAM-A might be required for infection; however, a construct that lacked the 
predicted PDZ binding motif (last three amino acids of fJAM-A, Phe-Leu-Val) was as 
efficient as the wild type receptor in mediating FCV infection of CHO cells. Taken 
together, our data suggest a model where FCV binding to the fJAM-A ectodomain 
transduces signals through its transmembrane and cytosolic domains that are required 
for infection. Evidence suggesting such a model for CVB was reported by Coyne and 
Bergelson (2006), where interaction of CVB with the cellular receptor decay-
accelerated factor activates kinases that trigger actin rearrangements  and 
phosphorylation events necessary for mediating viral infection (Coyne & Bergelson, 
2006). 
 Makino et al. (2006) reported that fJAM-A expression on nonpermissive 
hamster lung cells conferred susceptibility to FCV infection. Here we show that 
expression of fJAM-A on the surface of five different cell lines was not necessarily 
sufficient to support productive infection for all FCV isolates. Not all of the cell lines 
that we investigated supported productive infection by all of the isolates; furthermore 
the ability of FCV isolates to productively infect each cell line tested varied. Only 
Vero cells were able to support productive infection by all the FCV isolates we 
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 examined.  While native non-transfected Vero cells have been reported to support 
infection by some FCV isolates (Makino et al., 2006), none of the isolates we tested 
were capable of infecting Vero cells in the absence of fJAM-A. 
 The capacity of different FCV isolates to infect CHO-K1 cells that expressed 
fJAM-A varied. Indeed, we found that some isolates (FCV-131 and Kaos) were unable 
to productively infect these cells. Stuart and Brown (2007) reported that cell binding 
and infection by FCV is partially mediated by an N-linked glycoprotein containing α-
2,6-linked, but not α-2,3-linked sialic acids (Stuart & Brown, 2007). CHO cells lack 
the sialyltransferase necessary for generating α-2,6-sialic acid linkages and express 
predominantly α-2,3-linked sialic acid glycans (Lee et al., 1989). Therefore, our 
results infer that at least a subset of FCV isolates are capable of binding and infecting 
fJAM-A expressing cells independently of α-2,6-sialic acid linkages. fJAM-A contains 
a single putative N-linked glycosylation site at residue N184 in D2. The glycosylation 
status of this site, as well as the role of glycosylation in FCV binding and infection, 
warrant further investigation. It is also possible that there is an additional surface 
receptor for FCV. The findings that not all FCV isolates were capable of infecting 
non-permissive cell lines expressing fJAM-A lends support to the idea that fJAM-A 
alone is not sufficient for FCV infection by all isolates and that additional co-receptors 
may be required. 
  In the last 10 years there have been sporadic reports of highly virulent 
outbreaks of FCV disease in cats (Coyne et al., 2006, Hurley et al., 2004, Pedersen et 
al., 2000, Schorr-Evans et al., 2003). The virus isolates responsible for these outbreaks 
have been termed virulent systemic (VS-) FCV (Hurley et al., 2004). The pathology 
associated with VS-FCV outbreaks indicates breakdown of epithelial and endothelial 
barrier function (Pedersen et al., 2000, Pesavento et al., 2004). These observations 
may reflect the capacity of FCV to target fJAM-A, as it is known that JAM-A is 
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required for maintenance of epithelial and endothelial tight junctions. It is possible that 
FCV can disrupt the homophilic interactions that occur between JAM-A molecules on 
apposing cells and thus disrupt tight junctions and barrier integrity, an effect proposed 
for secreted adenovirus fiber protein (Walters et al., 2002).  
 JAM-A is also expressed on platelets, including feline platelets (Stokol and 
Parker, unpublished data). In some cases of VS-FCV, thrombocytopenia has been 
noted together with disseminated intravascular coagulation (Foley et al., 2006, Hurley 
et al., 2004, Pedersen et al., 2000, Schorr-Evans et al., 2003). It is possible that large 
amounts of FCV in the blood might disrupt normal platelet function. A monoclonal 
antibody (F11) that binds human JAM-A induces platelet secretion and aggregation. 
Binding of F11 to the surface of platelets is blocked by a peptide that incorporates the 
first 23 residues of the hJAM-A D1 (residues 28 to 50) (Babinska et al., 2002a). As we 
have shown, FCV likely interacts with residues D42 and K43 on fJAM-A. Therefore, 
it is possible that FCV binding to fJAM-A might induce secretion and aggregation of 
feline platelets, and that this in turn might be responsible for some of the pathogenic 
sequelae seen with VS-FCV disease. We are currently examining these and other 
possibilities. 
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CHAPTER 4 
Genetic and biophysical evidence for large-scale conformational changes in the 
capsid of a calicivirus upon interaction with its functional receptor  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Manuscript in preparation. This manuscript will include the following additional 
authors: Yi Zhou, Patrick Lightfoot, B. V. Venkataram Prasad and John S. L. Parker. 
Drs. Yi Zhou and B. V. Venkataram Prasad were responsible for generating the 
structural data for FCV-5 using virus purified by myself and Patrick Lightfoot. Figures 
4.2 and 4.3A-C were generated by Dr. Yi Zhou] 
128 
 4.1 Abstract 
 The capsid of nonenveloped feline calicivirus (FCV) mediates viral 
attachment, entry and the cytosolic delivery of the viral genome. Nonenveloped viral 
capsids are metastable structures that undergo conformational changes during virus 
entry that allow them to interact with the cell membrane. For members of the 
Caliciviridae, neither the nature of these structural changes in the capsid nor the factor 
responsible for inducing these changes is known. Feline junctional adhesion molecule 
A (fJAM-A) is sufficient to mediate attachment and infectious viral entry of FCV. 
Here we show that the infectivity of some FCV isolates is neutralized upon incubation 
with the soluble receptor at 37°C. We used this property to select for mutants that 
were resistant to preincubation with the soluble receptor. We isolated and sequenced 
24 of these soluble receptor resistant mutants and have further characterized the 
growth properties and receptor-binding properties of 8 mutants. To identify the 
location of the mutations within the capsid protein within the structure of FCV, we 
obtained a 3.6 Angstrom structure of FCV. The location of mutations within the capsid 
structure indicate that many of the soluble-receptor resistant (srr) mutants have 
mutations in their capsid protein that map to the surface of the P2 domain, are buried 
at the protruding domain dimer interface, or are present in inaccessible regions of the 
capsid protein. Taken together with data showing that both the parental FCV and the 
srr mutants undergo increases in hydrophobicity upon incubation with the soluble 
receptor at 37 °C, these findings indicate that this model calicivirus undergoes 
significant conformational change upon interaction with its receptor. These changes 
are likely to be important for subsequent interaction of the capsid with cellular 
membranes and for membrane penetration and genome delivery. 
 
 
129 
 4.2 Introduction 
 The interactions between viruses and receptors on the surface of host cells 
strongly influence viral pathogenesis and regulate morbidity and mortality in the host. 
This is because these interactions determine the types of cells that can be infected, the 
pathway of entry into the cell and the efficiency of productive infection. 
 Interactions between nonenveloped virus capsids and their receptor(s) trigger 
one or more steps required for infectious entry. These steps can include interaction 
with other receptors, exposure to low pH or endosomal proteases or other factors. 
Ultimately, one or more of these interactions lead to changes in capsid conformation; 
such changes may result in the exposure of hydrophobic regions or release of a lipid-
seeking factor that can interact with, and disrupt the limiting cellular membrane to 
allow the capsid and/or the genome to be delivered to the interior of the cell [as 
reviewed in (Tsai, 2007)]. 
 The Caliciviridae are small nonenveloped viruses containing a positive-sense 
RNA genome (~7-8 kb) that cause disease in humans and animals. Several important 
disease-causing members of the Caliciviridae, including human noroviruses, cannot be 
propagated in tissue culture systems. This has slowed progress on studies of the 
mechanisms of cellular entry of these viruses. In contrast, feline caliciviruses 
propagate readily in tissue culture and two cell surface receptor molecules, feline 
Junctional Adhesion Molecule-A (fJAM-A) and α2,6 sialic acid are known (Makino et 
al., 2006, Stuart & Brown, 2007).  
 JAM-A is a type I transmembrane glycoprotein (MW 36-41 kDa) member of 
the immunoglobulin superfamily (IgSF); it consists of an N-terminal signal peptide, an 
extracellular domain (composed of two Ig-like domains - a membrane-distal D1 and a 
membrane-proximal D2), a transmembrane domain, and a short cytoplasmic domain 
that contains a type II PDZ domain-binding motif (Ebnet et al., 2000, Mandell & 
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 Parkos, 2005). We have previously shown that the D1 domain of the fJAM-A 
ectodomain is necessary and sufficient for FCV binding, and that preincubation of 
FCV with soluble fJAM-A results in virus neutralization (Ossiboff & Parker, 2007). 
Additional roles that fJAM-A and α2,6 sialic acid might play in FCV entry, however, 
have not been investigated.  
 The virions of caliciviruses are composed of 180 copies of a single capsid 
protein. Crystallographic structures have been determined for two members of the 
Caliciviridae, recombinant virus like particles of Norwalk virus (genus Norovirus) and 
native San Miguel sea lion virus (SMSV) virions (genus Vesivirus) (Chen et al., 2006, 
Prasad et al., 1999). The viral capsid consists of 90 dimers of the capsid protein 
arranged in T = 3 icosahedral symmetry. Each capsid protein contains three structural 
domains, an N-terminal arm (NTA), shell (S), and protruding domain (P), which is 
further subdivided into two sub-domains (P1 and P2) (Chen et al., 2006, Prasad et al., 
1999). The most exterior sub-domain, P2, is structurally conserved between Norwalk 
virus and SMSV, but there is little sequence conservation. Two hypervariable regions 
that were identified in the primary sequence of FCV contain neutralizing epitopes 
(Guiver et al., 1992, Neill et al., 2000, Tohya et al., 1997). On the SMSV capsid 
structure these hypervariable regions map to loops that are predominantly surface-
exposed. The surface residues at the dimeric interface between two capsid monomers 
are conserved within individual calicivirus genera and it has been suggested that this 
interface might be important in receptor binding (Chen et al., 2006). A cryo-electron 
microscopy reconstruction of the FCV vaccine strain F9 complexed with the 
ectodomain of fJAM-A (modeled on the crystal structures of SMSV and human JAM-
A, respectively) shows that FCV engages its receptor by way of the outer face of the 
P2 domain (Bhella et al., 2008). The reconstructions by Bhella et al. (2008) also 
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 showed that compared to cryo-EM reconstructions of the virus alone, binding of 
fJAM-A caused a rotation in the P dimer. 
 The selection of mutant viruses resistant to neutralization with soluble 
receptors has been used to identify virus residues important in either directly binding 
to or modulate the binding of virus to receptor (Colston & Racaniello, 1994, Kaplan et 
al., 1990, Saeki et al., 1997). Soluble receptor-resistant (srr) mutants of poliovirus 
contained mutations to both surface exposed and internal residues that were shown to 
regulate both receptor attachment and conformational changes in the capsid (Colston 
& Racaniello, 1994, Racaniello, 1996). Here we report 24 srr mutants and the location 
of their capsid mutations on a 3.6 Å structure of the virus. In addition, we describe the 
growth kinetics and receptor binding properties of a subpanel of 8 srr mutants. Using 
spectrofluorimetry, we show increased hydrophobicity of the capsid upon interaction 
with soluble fJAM-A suggesting that FCV undergoes a conformational change 
following incubation with soluble receptor. In the 24 srr mutants, we identified 20 
unique mutations that were present on surface-exposed and buried regions of the 
capsid protein. FCV-5, three srr mutants, and two field isolates of FCV demonstrated 
increases in hydrophobicity upon incubation with the soluble receptor at 37 °C. Taken 
together, these findings indicate that this model calicivirus undergoes significant 
conformational changes upon interaction with its receptor. 
 
4.3 Methods 
 Cells and viruses. Crandell-Reese feline kidney (CRFK; ATCC #CCL-94) 
cells were grown in Eagle’s minimal essential medium (EMEM; CellGro) 
supplemented with 5% fetal bovine serum (HyClone), 100 U ml-1 of penicillin, 100 μg 
ml-1 streptomycin, 0.25 μg ml-1 amphotericin B, 1 mM sodium pyruvate, and non-
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 essential amino acids (CellGro). Suspension Chinese hamster ovary (CHO-S) cells 
(Invitrogen) were grown in CHO-Serum Free Medium (-SFM; Gibco). 
 The F9 vaccine strain (VR-782) of FCV was obtained from the ATCC. The 
viral isolates FCV-5, Deuce, Kaos, FCV-127, FCV-131, and FCV-796 were 
previously characterized (Ossiboff et al., 2007). FCV-Urbana viral stock was 
generated from a full-length infectious clone as previously described (Sosnovtsev & 
Green, 1995, Sosnovtsev et al., 1997). Briefly, CRFK cells were infected with 
vaccinia virus expressing T7 RNA polymerase (MVA/T7); 1 h following infection the 
FCV-Urbana infectious clone (pQ14) was transfected into the cells using FuGENE 6 
(Roche). Samples were lysed at 18 h p.i. by successive freeze-thaw cycles and viral 
plaques were selected. The viral capsid gene was sequenced to verify that FCV-
Urbana was present. Third passage viral stocks were prepared from twice plaque-
purified viruses amplified in CRFK cells. Plaque assays were performed as previously 
described (Ossiboff et al., 2007). 
 Antibodies and reagents. A rabbit antiserum against the purified fJAM-A 
ectodomain was previously described (Ossiboff & Parker, 2007). Virus was detected 
with either an anti-FCV mouse MAb (S1-9; Custom Monoclonals International) or 
rabbit anti-FCV-5 antiserum. The fJAM-A extracellular domain (amino acid residues 
26-232) was purified as previously described (Ossiboff & Parker, 2007). Recombinant 
protein was purified by glutathione affinity chromatography. When GST-free fJAM-A 
was desired, N-terminal GST and His tags were cleaved from the recombinant protein 
using HRV 3C protease (Novagen).  
 Neutralization of FCV-5 by fJAM-A. To investigate the effect of temperature 
on the neutralization of FCV-5 by fJAM-A, ~1 × 105 plaque forming units (p.f.u.) of 
FCV-5 in Dulbecco’s modified Eagle’s medium (DMEM; CellGro) + 0.1% BSA 
(Calbiochem) were incubated either in the presence or absence of soluble fJAM-A (4.3 
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 μM) at 4°C for 3 h. Samples were then incubated for an additional 30 min at 4, 16, 24, 
or 37°C, and infectious titer of the samples was determined by plaque assay. To 
construct neutralization curves of FCV-5 by fJAM-A, ~1 × 105 plaque forming units 
(p.f.u.) of FCV-5 in DMEM + 0.1% BSA was incubated with different concentrations 
of soluble GST-fJAM-A or fJAM-A lacking the GST tag at 37°C for 30 min. The 
samples were then placed on ice or frozen at -80°C and the remaining viral titer 
assayed. 
 Selection of soluble receptor resistant (srr) mutants of FCV-5. Aliquots of 
FCV-5 (1 × 105 p.f.u.) were incubated with GST-fJAM-A (55 μM) at 37°C for 30 min, 
plaque titrated on CRFK cells in 6 well plates and overlaid with EMEM containing 
5% fetal bovine serum and 1% Bacto Agar. Following incubation at 37°C in 
humidified 5% CO2 for 48 h, individual plaques were selected and amplified without 
selection on CRFK cells in 12-well plates (Corning). Once wells showed 100% 
cytopathic effect (CPE), a small aliquot from each well was again incubated with 55 
μM GST-fJAM-A at 37°C for 30 min and then used to infect CRFK cells in 12-well 
plates. In wells that developed CPE, a sample of the lysate was subjected to an 
additional round of GST-fJAM-A neutralization, and samples were amplified on 
CRFK cells in a 96-well plate (Corning). Twenty-four wells showing CPE were 
chosen at random and twice plaque-purified.  
 Sequencing the major capsid protein (VP1) of the srr mutants. The 
recovery of viral RNA, RT-PCR and sequencing of the capsid protein of the srr 
mutants was performed as previously described (Ossiboff et al., 2007). Briefly, total 
RNA was extracted from infected-cell lysates (RNeasy Mini; Qiagen), and first strand 
cDNA synthesis of the capsid region of the genome was performed using a degenerate 
primer and Accuscript High-Fidelity reverse transcriptase (Stratagene). The capsid 
open reading frame was then amplified from the first strand cDNA template (primers 
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 available upon request). The resulting ~2.1 kb PCR products, encompassing the 
entirety of the capsid ORF, were purified and sequenced directly. 
 Purification of FCV. Confluent roller bottles (Corning) of CRFK cells were 
infected with FCV (multiplicity of infection [MOI] = 5) and maintained in a roller 
incubator for 8 h at 37°C. At 8 h p.i., cells were removed from the plastic surface by 
physical agitation and the cells were collected by centrifugation of the medium at 500 
× g. The cell pellet was resuspended in 250 mM NaCl, 85 mM Tris Base, pH 7.5 and 
frozen at -80°C. The pellet was thawed, briefly sonicated to lyse the cells and 
trichlorotrifluoroethane was used to extract the virus from the cell lysate. To clarify 
the phases, the trichlorotrifluoroethane/lysate mixture was centrifuged for 10 min at 
5850 × g. The aqueous phase was removed and the trichlorotrifluoroethane extraction 
step repeated. Following the second centrifugation, the aqueous phase was placed on a 
CsCl gradient (1.30 – 1.45 g/ml) in an ultracentrifuge tube (Beckman) and centrifuged 
at 97,000 × g for 16 h. Visible virus bands were collected and dialyzed exhaustively 
against virion buffer (150 mM NaCl, 10 mM Tris Base, 15 mM MgCl2, pH 7.2) for 
48-72 h at 4°C. Purified virus was stored at 4°C. 
 Crystallization. Crystallization trials of FCV-5 were carried out using the 
hanging-drop vapor diffusion method at room temperature. Crystal screens 1 and 2 
from Hampton Research were used to explore various conditions. Typically, for each 
condition, 2 μl of the virus solution, at a concentration of 3 mg/ml, was mixed with 2 
μl of the well solution and equilibrated with 0.5 ml of the well solution. Initial 
screening produced crystals under a few conditions including the Crystal Screen 1 
condition 3 (0.4 M Ammonium phosphate) and condition 13 (30% PEG 400, 0.1 M 
Tris HCL pH 8.5, 0.2 M Sodium Citrate). After crystallization condition optimization 
and synchrotron on-site screening, crystals of the best diffraction quality were 
obtained using a well solution containing 0.45 M Ammonium phosphate with Additive 
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 Screen Reagent C10 (1.0 M Glycine). Cryo-protection of crystals was obtained by 
soaking the crystals in the mother liquor with increasing concentration of PEG 400 
through six steps: 5%, 10%, 15%, 20%, 22.5% and 25%. The equilibration time at 
each solution was at least 10 minutes. The crystals were then flash frozen in liquid 
nitrogen and shipped to synchrotron sites for data collection. 
 Data collection and analysis. The diffraction data from single crystals were 
collected under cryo-conditions at APS 19ID station with monochromatic X-rays 
(wavelength=0.9795A) and a detector to crystal distance of 480 mm on an ADSC 3×3 
CCD detector using an oscillation angle of 0.3° and an exposure time of 3 seconds. 
Indexing, integration, scaling, post-refinement, and reduction of the data were carried 
out using the HKL2000 and D*TREK packages. Analysis of the diffraction data 
clearly indicated that the FCV-5 crystal belonged to the orthorhombic space group 
I222. The data between 30 and 3.6Å from 300 frames were scaled with an Rmerge factor 
of about 22%. The overall completeness of the data to 3.6Å resolution is about 90.1%. 
To determine the precise orientation of the virus particle in the unit cell, self-rotation 
functions were calculated using the program GLRF. These calculations showed all the 
peaks corresponding to 5-fold (κ=72°), 3-fold (κ=120°), and 2-fold (κ=180°) axes, 
which are expected from a particle with icosahedral symmetry. In the I222 space 
group, consistent with the unit cell dimensions and the particle radius, which is 
estimated to be 200Å, the particle position is uniquely defined by the intersection of 
the crystallographic 2-fold axes. In such a setting, an icosahedral particle can assume 
one of the two possible orientations. This ambiguity in orientation was clearly 
resolved by the self-rotation function calculations using the X-ray diffraction data. 
Each crystallographic asymmetric unit is composed of 1/4th of the virion with a non-
crystallographic 15-fold symmetry. Similar packing of icosahedral particle has been 
observed in Norwalk virus. 
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  Crystal structure determination and refinement. A properly positioned and 
oriented SMSV-4 capsid was placed in a FCV-5 unit cell. One initial model at a 
resolution of 10 Å was calculated from the 15 copies of SMSV-4 related first by 
icosahedral 5-fold symmetry then by icosahedral 3-fold symmetry. Phase refinement 
and extension were carried out by iterative cycles of real space electron density 
averaging, solvent flattening and back transformation with the RAVE and CCP4 
program packages. The phases were extended to the final 3.6 Å resolution with each 
step less than one reciprocal space point. An initial mask was constructed from the 
cryo-EM reconstruction with the program MAMA, and the mask was edited each step 
to avoid truncation of the density. The averaged 3.6 Å density map is of good quality 
and readily interpretable. After initial model building and the final refinement, the 
structure has an Rfree of 0.39, calculated using 10% of the data that were not included 
in the refinement, and a final R factor of 0.37. 
 Neutralization of srr mutants by fJAM-A. To verify that the selected srr 
mutants were resistant to neutralization by soluble receptor, a subpanel of 8 srr 
mutants (~1 × 105 p.f.u.) in DMEM + 0.1% BSA were incubated at 37°C either in the 
presence or absence of GST-fJAM-A (45 μM) for 30 min. Infectious titer of samples 
was determined by plaque assay. 
 Virus-binding assay by flow cytometry. FCV binding to CHO-S cells 
transiently expressing fJAM-A was detected as previously described (Ossiboff & 
Parker, 2007). Briefly, CHO-S cells (106 cells per sample) were transiently transfected 
with a DNA construct encoding fJAM-A. At 24 h post-transfection the cells were 
washed and incubated with FCV (MOI = 5) in phosphate-buffered saline (PBS) (137 
mM NaCl, 3 mM KCl, 8 mM Na2HPO4 [pH 7.5]) plus 1% BSA (PBSA) on ice for 30 
min. After washing to remove unbound virions, the cells were incubated with fJAM-A 
rabbit antiserum and anti-FCV mouse Mab in PBSA on ice for 30 min. The cells were 
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 then washed in PBSA, fixed in 2% paraformaldehyde in PBS, and incubated with 
Alexa 647-conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-mouse IgG 
for 30 min at room temperature. The cells were analyzed using a FACSCalibur 
(Becton Dickinson). Cells expressing fJAM-A on their surface were gated and 
analyzed for virus binding (10,000 cells were gated for each sample). 
 Plaque reduction of srr mutants by fJAM-A antiserum. Confluent CRFK 
cells in 60 mm dishes (Corning) were incubated PBSA with or without fJAM-A rabbit 
antiserum for 30 min at room temperature. Virus (~100 p.f.u per dish) was adsorbed 
for 1 h at room temperature. The monolayers were then overlaid with EMEM 
containing 5% fetal bovine serum and 1% BactoAgar. After incubation at 37°C for 48 
h in humidified 5% CO2, the overlay was removed and the cells were fixed with 10% 
buffered formalin, and stained with 1% (wt/vol) crystal violet solution. The plaques 
were counted, and percent reduction from controls was calculated. 
 Single- and multiple-cycle growth kinetics of srr mutants. CRFK cell 
monolayers were infected with srr mutants at multiplicities of 5 and 0.01 for single- 
and multiple-cycle growth curves, respectively. Virus was adsorbed to cells for 1 h at 
room temperature in DMEM plus 0.1% BSA; EMEM plus 5% FBS supplemented as 
above was then added and the cells were incubated for at 37 °C in 5% CO2. At various 
times post-infection (p.i.), samples were collected and stored at -80 °C for later 
titration. Prior to plaque assay, all samples were frozen and thawed three times. Virus 
growth at each time point was calculated by subtracting the log10(p.f.u. ml-1) at T = 0 
from the log10(p.f.u. ml-1) measured at the time point. Results are expressed as the 
change in plaque titer over time. 
 ELISA binding of FCV to fJAM-A. Purified fJAM-A ectodomain (1 μg ml-1) 
in carbonate/bicarbonate buffer (Sigma) was bound to 96-well ELISA plates (100 ng 
per well) at 4°C overnight. The wells were blocked with PBS containing 0.05% 
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 Tween 20 (PBS-T) plus 0.5% BSA for 1 h at room temperature and washed three 
times with PBS-T. Two-fold dilutions of purified virus (starting concentration 200 μg 
ml-1) were prepared in PBS-T + BSA; 100 μl of each dilution of the virus was bound 
to plates for 3 h on ice. After the plates were washed, bound virus was detected with 
rabbit anti-FCV-5, followed by HRP-conjugated goat anti-rabbit IgG. Antibodies 
diluted in PBS-T + BSA were incubated with the plates for 90 min on ice. Following 
washing, substrate, 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) (Sigma) in a 
citric acid-sodium phosphate buffer was added to each well and incubated for 60 min 
at room temperature. Absorbance was measured at 595 nm on a Microplate 
Biokinetics Reader (BioTek Instruments). The mean ± SE of 3 plates (2 replicates per 
plate) is shown. 
 ELISA competitive binding of FCV in the presence of soluble fJAM-A. 
Purified fJAM-A ectodomain (1 μg ml-1) in carbonate/bicarbonate buffer was bound to 
96-well ELISA plates (100 ng per well) at 4°C overnight. The wells were blocked 
with PBS-T + BSA for 1 h at room temperature and washed three times with PBS-T. 
Two-fold dilutions of fJAM-A ectodomain were prepared in PBS-T+ BSA with 750 
ng purified virus (starting fJAM-A concentration 5.3 μM); 100 μl of each dilution of 
the fJAM-A/virus mixture was bound to plates for 3 h on ice. Plates were washed, and 
virus binding detected as described for assay to determine virus binding to fJAM in 
absence of soluble receptor. Absorbance readings for each virus were normalized, and 
the mean ± SE of 3 plates (2 replicates per plate) is shown. 
 Detection of bis-ANS binding to FCV by fluorescence spectroscopy. 
Purified virus (60 μg ml-1, a 0.5 μM concentration of the FCV VP1 dimer) or 1.5 μM 
purified receptor (fJAM-A or hJAM-A ectodomain) diluted in virion buffer were 
incubated in a 400 μL fluorometer cell (Varian) at 37°C for 10 min to allow 
temperature equilibration. To detect bis-(8-anilinonaphthalene-1-sulfonate) (bis-ANS) 
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 binding to native virus and receptor, bis-ANS was added to the sample to a final 
concentration of 3 μM. Bis-ANS was excited at 395 nm (slit width 5 nm) and emission 
collected at 495 nm (slit width 10 nm) at 2 second intervals for 10 min on a Cary 
Eclipse spectrofluorometer (Varian). To investigate the binding of bis-ANS to 
preincubated virus and receptor, virus and receptor were mixed and incubated for 10 
min at 37°C. Bis-ANS was added (3 μM) and sample readings were performed as 
detailed above. All spectrofluorometer readings were taken with the photomultiplier 
tube set at 700 V. 
 fJAM-A neutralization of a panel of FCV isolates. To investigate the ability 
of GST-fJAM-A to neutralize a panel of FCV isolates, 1 × 105 p.f.u. of virus in 
DMEM + 0.1% BSA was incubated with absence or presence (final concentration 45 
μM) of soluble GST-fJAM-A at 37°C for 30 min. A plaque assay was used to 
determine the remaining viral titer of the samples. 
 Statistical analyses. Analyse-it (Analyse-it Software) statistical analysis add-
in for Microsoft Excel was used to perform ANOVA where necessary. Graphs were 
prepared using Kaleidagraph (Synergy Software) and Adobe Illustrator CS3 (Adobe). 
Protein images were prepared using PyMOL (DeLano Scientific) (Delano, 2002). 
 
4.4 Results 
 FCV-5 is neutralized by preincubation with soluble fJAM-A ectodomain 
at 37°C. Preincubation of nonenveloped viruses such as rhinoviruses and polioviruses 
with their functional receptors neutralizes virus infectivity (Greve et al., 1991, Kaplan 
et al., 1990). In a previous study, we showed that preincubation on ice of FCV-5 with 
a purified soluble GST-fused form of the ectodomain of fJAM-A modestly reduced 
infectivity (Ossiboff & Parker, 2007); FCV-5 is a field isolate responsible for highly 
virulent, systemic disease in cats. During these experiments we noted that if the virus-
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receptor preincubation was carried out at 37°C rather than 4°C, substantially more 
infectivity was lost. To quantify the extent to which FCV-5 was neutralized by 
preincubation with soluble receptor at 37°C and to assess the influence of receptor 
concentration and the form of soluble fJAM-A ectodomain on neutralization, we 
preincubated ~ 105 p.f.u. of FCV-5 with increasing concentrations of purified GST-
fJAM-A or with a soluble form of fJAM-A in which the GST had been removed 
(sfJAM-A) for 30 min at 37°C. We found a clear relationship between the 
concentration of soluble receptor and the extent of virus neutralization with 
concentrations of GST-fJAM-A > 27.5 μM (Figure 4.1) and of sfJAM-A > 2.8 μM 
(data not shown) causing ~ 250-fold loss of viral titer. Cleavage of GST from the N-
terminus of the fJAM-A ectodomain enhanced the ability of the protein to neutralize 
FCV-5 by 10-fold. As GST was fused to the D1 portion of the ectodomain, which we 
have shown is necessary for FCV binding, it seems likely that GST sterically hindered 
the FCV-ectodomain interaction.  
 As we had previously found only a modest reduction in FCV-5 infectivity 
when virus and GST-fJAM-A were preincubated at 4°C, we assessed the loss of 
infectivity following preincubation of virus with sfJAM-A at 4, 16, 20, and 37 °C. We 
found a temperature-dependence to the loss of infectivity with a 4-fold loss of 
infectivity at 4°C compared to ~ 250-fold loss of infectivity at 37°C (Table 4.1). We 
conclude that soluble forms of the fJAM-A ectodomain can substantially neutralize 
FCV infectivity when preincubated at 37°C and that neutralization is temperature- and 
concentration-dependent and saturable. 
 Selection of soluble receptor-resistant (srr) mutants of FCV. During the 
above experiments we found that some residual infectivity always remained after 
preincubation of FCV-5 with sfJAM-A at 37°C. We hypothesized that resistant mutant 
viruses were being selected. As we expected that analysis of these mutants would shed 
  
 
 
 
 
 
 
Figure 4.1. Neutralization of FCV-5 by soluble fJAM-A. FCV-5 (~ 1 × 105 p.f.u.) was 
incubated with varying concentrations of soluble GST-fJAM-A at 37 °C for 30 min. 
The virus samples were then plaque titrated on CRFK cell monolayers. The results 
shown indicate the mean and standard deviation of three independent experiments. 
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Table 4.1. Temperature dependant neutralization of FCV-5 
Incubation temperaturea Change in log titer ± SDb 
4° - 0.6 ± 0.2 
16° - 1.4 ± 0.3 
24° - 2.1 ± 0.2 
37° - 2.4 ± 0.1 
aAll samples were incubated at 4°C for 3 h and then for 30 min at 
the temperature indicated 
bChange in log titer (pfu/ml; as determined by plaque assay on 
CRFK cells) of ~1 × 105 p.f.u. of virus incubated with 4.4 μM 
sfJAM-A from samples incubated with buffer alone, ± standard 
deviation of at least three replicates. 
 
light on possible capsid residues important in binding to fJAM-A or receptor-induced 
conformational changes in the capsid associated with neutralization, we selected 24 
mutants that were resistant to preincubation with the soluble receptor. All of the 
mutants contained one or two point mutations within the capsid protein (Table 4.2) 
giving a total of 20 unique mutations. Three of these mutations were present in the 
leader sequence of the capsid, which is cleaved from the capsid precursor protein 
during capsid assembly by a virus-encoded proteinase (Carter et al., 1992, Neill et al., 
1991, Sosnovtsev et al., 1998); however, all of the mutants that contained mutations in 
the leader sequence also had an additional mutation in another region of the capsid 
protein. Several residue changes were found in more than one mutant. These changes 
were at positions G329 (3 mutants), T438 (2 mutants), K480 (3 mutants), V516 (5 
mutants), and K572 (2 mutants). These findings indicated that srr mutants of FCV-5 
were readily obtained and propagated in vitro. 
 Overview of the crystal structure. In order, to map the location of srr 
mutations on the capsid we determined the crystal structure of FCV-5 at 3.6 Å 
resolution by molecular replacement and real space averaging (Figure 4.2). The 
structure was refined to a crystallographic R-factor of 0.37 (Rfree=0.39) at 3.6 Å  
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 Table 4.2. Identification of capsid mutations in srr mutants 
Mutationa Number of Mutants 
A168S + F486L 1 
T202A + T447I 1 
G329D 1 
G329S 1 
D15N + G329S 1 
E401K 1 
D434N + I661T 1 
T438I 1 
T438A 1 
N443S 2 
I94T + S465N 1 
K480R 1 
K480Q 1 
K480E + N483S 1 
V516I 2 
V516A 3 
P116T + I535V 1 
K572E 1 
K572Q 1 
I94T + Y575H 1 
aMutations are identified by the wild-type amino acid, amino 
acid position, and mutant amino acid.  
 
resolution. As in other T=3 viruses, the icosahedral asymmetrical unit consisted of 
three independent but chemically identical subunits (Fig. 2B). These subunits are 
traditionally designated as A, B and C. The present model of the FCV-5 icosahedral 
asymmetrical unit consist of residues 129-662 of the A and C subunit, and 133-662 of 
the B subunit. 
 The polypeptide fold. The structure of each subunit comprises an NTA, an S 
domain and a P domain, similar to that seen in the recombinant Norwalk virus capsid 
(rNV) and SMSV-4. Residues 170-329 fold into a canonical eight-stranded beta-barrel 
structure, which has been seen in rNV, SMSV-4 and many other viral capsid proteins. 
These eight strands, conventionally denoted as B-I, form two four-stranded sheets,  
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Figure 4.2. X-ray structure of Feline Calicivirus (FCV-5) capsid. (A) The X-ray 
structure of FCV-5 viewed along the icosahedral two fold axis. Location of a set of 
A/B and C/C dimers and icosahedral 5-fold and 3-fold axes are shown. (B) A ribbon 
representation of the B subunit structure. The N-terminal arm (NTA) (green), S 
domain (blue), and P1 (red) and P2 (yellow) sub-domains are indicated. 
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 BIDG and CHEF. Two α helixes are situated between strands C and D and strands E 
and F, respectively. Structural comparison of the S domains of FCV-5 and SMSV-4  
revealed that the most significant variations were located in the loop region connecting 
strands E and F. 
 The P domain of FCV-5 is comprised of residues 330-662 and is linked to the 
S domain by a flexible hinge. The P domain is further divided into two sub-domains: 
P1 and P2. The P1 sub-domain, consisting of two segments of polypeptide (residues 
330-381 and 551-662), folds into a structure similar to that seen in that of SMSV-4. 
The P2 sub-domain, the outermost portion of the capsid protein, has been considered 
as a large insertion into the P1 sub-domain. In the P2 sub-domain, both SMSV-4 and 
FCV-5 form a compact barrel structure consisting of six strands, sequentially labeled 
as A'-F' (Figure 4.3 A&B). However, the six strands in FCV-5 vary in length and 
relative orientation, compared to their counterparts in SMSV-4. These six strands are 
connected by loops of various lengths. Structure superimposition showed that loop 
C'D' in FCV-5 is significantly shorter than that of SMSV-4 (Figure 4.3C). The P2 sub-
domain consists of residues 382-550 and contains 7 fewer residues than that of 
SMSV-4. Structural comparison showed that those “inserted” residues are mainly 
distributed in the loop connecting strands C' and D'. 
 Structural comparison between different subunits. Pair-wise superposition 
calculations indicated that the structure of the P domain of FCV-5 adopts a very 
similar structure in all three subunits. The S domain, however, shows larger variations 
between the different subunits to facilitate the assembly of a T=3 capsid. In addition, 
the A and C subunits have 4 more disordered N-terminal residues than the B subunit. 
Superposition of the whole subunit structure revealed that the A subunit forms a more 
compacted structure, as evidenced by the closer association of the S and P domains. 
The interactions between the S and P domains are less prominent in the B subunit,  
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Figure 4.3. Ribbon representation of the P2 sub-domain in FCV-5 (A) and SMSV-4 
(B). The β-strands are labeled from A' to F' in each case. (C) The superposition of the 
P domain of FCV-5 (red) and SMSV-4 (blue) shows that the six β-strands in the P2 
sub-domains are similarly spatially arranged into a compact barrel, despite the low 
sequence similarity. (C-E) Positions of conserved residues and antigenic sites on the 
P2 sub-domain of the C/C dimer of FCV-5. (D) Neutralizing epitopes mapped on P2 
(grey). Antigenic sites (Ags1-4; colored pink) represent B-cell linear epitopes 
identified by Radford et al (Radford et al., 1999). Monoclonal antibody escape 
mutations identified by Tohya et al are colored red (Tohya et al., 1997). (E) Degree of 
conservation of surface-exposed residues on the P2 sub-domain as predicted by 
Consurf 3.0. Solid yellow line indicates dimer interface; dotted yellow line indicates 
axis of conservation. (F) Locations of N-terminal and C-terminal HVRs, region C and 
central conserved portion of region E mapped on surface of P2 sub-domain.
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 resulting in a more relaxed structure. The C subunit has the most open conformation, 
with the fewest interactions between the S and P domains. These differences 
contribute to the bent and flat conformations of the A/B and C/C dimers, respectively, 
as has been seen in the SMSV-4 and rNV structures. 
 Mapping of neutralizing epitopes and conserved surface regions on the P2 
sub-domain of FCV-5. Hypervariable regions (C and E regions) of the FCV capsid 
sequence have been previously identified and neutralizing epitopes have been mapped 
to residues within the E region predominantly (Figure 4.3F) (Radford et al., 1999, Seal 
& Neill, 1995, Tohya et al., 1991, Tohya et al., 1997). Using the FCV-5 structure we 
mapped the location of 4 linear B-cell epitopes identified in FCV-F9 using a peptide 
library (Radford et al., 1999). All of these sites lie on the margins of the P2 sub-
domain with one site, Ags4, at the dimer interface (Figure 4.3D). Similarly, the 
location of antibody escape mutations found in mutants of FCV-F4 are also located on 
the margins of the P2 sub-domain within hypervariable regions (Figure 4.3D) (Tohya 
et al., 1997). To more accurately assess the conservation of individual surface-exposed 
residues on the P2 sub-domain, we used CONSURF 3.0, which maps the rate of 
evolution as determined by an empirical Bayesian estimation among homologous 
proteins onto the 3-D structure (Landau et al., 2005). As input we used an alignment 
of 47 different FCV capsid sequences to derive an evolutionary conservation score 
that was used to color code individual residues on the surface of the FCV-5 capsid 
structure (Figure 4.3E). This analysis revealed a patchwork of conserved surface 
residues along the dimeric interface of the P domain that also extended laterally at a 
45° angle to the dimer interface on the surface of each monomer (Figure 4.3E). This 
patch of conserved residues was surrounded by highly variable residues on the 
margins of the P2 sub-domain (Figure 4.3E). 
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  Mapping srr mutations on the FCV-5 structure. Sequencing of the capsid 
protein of the 24 srr mutants revealed 17 unique amino acid changes from the parental 
FCV-5 mature capsid protein sequence. We mapped the location of these changed 
residues on the structure of FCV-5 (Figure 4.4). Three mutations were found in the 
NTA and S domains, and 14 mutations were present in the P domain (Figure 4.4A). Of 
the 24 mutants investigated, 21 (87.5%) contained mutations that mapped to the P 
domain of the capsid, and 18 of those mutations were to residues within the P2 sub-
domain.  
 Of the mutations found in the NTA and S domains, one change was to a 
residue (A168S) within the NTA, but this mutation was accompanied by a second 
amino acid change in the P2 domain (F486L). Similarly, a mutant with a change in the 
shell domain (T202A) also had a change in the P2 domain (T447I). Three srr mutants 
contained mutations at residue G329 in the shell domain on a loop that connects the 
shell with the protrusion domain. Residues G329 is located at the point of the flexible 
hinge, and mutations at G329 (D/S) were present alone or in addition to a change in 
the leader sequence of the capsid (D15N) (Figure 4.4B, Table 4.2). Mutations to 
residue G329 were the only changes identified that occurred independently of an 
additional mutation within the P domain. 
 Three of the 21 mutated residues identified in the P domain were present 
within P1 sub-domain (K572E/Q, Y575H, and I661T). Residues K572 (E, Q) or Y575 
(H) were buried at the dimer interface of the capsid structure (Figure 4.4B). Residue 
I661 was located at the base of the P1 sub-domain, in close proximity to the S domain 
(Figure 4.4B); the mutant containing the I661T change also had a second change 
within the P2 domain (D434N). The other 11 P domain mutations were in the P2 sub-
domain. Eight of these mutated residues were within surface-exposed loops of P2: 
E401K, D434N, T438A, N443S, T447I, S465N, K480R/Q/E, V516I/A, and I535V  
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Figure.4.4. Position of mutations found in srr mutants in the structure of FCV-5. (A) 
The residues mutated in the srr mutants are illustrated on a schematic of the FCV 
capsid protein. The location of the different structural domains in the primary capsid 
sequence is indicated. (B) The location of the mutations in the FCV-5 atomic 
resolution structure. 
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 (Figure 4.4B). Three of these surface-exposed residues were mutated in more than one 
srr mutant: N443 (2 mutants), K480 (3 mutants), and V516 (5 mutants). Two mutants 
had mutations to residues at the P2 dimer interface; one mutant possessed a change in 
the surface-exposed residue N483 (S), while another mutant contained a change to the 
buried residue F486 (L). Lastly, two mutants had mutations to residue T438 (I,A) that 
is buried in the present structure and maps to a loop near the surface of the P2 sub-
domain. In summary, the location of mutations present in srr isolates mapped to three 
general regions of the structure of FCV-5: (i) Surface-exposed residues on the P2 
domain; (ii) residues that are buried or not easily accessible from the surface of the 
capsid; and (iii) the hinge region of the capsid. 
 srr mutants are resistant to neutralization by sfJAM-A, but retain the 
capacity to bind fJAM-A and require cellular fJAM-A for infection. From the 
original 24 srr mutants, we selected a representative subpanel of 8 mutant viruses to 
further characterize; All of these 8 mutant viruses were resistant to neutralization with 
sfJAM-A (Figure 4.5). To verify that the eight selected srr mutants still bound to 
fJAM-A expressed on the cell surface, we used flow cytometry to measure the 
capacity of each of the mutants to bind to fJAM-A expressed on the surface of CHO-S 
cells (Figure 4.6). We found that all of the mutants bound to CHO-S cells expressing 
fJAM-A. One of the mutants, K572E, however, bound to 50% fewer cells than the 
parental FCV-5. All of the mutants still required fJAM-A as a functional receptor, as 
pretreatment of CRFK cells with a rabbit antiserum against fJAM-A completely 
blocked infection by the mutants. We conclude from these findings that the subpanel 
of 8 srr mutants still bind and require cellular fJAM-A for cell infection. 
 At low multiplicity of infection, the growth of some srr mutants differs 
from parental FCV-5. To evaluate if the growth properties of the srr mutants differed  
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Figure 4.5.  Neutralization of srr mutants by soluble fJAM-A. A subpanel of 8 srr 
mutants and FCV-5 (1 × 105 p.f.u.) were incubated in the presence or absence soluble 
GST-fJAM-A (55 μM) at 37 °C for 30 min. The infectivity of each sample was 
assayed by plaque-titration. The change in log titer was calculated by subtracting the 
titer of samples incubated with receptor from samples incubated without. The mean 
change in log10 titer ± SD of three replicates of a representative experiment is shown. 
 
 
 
 
 
 
153 
  
 
Figure 4.6. Binding of srr mutants to CHO cells expressing fJAM-A. Non-permissive 
CHO-S cells were transfected with a DNA construct encoding fJAM-A. At 24 h p.t. 
FCV (MOI = 5) was adsorbed to the cells on ice for 30 min. After washing with cold 
PBS to remove unbound virus, the cells were fixed and bound virus and cell surface 
fJAM-A were detected with mouse anti-FCV MAb and rabbit anti-fJAM-A antibodies, 
followed by Alexa 488-conjugated goat anti-mouse IgG and Alexa 647-conjugated 
goat anti-rabbit IgG. Virus binding and receptor expression were analyzed by flow 
cytometry. Virus binding was assayed by determining the percentage of fJAM-A-
positive cells that bound virus. The means of 3 independent experiments (2 samples of 
1 × 104 cells per experiment) ± SE are shown. 
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 from the parental FCV-5, we generated single- and multiple-cycle growth curves for 
each of the eight selected srr mutants. The growth kinetics and final yields following a 
single replicative cycle (MOI = 5) for the mutant viruses were similar to the parental 
FCV-5 (Figure 4.7A). However, we found that during multiple replicative cycles 
(MOI= 0.01) there was a significant difference between the growth kinetics of the 
parental FCV-5 and six of the srr mutants at 4 h p.i. (Figure 4.7B). Two of the eight 
mutants (K480Q and A168S/F486L) were similar to FCV-5 producing new infectious 
virions by 4 h p.i. In contrast, the other 6 srr mutants had decreased infectivity at 4 h 
p.i., indicating that the production of infectious virus particles was delayed; the 
observed decrease for the 6 mutants was statistically different from FCV-5 as 
determined by ANOVA (P < 0.005). By 8 h p.i., all of the viruses had attained similar 
increases in titer, and the final virus yields were all similar. We conclude that 6 of the 
panel of 8 srr mutants analyzed have slower growth kinetics than the parental FCV-5 
in cells infected at a low multiplicity. 
 Binding of srr mutants to fJAM-A. In order to assess the kinetics of binding 
of the srr mutants to fJAM-A, we purified three mutants (G329D, V516I, and K572E) 
and investigated their in vitro binding to plate-bound soluble fJAM-A in comparison 
to parental FCV-5 by ELISA (Figure 4.8A). All of the viruses showed saturable 
concentration-dependent binding to fJAM-A. The binding kinetics of FCV-5 and 
G329D were similar and saturation of binding to fJAM-A occurred at a similar 
concentration of virus. We found slight differences in the kinetics of binding of 
mutants V516I and K572E from those of FCV-5 and G329D with saturable binding 
occurring at higher concentrations of virus. We conclude that the three srr mutants 
investigated (G329D, V516I, and K572E) and FCV-5 all bind immobilized 
recombinant fJAM-A with relatively similar kinetics under in vitro conditions. 
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Figure 4.7. Growth of srr mutants. CRFK monolayers were infected with FCV-5 and 
the indicated srr mutants under (A) single- (MOI = 5) or (B) multiple- (MOI = 0.01) 
cycle conditions. The change in virus titer was determined by plaque assay. The mean 
log10 titer (log10 titer at each time point - log10 titer at T = 0) for each time point is 
shown; the error bars shown at 4 and 8 h p.i. for the multiple cycle growth represent 
the standard deviation of 4 replicates. The asterisks indicate significant differences 
between viral isolates as determined by ANOVA at these time points.  
Figure 4.8. Binding of srr mutants to immobilized fJAM-A in (A) the absence or (B) 
presence of increasing concentrations of sfJAM-A. ELISA plates were coated with 
100 ng of sfJAM-A ectodomain. Varying concentrations of purified FCV-5 and srr 
mutants G329D, V516I, and K572E were incubated with the immobilized protein for 
3 h on ice. To investigate the effect of soluble fJAM-A on the binding of virus to 
immobilized receptor, 750ng of each virus and varying concentrations of soluble 
receptor were incubated together with plate-bound fJAM-A for 3 h on ice. Bound FCV 
was detected with rabbit anti-FCV serum, followed by HRP-conjugated goat anti-
rabbit IgG. Colorimetric HRP substrate was added, and the amount of bound FCV-5 
was quantified by absorbance at 595 nm. The means of 3 and 4 plates, respectively (2 
replicates per plate) ± SE are shown. ANOVA was performed on three concentrations 
of soluble receptor (0.04, 0.33, and 2.7 μM) to determine statistical differences; 
significant differences between isolates at these concentrations are indicated by 
asterisks.
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  Relative affinities of srr mutants for fJAM-A. To determine if the purified 
srr mutants (V516I, K572E, and G329D) differed from FCV-5 in their affinity for 
fJAM-A, we performed a competition ELISA experiment (Figure 4.8B). Different 
concentrations of soluble fJAM-A were used to complete for binding of FCV to plate- 
bound fJAM-A at 4°C. We found that attachment of FCV to the plate-bound receptor 
was strongly inhibited at the highest concentrations of soluble fJAM-A. The binding 
of FCV to plate bound fJAM-A correlated inversely to the concentration of soluble 
receptor. A 50% decrease in binding of all of the different viruses to plate-bound 
fJAM-A occurred at concentrations of soluble fJAM-A of between 0.33 and 0.66 μM. 
All of the viruses exhibited similar competition curves; however, binding of mutant 
V516I to plate-bound fJAM-A was 50% inhibited at a slightly higher concentration of 
soluble fJAM-A as can be seen by the rightward shift in the competition binding curve 
(Fig. 8B). Statistical analysis (ANOVA) at three concentrations of soluble receptor 
(0.04, 0.33, and 2.7 μM) showed significantly more viral binding of mutant V516I 
than FCV-5 for all but the lowest concentration of receptor (P < 0.05). Interestingly, 
we found that preincubation of virus with low concentrations of soluble fJAM-A 
significantly enhanced binding to plate-bound fJAM-A when compared to virus alone 
(see discussion). In conclusion we show that the srr mutants G329D, V516I, and 
K572E demonstrate similar affinities for fJAM-A. 
 Bis-ANS binding reveals a change in FCV following preincubation with 
soluble fJAM-A. We hypothesized that the interaction of soluble receptor with FCV 
caused a change in conformation of the viral capsid. We, therefore, used binding of 
bis-ANS as a probe to investigate changes in hydrophobicity that occurred upon 
interaction of FCV with fJAM-A in solution. Bis-ANS is a fluorophore that binds to 
exposed hydrophobic regions of protein molecules (Rosen & Weber, 1969). The 
sequestration of bis-ANS in hydrophobic pockets of proteins is accompanied by a 
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large increase in the fluorescence quantum yield of the probe. Thus, bis-ANS can be 
used to probe for structural changes in viral proteins that are accompanied by changes 
in surface hydrophobicity (de Sousa et al., 1999, Ferreira et al., 2004, Gaspar et al., 
1997). We first preincubated virus or receptor alone in a cuvette in the 
spectrofluorometer at 37° C for 10 minutes and then added bis-ANS and collected 
fluorescence intensity readings over a period of 10 minutes at 37°C (Figure 4.9A&B). 
To quantify differences in bis-ANS fluorescence, we waited until the fluorescence 
emission readings had stabilized and then averaged the fluorescence intensity 
measurements over 1 minute. We recorded an increase in fluorescence intensity during 
the first 5-10 minutes after addition of bis-ANS to any of the protein samples; The 
fluorescence intensity stabilized by 10 min post-addition. This increase in fluorescence 
is likely caused by bis-ANS binding to surface-exposed hydrophobic pockets on the 
proteins (Figure 4.9 A,B). 
 To determine if the interaction of FCV with fJAM-A triggered a 
conformational change that would change the binding of bis-ANS to the proteins, we 
preincubated FCV with either hJAM-A [hJAM-A does not bind FCV (Ossiboff & 
Parker, 2007); Figure4. 9 A,C] or fJAM-A (Figure 4.9B,D) at 37°C for 10 minutes, 
then added bis-ANS and monitored changes in fluorescence intensity over 10 min. We 
found that the average stabilized bis-ANS fluorescence intensity of samples containing 
FCV-5 plus hJAM-A was equal to the sum of the intensities associated with 
incubation of bis-ANS with FCV-5 and hJAM-A individually (dotted line; Figure 
4.9C). These findings were expected and indicate that the overall binding of bis-ANS 
to either protein was unchanged when they were mixed. In contrast, the average 
stabilized fluorescence intensity of samples containing FCV-5 plus fJAM-A was 
greater than the sum of the bis-ANS fluorescence intensities of the two proteins when 
incubated individually (Figure 4.9D). We found similar results for the three srr  
Figure 4.9. Changes in bis-ANS binding upon interaction of FCV with sfJAM-A. At 
zero time, bis-ANS was added to the indicated purified virions, soluble JAM-A [(A) 
human or (B) feline], or virions preincubated with JAM-A. Fluorescence was recorded 
every 2 sec continuously for 10 min at excitation and emission wavelengths of 395 
and 495nm, respectively. (C, D) Stabilized fluorescence intensities measured during 
the last minute for each sample were averaged. Dotted lines indicate the additive 
average fluorescence intensity measured for both native virus and receptor. The means 
± SE (n = 3) are shown.
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 mutants (V516A, K572E, and G329D) and two field isolates (Kaos and FCV-131) 
tested. These findings suggested that an interaction between virus and fJAM-A had 
changed the conformation of one or both proteins such that more bis-ANS bound. In 
contrast, incubation of the vaccine strain F9 with fJAM-A led to a fluorescence 
intensity maximum that was less than what would be expected from the sum of the 
intensities associated with each protein individually indicating an overall decrease in 
the available binding sites for bis-ANS. From these findings we conclude that 
interaction of fJAM-A with FCV at 37°C leads to changes in the binding of bis-ANS 
that are indicative of changes in hydrophobicity of virus and/or receptor. 
 Not all FCV isolates are neutralized by sfJAM-A. The FCV-5 isolate that 
we used to select for srr mutants was recovered from a cat suffering from severe 
systemic disease. As this form of FCV disease is uncommon we hypothesized that not 
all isolates of FCV would be neutralized by incubation with soluble fJAM-A at 37°C. 
To test this hypothesis, we incubated ~105 p.f.u. of 6 additional FCV isolates with 45 
μM GST-fJAM-A at 37°C; these virus isolates included the vaccine strain F9, two 
additional isolates from cats suffering from virulent systemic disease, the FCV-Urbana 
isolate and three other field isolates recovered from cats with mild to moderate 
severity FCV disease. We found several additional FCV isolates that were neutralized 
by preincubation with sfJAM-A at 37°C; however, the vaccine strain F9, FCV-Urbana 
and the two isolates recovered from animals with milder disease were not neutralized 
under these conditions (Figure 4.10). We conclude that there are natural differences 
among FCV isolates in their responses to incubation with sfJAM-A at 37°C. 
 
4.5 Discussion 
 Nonenveloped viruses must deliver their genetic material across the membranous 
barrier surrounding the host cell. Unlike enveloped viruses which  
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Figure 4.10. Ability of soluble fJAM-A to neutralize select FCV isolates. A panel of 6 
FCV field isolates (FCV-5, Kaos, Deuce, FCV-127, FCV-131, and FCV-796) and 2 
tissue culture adapted strains (F9 and Urbana) (1 × 105 p.f.u.) were incubated in the 
presence or absence soluble GST-fJAM-A (45 μM) at 37 °C for 30 min. The 
remaining infectivity in each sample was assayed by plaque titration. The change in 
log titer was calculated by subtracting the titer of samples incubated with receptor 
from samples incubated without. The mean change in log10 titer ± SD (n = 4) is 
shown. 
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 possess a lipid membrane and enter host cells by promoting fusion of the viral and 
host membranes, nonenveloped viruses must disrupt cellular membranes to deliver the 
intact capsid or their genome into the interior. Here we present genetic and biological 
evidence indicating that feline calicivirus, a nonenveloped member of the 
Caliciviridae, undergoes structural rearrangements following interaction with its 
cellular receptor, fJAM-A that for some isolates lead to virus inactivation. 
 Several nonenveloped viruses including human rhinoviruses, polioviruses, and 
hepatitis A virus are neutralized by preincubation with their functional receptors 
(Kaplan et al., 1990, Marlin et al., 1990, Silberstein et al., 2001). However, the extent 
to which infectivity is lost at physiologic temperatures differs. For polioviruses and 
some human rhinoviruses, the receptor can induce irreversible conformational changes 
that inactivate the virus (Colston & Racaniello, 1994, Greve et al., 1991). Reductions 
in titer following preincubation with receptor can also be more modest and can be 
explained by competitive inhibition of cell surface receptor binding as occurs for 
rabies virus and its cellular receptor neurotrophin (Langevin & Tuffereau, 2002). 
These differences reflect different mechanisms of receptor-mediated neutralization. 
Greve et al (1991) described three mechanisms of receptor-mediated neutralization for 
human rhinoviruses. One mechanism involves simple competition of soluble receptor 
for receptor binding sites on cells. A second mechanism involved a receptor-mediated 
reversible conformational change that prevented infection. A third mechanism was 
that virus-receptor interaction led to irreversible capsid changes that were 
incompatible with infection (Greve et al., 1991). Differences between serotypes in the 
effects of soluble ICAM-1 receptor on neutralization of rhinoviruses were 
subsequently recognized (Hoover-Litty & Greve, 1993). Similarly, we found that 
some, but not all isolates of FCV were neutralized by preincubation with a soluble 
form of fJAM-A. The molecular events that result in FCV neutralization are unknown. 
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 While it is possible that the mechanism of neutralization is due to steric hindrance or 
occupation of receptor binding sites, the prominent temperature-dependent nature of 
the process strongly suggests that receptor-induced conformational changes are a 
contributing factor. Receptor-induced conformational changes in human rhinoviruses 
and poliovirus are temperature-dependent (Gomez Yafal et al., 1993, Hoover-Litty & 
Greve, 1993). Polioviruses undergo an irreversible transition from a 160S to a 135S 
particle when they are incubated with soluble receptor at 37°C; this reaction has a 
clear temperature threshold with little to no neutralization occurring at temperatures 
below 33 °C (Gomez Yafal et al., 1993, Tsang et al., 2001). In contrast, although 
FCV-5 receptor-mediated neutralization was clearly temperature-dependent, there was 
no obvious temperature threshold, but rather a gradual diminishment of the 
neutralizing effect as the temperature decreased from 37°C to 4°C. 
 Analysis of soluble receptor (srr) mutants in poliovirus and murine 
coronavirus identified virus residues that either directly or indirectly facilitated 
receptor binding (Colston & Racaniello, 1994, Kaplan et al., 1990, Saeki et al., 1997). 
Of the 24 srr mutants FCV-5 we isolated for FCV-5, mutations to 20 unique residues 
were identified. Many of these mapped to surface exposed residues on top of the P2 
domain of the capsid; however, several mutated residues were buried in or 
inaccessible from the surface of the structure. These findings are similar to those for 
poliovirus srr mutants, which contained mutations to both internal and surface 
exposed residues. The mutated residues for poliovirus mapped to a hydrophobic 
pocket in the structure. It is believed that changes to residues in this hydrophobic 
pocket regulate receptor attachment and conformational changes within the virus 
particle (Colston & Racaniello, 1994, Racaniello, 1996).  
 Mutations at some capsid residues were found in more than one of the panel of 
srr mutants we examined, suggesting that these residues are within critical regions of 
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 the capsid that are necessary for structural flexibility or receptor interactions. Residue 
G329, mutated in three srr mutants, is located in a short loop between the S and P 
domains of the capsid protein; this loop is hypothesized to be a flexible hinge that 
allows for movement of the P domain in relation to the S domain. The flexible hinge 
region is common to all Caliciviruses. Cryo-electron microscopy reconstructions of 
murine norovirus in complex with neutralizing Fab fragments show that this hinge 
region is extended, moving the P domain up off of the surface of the shell domain 
(Katpally et al., 2008). In addition, a recent cryo-electron microscopy structure of 
FCV F9 complexed with the fJAM-A ectodomain indicated that compared to the 
uncomplexed capsid, the P domain of capsid bound to fJAM-A moved with respect to 
the S domain and suggested that hinging was required for this movement (Bhella et 
al., 2008). Our findings support the hypothesis that flexibility in this hinge region is 
important to permit conformational changes of the structural domains of the calicivirus 
capsid in relation to each other and indicate that this region actively moves during 
receptor interactions. Moreover our findings indicate that changes at residue G329 can 
radically alter the susceptibility of FCV to neutralization by soluble receptor. 
 As shown here for the structure of FCV-5, dimers are formed between the P 
domains of FCV capsid proteins. Intriguingly, residues at the P domain dimer 
interface were mutated in several srr mutants. It is not immediately clear how these 
changes would impart resistance to neutralization. One possibility, however, is that 
following binding to fJAM-A, the dimer interface of the P domain opens and residues 
that are normally buried are exposed. Mutant K572E is in the P1 domain and is 
relatively inaccessible from the surface of the capsid. This mutant had decreased 
binding to cell surface expressed fJAM-A. However, in vitro binding assays using 
purified virus and receptor indicated that the mutant possessed similar binding kinetics 
to both the parental FCV-5 and the two other srr mutants investigated. For the cell-
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 based assay, a monoclonal antibody was used to detect FCV binding, while a 
polyclonal antibody was used for the plate-based assays. It is possible, therefore, that 
the mutant K572E has an altered epitope that results in decreased recognition by the 
monoclonal antibody. An alternative possibility is that the results of the cell expressed 
assay, in which all receptors are oriented properly, is truly indicating a difference in 
the recognition and binding of mutant K572E to the receptor.  
 An obvious mechanism by which the srr mutants might avoid neutralization 
would be to have altered binding to fJAM-A and we expected to identify srr mutants 
that contained mutations which conferred altered receptor binding properties. One 
surface exposed residue, V516, was mutated in 5 srr mutants. While the binding of 
mutant V516I was not altered in the cell-based binding experiments, it did 
demonstrate higher affinity for immobilized fJAM-A in the presence of higher 
concentrations of soluble fJAM-A (see Fig. 8B). However, neither of the other two srr 
mutants used to investigate in vitro binding kinetics displayed altered kinetics from the 
parental strain. These results are in contrast to the findings for poliovirus, where all the 
reported srr mutants demonstrated a reduction in binding affinity (Colston & 
Racaniello, 1994). It is surprising that none of our srr mutants showed a substantive 
change in binding to fJAM-A as many of the mutations map to surface regions of the 
capsid that overlap with the receptor binding site predicted by Bhella et al (Bhella et 
al., 2008). 
 Another unexpected observation was that the binding of purified FCV to 
immobilized fJAM-A was enhanced by presence of soluble fJAM-A in low 
concentrations (see Fig. 8B). As fJAM-A can form dimers, and FCV binding does not 
seem to require or occlude the fJAM-A dimerization interface (Bhella et al., 2008, 
Ossiboff & Parker, 2007), this enhanced binding may be mediated by fJAM/fJAM 
interactions between immobilized and virus-bound soluble receptor. An alternative 
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 explanation is that the binding of soluble fJAM-A to FCV capsids enhances the 
binding to the immobilized receptor allosterically.  
 Single-step growth curves for srr mutants of poliovirus demonstrated that 
while all of the mutants attained similar overall titers, their titers were lower than wild 
type P1/Mahoney poliovirus at early time points post-infection. This delayed increase 
in titer was attributed to an assembly defect as all of the mutants bound as efficiently 
as wild type poliovirus to cells at room temperature (Colston & Racaniello, 1994). In 
contrast, we found that parental FCV-5 and a subpanel of srr mutants of FCV-5 had 
similar kinetics of replication during single step growth curves. Most of the srr 
mutants, however, had significantly decreased titers in comparison to parental FCV-5 
at 4 h.p.i during a multiple-step growth experiment. There are several possible 
explanations for our findings. One would be that the efficiency of viral entry of the 
mutants is decreased with a consequent lag in the onset of viral replication. However, 
it is also possible that capsid assembly is slowed; this explanation seems less likely as 
all of the mutants achieved similar titers to parental FCV-5 at later time points during 
multiple-step growth. Changes in the efficiency of viral entry could be attributed to 
changes in receptor binding, cellular trafficking, and/or uncoating. Mutant K572E 
demonstrated decreased binding to cell-surface expressed fJAM-A, and it was also one 
of isolates with delayed kinetics. Therefore, one possibility for the observed difference 
in growth in this mutant is decreased binding to the receptor. However, mutant G329D 
bound to both cell-expressed and plate-bound fJAM-A to the same extent as parental 
FCV-5 and mutant V516I demonstrated increased affinity for the receptor. Yet, these 
mutants possessed decreased capacity for growth during early time points of multiple 
replicative cycle growth. This suggests that the process of entry differs in these 
mutants. We previously showed that lower virulence field or tissue-culture adapted 
FCV isolates had delayed multiple cycle growth kinetics during multiple cycle growth 
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 when compared to more virulent isolates (including FCV-5) (Ossiboff et al., 2007). 
Although the virulence of these srr mutants is currently unknown, it is possible that by 
selecting for mutants resistant to neutralization by soluble receptor, we may have also 
selected for viruses with altered virulence. 
 Since nonenveloped viruses must penetrate cellular membranes to deliver their 
genetic material, it is hypothesized that they undergo conformational alterations that 
are required for membrane penetration [as reviewed in (Tsai, 2007)]. With the finding 
that fJAM-A neutralization of FCV was temperature-dependent and the identification 
of srr mutants possessing mutations to only buried residues, we investigated the 
possibility that interaction with fJAM-A was inducing a conformational change in 
FCV using bis-ANS binding to detect changes in hydrophobicity. We found that 
incubation of several FCV isolates with soluble fJAM-A at physiologic temperatures 
resulted in an increase in hydrophobicity of the FCV/fJAM-A complex as detected by 
changes in bis-ANS binding. This change was specific for incubation with fJAM-A, as 
incubation with the human homolog, fJAM-A did not result in a net change of 
hydrophobicity. Several viruses expose hydrophobic regions of viral proteins 
secondary to structural changes (Carneiro et al., 2001, de Sousa et al., 1999, Gaspar et 
al., 1997). Receptor-induced conformational changes have also been demonstrated for 
envelope glycoproteins of Newcastle disease virus and HIV-1 by gangliosides and 
CD4, respectively, using changes in hydrophobicity as determined by bis-ANS 
binding (Ferreira et al., 2004, Jones et al., 1998). Therefore, it is likely the observed 
changes in bis-ANS indicate a conformational change within the virus capsid. An 
alternative explanation is that the increases in hydrophobicity we observed were due to 
changes in the receptor, not the virus. However, as there is substantial evidence for 
viral protein conformational changes following interaction with cellular receptors, and 
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 such conformational changes are likely a requirement of all nonenveloped viruses, this 
explanation is less likely. 
 As described for the neutralization of human rhinoviruses by soluble ICAM-1 
(Greve et al., 1991), we hypothesized that one method of FCV-5 neutralization by 
soluble fJAM-A was the induction of a conformational change within the virus 
particle that rendered it incapable of infecting cells. As such, we further hypothesized 
that the srr mutants would not exhibit a change in hydrophobicity upon incubation 
with soluble receptor. However, we found that the srr mutants demonstrated an 
increase in hydrophobicity similar to that observed for FCV-5. One possible 
explanation of this finding is that FCV neutralization by soluble receptor is not due to 
an induced conformational change. However, a more likely possibility is that there are 
several intermediates that form during the interaction of FCV with fJAM-A and the 
resulting steps required for entry. Two structural intermediates of picornaviruses can 
form following interaction with receptor or when subjected to the appropriate 
environmental conditions, the 135S A particle and the 80S empty particle (Crowell & 
Philipson, 1971, De Sena & Mandel, 1977, Fenwick & Cooper, 1962, Lonberg-Holm 
& Korant, 1972); furthermore, it is postulated that there are additional intermediates 
that are as of yet unidentified (Hogle, 2002). Therefore, our working model is that 
mutants resistant to neutralization undergo an initial conformational change upon 
interacting with fJAM-A that is either reversible or results in a stable, infectious 
intermediate.  
 Recently a cryo-electron microscopy reconstruction of the FCV F9 strain 
complexed with fJAM-A at 18 Å revealed that fJAM-A interacted with the top of the 
P2 sub-domain of the F9 capsid (Bhella et al., 2008). This interaction caused a ~ 13° 
anti-clockwise rotation of the P dimers about their two-fold axes of symmetry 
indicating substantial conformational change of the capsid upon binding of receptor. 
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 Interestingly, we found that in contrast to the other FCV isolates we investigated the 
binding of bis-ANS to the F9 capsid when preincubated with sfJAM-A was lower than 
binding of bis-ANS to the virus alone (see Fig. 9D). Given the structural evidence for 
a conformational change in F9, the likely explanation is that fJAM-A binding induces 
a conformational change of the F9 capsid that masks hydrophobic patches rather than 
uncovering them. Therefore, given our observations of increased bis-ANS binding to 
other FCV isolates when preincubated with fJAM-A, it seems possible that the capsid 
conformational changes reported by Bhella et al. for the vaccine isolate F9 are not 
representative of changes that occur in the capsids of other FCV field isolates. 
 A further investigation of FCV isolates, including low passage field isolates 
and tissue culture adapted lab strains, indicated that not all FCV isolates are sensitive 
to fJAM-A neutralization (see Fig. 10). One naturally neutralization resistant isolate, 
FCV-131, also exhibited increased hydrophobicity following incubation with soluble 
receptor. Like the srr mutants, it seems likely that some field isolates undergo a 
conformational alteration following interaction with fJAM-A, but do not lose 
infectivity. Other isolates, however, may undergo more drastic, global conformational 
alterations that result in either a complete loss of or significant decrease in infectivity. 
While altered poliovirus 135S particles are still infectious, they are ~ 104 less 
infectious than native particles (Curry et al., 1996). Interestingly, we found that 
sensitivity of different FCV isolates to neutralization correlated with their virulence in 
cats. Feline calicivirus is a common pathogen of cats that typically causes no disease 
or mild upper respiratory disease and oral ulceration, with fatal disease being unusual. 
However, highly virulent isolates of FCV occur that can cause systemic signs of 
disease and result in mortality rates as high as 50% (Hurley et al., 2004, Pedersen et 
al., 2000, Pesavento et al., 2004, Schorr-Evans et al., 2003). In our panel, the most 
virulent isolates were susceptible to fJAM-A neutralization, while low virulence 
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isolates displayed resistance. It is possible that the in vitro assay of receptor 
neutralization is highlighting an important determinant of in vivo virulence. 
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Summary and conclusions  
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  Feline calicivirus (FCV) is a common and emerging feline infectious disease of 
veterinary significance. Outbreaks of highly virulent viruses, first reported in 1998, 
have continued to surface sporadically causing mortality rates as high as 50%. It 
appears that currently available commercial vaccines afford little to no protection 
against these highly virulent isolates. Consequently, there is a great need in veterinary 
medicine for specific diagnostics and therapeutics to help identify and treat outbreaks 
of highly virulent FCV, in addition to improved vaccines to help prevent them. Other 
clinically relevant members of the Caliciviridae cause outbreaks of acute 
gastroenteritis in humans and vesicular, hemorrhagic and respiratory disease in 
animals. But unlike FCV, studies on many caliciviruses are limited by the lack of 
tissue culture systems. As such, FCV can serve as a model for the Caliciviridae family 
to better understand the basic principles of calicivirus infection and pathogenesis. The 
study of feline calicivirus (FCV), therefore, has important implications for both 
veterinary and human medicine. 
 In the work presented within this dissertation, I have investigated the in vitro 
properties and partial genome sequence of a panel of FCV isolates in order to identify 
in vitro correlates of in vivo virulence. I also investigated the molecular details of the 
interaction of FCV with its functional receptor, feline junctional adhesion molecule A 
(fJAM-A). 
 The results I present here show that while a panel of FCV isolates, which 
included seven isolates from five distinct VS-FCV outbreaks (‘VS isolates’), shared 
many common properties, two noteworthy differences were  identified. First, although 
all of the FCV isolates investigated had similar kinetics of growth under single-cycle 
conditions, VS isolates infected tissue-culture cells more efficiently under multiple-
cycle growth conditions. Such efficiency suggests that differences in virus attachment 
or entry may determine the increased growth of VS-FCV isolates and perhaps play a 
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 role in the increased pathogenicity of VS-FCV isolates. Second, I found that cells 
infected with VS isolates showed cytopathic effects earlier than cells infected with 
non-VS isolates. However, sequence analysis and alignments of the capsid and pro–
pol regions of the genome did not reveal any conserved changes that correlated with 
virulence; furthermore, phylogenetic analysis suggested that, as VS-FCV isolates were 
no more related to each other than low virulence or tissue culture isolates, VS isolates 
have arisen independently several times since first being described. 
 To investigate the FCV-fJAM-A interaction, I expressed the fJAM-A 
ectodomain as a recombinant protein in bacteria. I also used this protein to generate 
fJAM-A specific rabbit antisera. Preincubation of soluble fJAM-A ectodomain or the 
D1 domain alone with FCV resulted in neutralization, suggesting that the virus 
interacted with the D1 domain. Virus binding assays using a cell-expressed panel of 
chimeric and mutant receptors confirmed that FCV binds to the membrane-distal D1 
domain of fJAM-A. Using site-directed mutagenesis of select D1 residues, I identified 
three mutations (D42N, K43N, and S97A) that resulted in significantly decreased 
binding of virus to the receptor. However, while the D1 domain was sufficient to 
permit FCV binding, the entire fJAM-A receptor was required to confer susceptibility 
to infection. Finally, I showed that expression of fJAM-A alone on the surface of a 
non-permissive cell line did not confer susceptibility to FCV infection by all of the 
FCV isolates investigated. 
 Having shown that soluble fJAM-A ectodomain neutralized a virulent systemic 
FCV isolate (FCV-5) following preincubation, I proceeded to select for FCV-5 
mutants that were resistant to neutralization. I obtained a panel of 24 soluble receptor 
resistant (srr) mutants that contained mutations to 20 unique residues within the 
capsid. I developed a protocol for FCV purification that I used to purify FCV-5. The 
purified virus was used to determine a 3.6 Å crystal structure of the virus. Using the 
180 
 crystal structure, the mutations were mapped to the FCV-5 capsid. I found that srr 
isolates contained mutations to both surface-exposed and buried residues. By 
characterizing a subpanel of mutants, I showed that while resistant to neutralization by 
soluble receptor, srr isolates still utilized fJAM-A as a functional receptor. Although 
the mutants possessed similar single cycle growth kinetics, 6 of the 8 srr mutants 
demonstrated delayed kinetics of growth at early time points post-infection. As 
detected by an increase in hydrophobicity, I found that incubation of both parental 
FCV-5 and select srr isolates with soluble fJAM-A resulted in a conformational 
change. Additionally, incubation of select field isolates of varying clinical histories 
with soluble receptor also showed an increase in hydrophobicity. In contrast, the 
attenuated vaccine strain F9 demonstrated a net decrease in hydrophobicity, indicating 
either (i) it is not undergoing a conformational change, or (ii) the nature of the induced 
conformational change masks hydrophobic patches. Finally, I demonstrated that not 
all FCV field isolates tested were susceptible to neutralization by soluble fJAM-A. 
Furthermore, I noted a correlation between strain virulence and susceptibility to 
neutralization, with highly virulent isolates demonstrating sensitivity to neutralization, 
while low virulence field isolates and tissue culture adapted strains showed 
neutralization resistance. 
 In this thesis, I have enhanced the understanding of the interaction of FCV 
with its cellular receptor, fJAM-A, at the molecular level. I also identified in vitro 
properties of FCV isolates that correlate with their virulent nature. Furthermore, I 
developed a panel of reagents and protocols that will allow for further elucidation of 
calicivirus infection and pathogenesis. 
 The studies presented within this dissertation identified a few properties of 
FCV that correlated with the virulent nature of the isolates. Viruses isolated from cats 
suffering from the most severe clinical signs exhibited the capacity in vitro to produce 
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 infectious virus at earlier time points than low virulence or tissue culture adapted 
strains when infected at a low multiplicity of infection; in contrast, all isolates 
demonstrated similar growth kinetics when infected at a high multiplicity of infection. 
There are three possible explanations for these findings. First, the highly virulent 
viruses may possess a stronger affinity for the receptor. As such, at lower 
concentrations of virus, more cells would be infected initially in multiple cycle 
growth. The second possibility is that they are able to enter cells more efficiently than 
isolates that displayed slower growth kinetics. In this explanation, viruses all bind 
receptor with similar affinity, but there are differences in virus entry post-receptor 
binding. There is also the possibility of a third explanation in which the release of 
progeny virus from infected cells differs between the isolates.  However, at such early 
time points post-infection, the detected virus is most likely produced from the first 
round of replication and still cell-associated. Furthermore, the multiple cycle growth 
kinetics of all isolates are similar at later times post-infection. Given this evidence, a 
difference in the receptor binding or entry between the high and low virulence isolates 
is the most likely reason for the observed differences in growth kinetics. 
 FCV isolates also differed in their sensitivity to neutralization by the soluble 
receptor. Highly virulent isolates exhibited a significant loss of infectious titer (> 3 log 
plaque forming units) following preincubation with fJAM-A ectodomain at 37°C. In 
contrast, tissue culture adapted and low virulence field isolates were completely 
resistant to neutralization. Interestingly, mutants of the virulent systemic isolate FCV-
5, selected for resistance to neutralization by soluble fJAM-A, showed altered growth 
kinetics. Instead of demonstrating the increase in log titer at early time points of 
multiple cycle growth characteristic of the parental strain, 6 of the 8 srr mutants 
investigated showed a decrease in infectious titer; this is a result characteristic of low 
virulence and tissue culture isolates. Taken together, these findings suggest that the 
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 processes of infectious entry in tissue culture cells and neutralization by soluble 
receptor are linked to isolate virulence.  
 I propose the following model for FCV virulence (Figure 5.1). Highly virulent 
isolates of FCV exist in a highly metastable state. Under the conditions used to assay 
for virus neutralization and changes in hydrophobicity described in this dissertation, 
only receptor and physiologic temperatures are required to convert native infectious 
particles to hydrophobic neutralized particles. These structural alterations may permit 
interaction with cellular membranes and initiate infectious entry. Hydrophobicity data 
of low virulence FCV isolates and srr mutants indicates that incubation with soluble 
receptor at physiologic temperature also results in an increase in bis-ANS fluorescence 
intensity, suggesting a conformational change has occurred. But in contrast, the results 
of the neutralization experiments identify that these particles are still infectious. In this 
model, native infectious particles of low virulence isolates first convert to an 
intermediate hydrophobic infectious conformer. To undergo further conversion to 
particles able to initiate infectious entry (hydrophobic neutralized), these low 
virulence isolates likely require conditions or factors that have not yet been 
determined. The ‘rapid’ conversion of the highly virulent isolates would allow for 
faster entry than the less virulent strains, permitting the virus to produce progeny at 
earlier time points in the host. This advantage would then facilitate the rapid spread of 
the highly virulent isolates within the host, as well as potentially expanding tissue 
tropism by eliminating the requirement an additional cellular factor or condition. The 
rapid growth kinetics of FCV combined with more efficient entry of highly virulent 
strains may then allow the virus to stay just ahead of host defenses. 
 This model presenting virulent systemic isolates as highly metastable 
structures may also explain why outbreaks of virulent systemic FCV are isolated, 
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 Figure 5.1. Model of FCV virulence.  
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 infect a limited number of hosts (from a few to up to 50 cats), and then burn out 
without greater geographical spread (Pesavento et al., 2008). While a greater concern 
for veterinary medicine, these viruses may actually be less fit than their lower 
virulence counterparts.  
 As has been hypothesized for picornaviruses [as reviewed in (Hogle, 2002)], 
there are likely multiple viral intermediates during FCV infectious entry. The changes 
in hydrophobicity observed for low virulence and srr mutant isolates following 
incubation with receptor at physiological temperatures may indicate conversion to an 
altered particle that retains infectivity (hydrophobic infectious particles). The increase 
in hydrophobicity may also represent changes in the structure that are reversible, 
allowing hydrophobic infectious particles to revert back to native infectious particles. 
This reversion would then provide an explanation for why preincubation of some FCV 
isolates with soluble receptor does not affect their ability to infect cells. It would be 
interesting to test if hydrophobic infectious particles could be pushed to hydrophobic 
neutralized particles by altering conditions, such as incubating at supraphysiologic 
temperatures. 
 While the observed increase in hydrophobicity of any FCV isolate following 
incubation with soluble receptor is suggestive of a conformational change in vitro, 
additional studies are required to confirm this interpretation. The altered particles of 
picornaviruses were originally identified due to the nature of their sedimentation, with 
the native particle, A-particle and 80S particles all exhibiting unique sedimentation. 
Therefore, the sedimentation of native and receptor-incubated particles should be 
investigated. Another method commonly used to identify conformational changes 
within virus capsids is protease sensitivity. If FCV is truly demonstrating receptor-
induced conformational changes, then protease cleavage sites present in the native 
virus may be either exposed or hidden in the altered particle. Accordingly, treating 
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 native and receptor-incubated virus with proteases would then result in different sized 
peptide fragments, as determined by gel electrophoresis.  
 Structural studies of an FCV field isolate in complex with fJAM-A would 
provide an understanding of the molecular changes occurring within the capsid. A 
cryo-EM reconstruction has been recently published for the FCV vaccine strain F9 in 
complex with soluble fJAM-A ectodomain (Bhella et al., 2008). They found rotational 
conformational changes in the P- and S-domains following receptor binding. 
However, I have shown that following preincubation with receptor, F9 has decreased 
hydrophobicity, a unique finding for the isolates I investigated. As a vaccine strain, F9 
was passaged and attenuated in tissue culture. It is possible that one of the mechanisms 
of virus attenuation was to alter the conditions of receptor-induced conformational 
changes within the capsid. To date, a collaborative effort with Dr. Prasad at Baylor 
College of Medicine to generate a cryo-EM reconstruction of FCV-5 in complex with 
fJAM-A ectodomain has had limited success. Under the conditions that have been 
investigated, preincubation of soluble receptor with virus has led to particle 
disassembly. These experiments should be continued by trying to find optimal 
conditions to capture the particle in an altered state. The use of small molecules such 
as bis-ANS, which can act as molecular wedges by binding to exposed hydrophobic 
pockets and locking the particle in an altered state, may also prove helpful (Lee et al., 
2004). 
 Another important determination to make will be if altered FCV particles can 
directly interact with lipid membranes. If the interaction of FCV with fJAM-A induces 
a physiologically relevant conformational change, then the altered particles may be 
able to interact with or even disrupt lipid membranes, a necessary function for 
nonenveloped virus entry. Liposome models have been used to demonstrate such 
interactions for some picornaviruses (Airaksinen et al., 2001, Davis et al., 2008, 
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 Tuthill et al., 2006). A couple of liposome-based experiments would provide 
important information for FCV entry. Liposomes containing fluorescent dyes, that 
while quenched within the liposome are dequenched when released, could be 
incubated with FCV preincubated with receptor. Liposome disruption by FCV would 
be evident by an increase in fluorescence of the total sample or a decrease in internal 
liposome fluorescence as determined by flow cytometry. In another set of 
experiments, liposomes could be decorated with fJAM-A ectodomain, and incubated 
with FCV. These assays could be used to demonstrate receptor-induced particle 
conformation in a membrane based system. This system could also be used for 
electron microscopy experiments to investigate the structural biology of the virus-
membrane interaction.  
 One aspect of the receptor-virus interaction that has been overlooked for many 
of the assays I have described within this dissertation is the glycosylation status of the 
receptor and the importance of a carbohydrate co-receptor in FCV receptor binding 
and entry. Stuart and Brown (2007) demonstrated that FCV binds to α2,6-linked sialic 
acids present on a N-linked glycoprotein; it is not known if that glycoprotein is fJAM-
A or perhaps an additional co-receptor. fJAM-A contains a single putative N-linked 
glycosylation site, present in the D2 loop of the ectodomain. The importance of this 
glycosylation site has not been determined. For my studies, soluble recombinant 
fJAM-A ectodomain was produced in bacteria, and was therefore not glycosylated. 
Additionally, the majority of the cell-based infection and binding assays were 
performed in Chinese hamster ovary (CHO) cells, which are unable to synthesize α2,6 
sialic acid linkages (Lee et al., 1989). Therefore, to investigate the effect of 
glycosylation of fJAM-A, the glycosylation status of cell-expressed receptor should 
first be determined. If it is found that fJAM-A is glycosylated, then both native fJAM-
A ectodomain and ectodomain glycosylation mutants should be expressed for 
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 purification in a mammalian cell line; binding and neutralization assays should be 
repeated with the glycosylated form of the fJAM-A ectodomain. 
 Finally, while there are likely many factors involved in the ability of some 
isolates of FCV to cause virulent systemic disease, the studies presented here suggest 
that the capsid protein plays a crucial role in the process. The creation of chimeric 
FCVs will allow this hypothesis to be tested both in vitro and in vivo. A reverse 
genetics system for FCV using a full length infectious clone of the tissue-culture 
adapted isolate Urbana has been previously described (Sosnovtsev & Green, 1995, 
Sosnovtsev et al., 1997). By swapping out the ORFs responsible for the two structural 
proteins (VP1 and VP2) of FCV-Urbana for those of a virulent systemic FCV (such as 
FCV-5), we can investigate the in vitro properties (including multiple cycle growth, 
ability to cause CPE, and plaque size/morphology) of the chimeric virus in comparison 
to the parental viruses. The point mutations identified by the analysis of the srr 
mutants can also be introduced into the chimeric system, allowing us to compare and 
contrast the effects of a single mutation in the capsid protein of the viruses on in vitro 
properties of the viruses. Ultimately, experiments looking at disease pathogenesis in 
cats infected with FCV-5, Urbana, and the chimeric virus can be used to determine if 
capsid protein alone is sufficient to confer a virulent systemic phenotype to FCV. 
 Future investigations of the molecular and structural details of the virus-
receptor interaction of FCV will hopefully serve to not only advance the ability of 
veterinary medicine to identify, treat, and prevent outbreaks of highly virulent isolates 
of FCV, but also the enhance the knowledge of the scientific community on the entry 
of nonenveloped viruses. 
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